Polymer nanocarriers to enhance the efficiency of platinum-based chemotherapeutics by Callari, Manuela
Polymer Nanocarriers to Enhance
the Efficiency of Platinum-Based
Chemotherapeutics
Manuela Callari
Doctor of Philosophy
August 2016
To my parents
i
Abstract
The aim of this Thesis was to design and prepare polymer nanocarriers capa-
ble of encapsulating, carrying and delivering platinum-based chemotherapeutics.
Polymer nanocarrier have been widely studied and employed as platinum drug
delivery systems with the primary scope to overcome limitations presented by
platinum-based chemotherapeutics. The conjugation of platinum onto polymers,
however, presents some challenges, and, although there has been great progress in
the field of drug delivery in the past years, to date only three polymer nanocarriers
for platinum drugs have found their way to the clinic.
In this Thesis, hydrophilic block copolymers were synthesised via reversible
addition fragmentation chain transfer (RAFT) polymerisation or N -carboxy-
anhydride ring-opening polymerization (NCA-ROP). Upon attachment of a hy-
drophobic platinum drug the block copolymer becomes amphiphilic and can
self-assemble in aqueous media into nanoparticles of different morphology de-
pending on the block copolymer features. Spherical micelles consisting of a
poly(methacrylic acid) core which conjugates and encapsulates the platinum
chemotherapeutic and a hydrophilic shell made of sugar blocks were prepared
and their biological activities compared in vitro. Among the sugars considered
here, fructose based micelles showed promising results in terms of their targeting
ability towards breast cancer cells. Consequently, fructose-shelled micelles were
selected to explore the effect of different loading quantities of platinum drug. It
was discovered that the amount of platinum in the core of the micelle highly influ-
ences the internal morphology of the micelle which, in turn, affects the micelle-cell
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interactions. Micelles with low drug drug loading had better cellular uptake and
higher toxicity than the micelles with high drug loading, despite having the same
fructose-based outer shell. Interestingly, this aspect had been neglected by liter-
ature so far, and is important to explore.
Micelles made of a fructose shell were then compared to micelles with a non-
targeting hydrophilic shell made of poly(ethylene glycol) methyl ether methacry-
late (PEGMEMA). The aim was to compare the process of cellular uptake and
the mechanism of platinum release inside the cell. For this scope, a fluorescent
platinum drug was synthesised as a probing tool.
Finally, a polymer vesicle based on PEG and poly(glutamic acid) was designed
to co-deliver a platinum drug and the cancer inhibitor, paclitaxel, simultaneously.
The two drugs have a synergistic effect when used in combination or co-delivered
by the vesicles. Moreover, a viability study using multicellular tumour spheroids
(MCTS) showed a significant decrease in cell proliferation when the MCTS were
treated with single drug, a combination of free drugs and dual-drug loaded vesicles
compared with untreated MCTS. An improvement is observed in the case of the
dual-drug vesicles.
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Chapter 1
State of Art
1.1 Introduction
Cancer is a invasive disease arising from a single cell in the body. Through
some fundamental change within this cell, it begins to divide and proliferate
in an uncontrollable manner regardless of the external requirement for cellular
growth. Normal cells often develop mutations in their DNA but cancer cells
have the ability to repair and recover from these mutations. If the repair process
is unsuccessful, the cell programs its own death. In case of unrepairable DNA
damage and failure in the apoptosis process, the cell can become malignant, and
thus, causes cancer. Cancer cells grow at a faster pace than healthy cells and can
spread throughout the body through the lymphatic system causing metastasis
(Figure 1.1).
The main challenge in treating cancer is that the biochemistry and molec-
ular mechanisms of cancer cells are similar to those of normal cells with only
subtle differences. The aim of the various cancer treatments is usually to kill
or remove malignant tumour cells. Currently, there are numerous clinical proce-
dures that are available for cancer treatment: radiotherapy, surgery, gene therapy
and chemotherapy. These treatments are often used in combination to enhance
the recovery process and to eliminate the possibility of cancer progressing any
further. At present, chemotherapy is one of the most commonly adopted meth-
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Figure 1.1: Schematic of cancer growth and progression
ods for cancer treatment. It includes the use of therapeutics such as cytotoxic
agents or relatively non-toxic hormonal agents to control further growth and/or
destroy cancer cells [1]. There are over 50 different drugs used in chemotherapy
and although some are used alone, frequently more drugs are used in various
combinations in order to improve the effectiveness of the treatment.
Many of the antitumour chemotherapeutics currently used in the clinic pos-
sess several limitations. The majority of these drugs have low molecular weight
(<500 g/mol) and poor solubility in water, making the administration to patients
challenging. After administration, the chemotherapeutics spread quickly through-
out the body damaging both healthy and tumour tissue. This causes the damage
of healthy organs and the weakening of the whole body, sometimes leading to
the death of the patient. Most conventional low molecular weight anticancer
drugs traverse in and out of blood vessels freely, unless the drug is linked with
a tumour-specific molecular ligand having high binding constant. Consequently,
their undesirable indiscriminate distribution in normal tissues causes severe side
effects: free diffusion of toxic drugs in a non-selective manner in the body, and
their inability to accumulate selectively in tumour tissues make them disastrous
to patients. Moreover, the drugs can be deactivated by proteins found in the
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blood plasma decreasing the circulation half-life of the drugs in the blood stream
and increasing the dose required.
Drug delivery systems increase the solubility of hydrophobic drugs. They
protect the drug from deactivation caused by their interaction with proteins in
the blood and prevent fast clearance by the Reticulo Endothelial System (RES),
such as the liver and spleen, so increasing the circulation half-life of drugs in the
blood stream and consequently reducing the drug dose required. Drug delivery
systems potentially increase cellular uptake bypassing drug resistance mechanism
of the cell and accumulating selectively in specific tissues through the Enhanced
Permeability and Retention effect (EPR effect) (Figure 1.2) [2, 3].
Figure 1.2: Schematic representation of the mechanisms by which polymeric
nanocarriers can deliver drugs to tumours. Passive tissue targeting is achieved
by extravasation of nanoparticles through the increased permeability of tumour
vasculature and ineffective lymphatic drainage (EPR effect). Active cellular tar-
geting (inset) can be achieved by functionalizing the surface of nanoparticles with
ligands that promote cell-specific recognition and binding. The nanoparticles can
(i) release their contents in close proximity to the target cells; (ii) attach to the
membrane of the cell and act as an extracellular sustained-release drug depot;
and (iii) migrate into the cell [3].
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While free drug can traverse blood vessels freely, polymeric carriers can pref-
erentially penetrate into tumour tissue, which shows hyperpermeable vasculature
and lack of lymphatic system, through passive targeting. Drug delivery systems
can also be tailored by introducing targeting functionalities that can be recognised
by receptors overexpressed in cancer cells. Finally, the drug can be released by
the delivery system in a triggered manner, avoiding peaks in drug concentration
in the blood which can be toxic to the patient.
The therapeutic window for any particular drug is defined by the upper toxic
limit and the lower efficacy threshold. Drug concentrations above the toxic limit
can be excessively harmful to the patient, while a drug concentration below the
lower threshold would be ineffective. The therapeutic window varies with the
drug and from patient to patient. When using conventional drugs, the concentra-
tion of the drug in the blood increases immediately after administration, peaks
and then declines quickly. Thus, multiple administrations are required to keep
the drug concentration in the body within the therapeutic window. When us-
ing a controlled drug delivery system, the drug concentration rises slowly after
administration reaching a plateau within the therapeutic window and remains
constant for a long period. As shown in Figure 1.3 conventional drugs need to
be administrated to the patient several times, nevertheless the concentration of
the drug within the therapeutic window will be limited. On the other hand, the
concentration of the drug will remain within the therapeutic window for a longer
period of time after injection when released from a controlled the delivery system.
Polymer nanocarriers (PNs) can be prepared by self-assembly of amphiphilic
block copolymers and different shapes and sizes can be achieved. The most
common PN architectures are core-shell micelles which consist of a hydropho-
bic core, where the drug is usually encapsulated, and a hydrophilic shell, which
allows the carrier to be soluble in an aqueous medium. Vesicular and cylindri-
cal morphologies can also be obtained by tailoring the block copolymer features.
One of the advantages of working with synthetic polymers is that a wide va-
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Figure 1.3: Drug concentrations at site of therapeutic action after delivery as a
conventional injection (blue line) and as a controlled release system (green line).
riety of monomers can be used. The polymerization techniques are now well
established and polymers with well-controlled composition, length and architec-
ture can be easily prepared. However, synthetic polymers only passively target
tumours unless purposefully modified with targeting moieties. They have amor-
phous structure unless they are amphiphilic and they have low biocompatibility
and biodegradability. For these reasons, their approval process for clinical use is
generally very long and, to date, only a few polymer drug delivery systems have
made it to the clinic. More recently, the focus of research has moved towards more
biocompatible and biodegradable polymers such as those based on carbohydrates
and peptides.
When engineering a polymer nanocarrier many parameters need to be consid-
ered: size, shape, surface chemistry and charge largely affect the efficacy of the
carrier. Particle size plays an important role in particle functions and it influences
its degradation, vascular dynamics, clearance and uptake mechanisms [4]. Parti-
cle size can also affect velocity, diffusion characteristics and adhesion properties
[5] resulting in different uptake efficiencies [6, 7, 8]. On the one hand, the PNs
need to be large enough to prevent rapid leakage into blood capillaries, on the
other hand, they have to be small enough to escape the capture of macrophages
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in the RES. Other than size, recent studies have shown that the PN shape can
also have an effect on its function, especially in biological processes, including
internalization, transport through the blood vessels and targeting the sites of
disease [9, 10, 11]. The surface characteristics of PNs have also been largely
studied. It has been observed that surface features can determine the life-span
of PNs during circulation in the blood stream [12]. An example is the effect of
surface charge which can affect cell internalization: positively charged particles
have been shown to exhibit higher internalization by macrophages and dendritic
cells compared with neutral or negatively charged particles [13], although this
effect could also be cell-type dependent [14]. Active targeting can be achieved by
decorating the surface of the PN with targeting ligands recognisable by specific
receptors overexpressed in cancer cells. Targeting ligands such as folic acid, anti-
bodies, cyclic RGD-peptides or aptamers, can enhance the cellular uptake of the
drug delivery system into cancer cells, reducing the amount of drug internalised
by healthy cells [15, 16, 17, 18, 19]. However, targeting ligands can also increase
the undesirable accumulation of PNs in the RES [20].
1.2 Literature review
1.2.1 Metal based anti-cancer drugs
Medicinal inorganic chemistry receives rising interests in the area of biomedi-
cal applications. Metals are not only part of vital processes in the body such
as enzyme driven reactions, but can also be used as therapeutic and diagnostic
agents. Application of metal containing compounds can range from MRI agents
(e.g. Gd, Mn), radiopharmaceutical diagnostic and therapeutic agents (99Tc
and 90Y), enzyme inhibitors to therapeutic agents (e.g. Li, Pt, Au, Bi) [21].
Platinum complexes are widely used for the treatment of cancer [22]. Cisplatin,
cis-diamminedichloroplatinum(II) (CDDP), was discovered in 1965 by Rosenberg
and his co-workers [23] and obtained FDA approval in 1978 for cancer treatment.
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The immediate success in cancer treatment was overshadowed by significant side
effects [24]. Since then a frantic search has begun to design derivatives with the
same efficiency, but significantly reduced side effects. However, apart from cis-
platin, very few platinum compounds have received worldwide approval for clinical
use. Among the most effective platinum drugs studied, oxaliplatin, satraplatin,
tetraplatin, iproplatin, and ormaplatin appear to be potent anticancer agents and
they are especially used to treat cisplatin resistant tumours [25, 26].
Platinum drugs consists of two different types of ligands (Figure 1.4). One
ligand, usually based on N, binds strongly to the Pt ion. Indeed, classic platinum
complexes have at least one ligand based on N with the activity of the platinum
drug increasing according to NR3 (inactive, R=alkyl), NHR2 <NH2R, NH3. The
other ligand is the leaving group, which is typically chloride or carboxylate. This
leaving group should be moderately bound to platinum. Highly labile ligands
such as NO−3 would result in high toxicity while strong ligands such as N
−
3 , SCN
−
or CN− cause the platinum complex to be inactive.
Figure 1.4: Representation of platinum based drugs.
The varying reactivities of these next generation platinum complexes have
different solubilities and different rates of aquation. Platinum complexes have
to be activated by substituting the chloride or carboxylate ligands with water, a
process which is facilitated by the low intracellular chloride concentration. The
anti-tumour activity of platinum complexes is accredited to the reaction between
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the metal and predominantly the DNA. Purines are thought to be the major tar-
get for platinum, which leads to cell death. However, some cells develop resistance
towards platinum drugs and do not respond to therapy [25, 27]. A major dis-
advantage of platinum drugs is their deactivation caused by reaction with thiols.
This occurs when the platinum drug travels in the blood stream and reaches the
target where thiols are abundant in peptides and proteins. In the cytoplasm, the
activated aqua species preferentially reacts with species containing sulphur such
as cysteine or methionineamino acids. These species include the tripeptide glu-
tathione or metallothioneins. In some platinum-resistant cancer cells, glutathione
and metallothionein levels are relatively high, so activated platinum is effectively
mopped up in the cytoplasm before DNA binding can occur, thereby causing
resistance [25]. While cisplatin was the first platinum anticancer drug, it has
major drawbacks as outlined above: not only the resistance of some cell types
against this drug, but also its high toxicity that can lead to significant side effects
[27].
The next generation of platinum drugs had either different amine ligands to
replace NH3 or different leaving ligands to replace chloride. Pt(IV) complexes,
however seem to have higher stability and reduced toxicity compare to Pt(II)
complexes. Most efforts have been focused on Pt(II) complexes but these cannot
be administered orally due to their low solubility and low bioavailability. The
chemistry of platinum(IV) is well understood and Pt(IV) complexes present a
promising alternative to Pt(II) complexes.
All these platinum drugs have DNA as their final target. Inspired by the suc-
cess of platinum drugs, structurally related metal complexes were investigated.
Ru(II) and Ru(III) exhibit indeed similar activities [26]. Among the range of
Ru-complexes tested, NAMI-A and KP1019 have already entered clinical trials
[28]. A unique feature of some ruthenium complexes is their activity towards
metastatic cancer. Osmium can be found right below ruthenium in the periodic
table. Designing an anticancer drug from osmiumis is more challenging since
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osmium compounds tend to be more toxic. However, a group of promising os-
mium complexes has recently been developed, which similarly to cisplatin binds
to the DNA at N7 of guanine [26]. While the intended target of these drugs
is mainly the DNA, other metal complexes have been developed that interfere
with cellular signalling pathways [26]. However, the mode of activity of some
drugs has yet to be verified in detail. Cobalt based drugs, for example, are
likely to inhibit cyclooxygenase -1 and -2, while some ruthenium drugs inhibit
kinase, which regulates the tumour protein p53. Gallium complexes in contrast
inhibit the ribonucleotide reductase, which enables the formation of deoxyribonu-
cleotides. Interesting is the rediscovery of gold complexes, which have been used
extensively in the past to treat rheumatoid arthritis. It is evident that they can
be highly efficient anticancer agents, especially in cases where the cell lines have
developed a resistance to cisplatin. Gold complexes interfere with glutathionere-
ductase (hGR) and thioredoxin reductase (hTrxR) located in the mitochondria
[29].
Cisplatin and the second-generation metal-drugs are highly effective in the
battle against cancer. The down side of treatment is the significant side effects
cause by the systemic distribution of the drug. Furthermore, the efficiency of in
vivo application succumbs to the low hydrolytic stability of some of these drugs
as well as the high reactivity towards proteins [25]. Metal-complexes (Figure
1.5) therefore benefit immensely from a drug delivery system that enables the
protection of the drug while enhancing the delivery of the drug to the cancer via
passive or active targeting [30]. [25]
1.2.2 Platinum Chemotherapeutics and mechanism of ac-
tion
As mentioned in the previous section, platinum drugs consist of two different
type of ligands: one permanent and one more labile (Figure 1.4). The kinetics of
ligand exchange is affected mainly by the following factors: the oxidation state
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Figure 1.5: Structure of common metal complex drugs [25]
of central metal atom, its geometry, the electron configuration and the ligand
effects [23]. Cisplatin is injected into the body rather than taken orally due to
solubility problems. The drug is supplied as a lyophilized powder containing
sodium chloride, mannitol and hydrochloric acid for pH balance. It is then recon-
stituted with 10mL of sterile water for injection [31]. Following administration
in the bloodstream, cisplatin encounters a relatively high chloride concentration
(approximately 100mM) that limits replacement of its chloride ligands by water
molecules and the process of aquation is prevented. Cisplatin enters the tumour
cells, mainly by diffusing through the cell membrane, where the chloride concen-
tration is relatively low (approximately 4 to 20mM) and hence one or both chloro
ligands of cisplatin are replaced by water, forming a reactive, positively charged
species that cannot readily leave the cell (Figure 1.6).
After hydrolysis cisplatin penetrates the nucleus and forms covalent bonds
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Figure 1.6: Representation of mechanism of action of cisplatin. Adapted from
[32].
with the DNA changing its structure. Because paltinum belongs to the group of
"soft" metal ions it reacts preferentially with N atoms rather than O atoms. In
fact, the preferred site in DNA is N7 of purine nucleobases. In double-stranded
DNA the only nitrogen atoms which are not involved in hydrogen bonds and
are available for coordination with Pt are N3 and N7 of purines. However, N3
is sterically hindred, therefore only N7 is left. In single-stranded DNA N1 of
the adenine and N3 of the cytosine are also capable of Pt binding. Finally,
all protonated nitrogen atoms of purines and pyrimidines have the lone pair of
electrons delocalized on the aromatic pi-system of the ring to which they belong
or are attached to, therefore they become available for coordination to Pt only
after deprotonation. N7 of both adenine and guanine can be platinated, however,
N7 of guanine shows a greater kinetic preference. This tendency results from
the stronger basicity of that nitrogen and from possible simultaneous hydrogen
bond interactions between ammine protons of cisplatin and O6 of guanine. The
reaction of cisplatin with DNA leads to the formation of at least six different
types of Pt-DNA adducts (Figure 1.7).
The major adduct formed by cisplatin was found to be the 1, 2 intrastrand
crosslink between adjacent guanine bases (d(GpG), 60-65% of all adducts); fol-
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lowed by 1, 2 intrastrand crosslink between adjacent adenine and guanine bases
(d(ApG), 20-25% of all adducts); 1, 3 and 1, 4 intrastrand crosslink between
purines separated by one or two intervening bases (d(GXG) or d(GXXG) where
X stand for a deoxyribonucleotide other than G, 3-7% of all adducts) [25]. The
structure of platinated DNA is significantly distorted, resulting in a decrease of
melting point, shortening, unwinding and local denaturation. This distortion
results in the inhibition of DNA replication and transcription (Figure 1.8).
Figure 1.7: Possible paltinum binding sites on DNA
Figure 1.8: Main adducts formed in the interaction of cisplatin with DNA: (A) 1,3
intrastrand crosslink; (B) 1,2 intrastrand crosslink; (C) 1,2 intrastrand crosslink.
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A large number of platinum(II)-based compounds structurally similar to cis-
platin have been developed and tested over the years [33, 34, 35]. Carboplatin and
oxaliplatin both possess some advantages over cisplatin but the issues of adverse
side effects and resistance persist. Hence, platinum(II)-based drugs administra-
tion is often limited [36]. Overlooking the drawbacks, platinum drugs are still the
most common treatment for cancer patients, with an estimated 50 to 70% be-
ing treated with platinum-based drugs. To circumvent the drawbacks of current
platinum(II)-based drugs there has been a search towards new platinum drugs
that are structurally different to cisplatin and demonstrate different modes of
binding. In recent years, a number of multinuclear platinum complexes have been
developed with the aim of increasing activity and overcoming cisplatin side effects
and resistance. A number of these complexes have shown activity in both cis-
platin sensitive and cisplatin resistant cell lines. The trinuclear platinum complex
BBR3464 (Figure 1.9) consists of two terminal trans-platinum(II) constituents ca-
pable of coordinate binding to DNA; each is bound to a 1,6-diaminocyclohexane
ligand that is connected to the trans-platinum(II) centre, which is capable of
minor binding. The relatively large positive charge (+4) of BBR3464, compared
to cisplatin, increases both its binding affinity for DNA and cellular uptake [37].
While BBR3464 has shown promising in vitro and in vivo activity compared to
cisplatin [38], phase II clinical trials have shown only partial responses with cis-
platin resistant ovarian and non-small-cell lung cancers. Minimal activity against
gastric carcinomas was also observed, with significant toxicity and side effects ex-
perienced by many patients, resulting in a poor maximum tolerated dose (MTD)
[39].
Figure 1.9: Chemical structure of BBR3464 [37].
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Another class of compounds that has been well investigated over the past
thirty years are platinum intercalators. The early work of Jennette et al. [40]
focused on terpyridine complexes (Figure 1.10a) and demonstrated the intercalat-
ing ability of square-planar platinum complexes. These compounds interact with
DNA through the reversible insertion of the molecule between the base pairs. This
causes unwinding and lengthening of the DNA, thereby preventing replication.
McFayden et al. [41], in the '80 developed a series of complexes containing
methylated derivatives of 1,10-phenanthroline (Figure 1.10b), with a structure-
activity relationship based on the degree and position of methylation. This work
has been extended by the Aldrich-Wright research group over the past years. A
wide range of intercalating and ancillary ligand combinations have been examined
to develop a structure-activity relationship.
(a) (b)
Figure 1.10: (a) Chemical structures of the terpyridine complexes of Jennette et
al. 1.10a; b) Chemical structure of the terpyridine complexes of McFayden et al.
[41].
The Aldrich-Wright group has studied the non-covalent interaction between
positively charged metallo-intercalators and the base-pair stack of DNA [42].
An investigation into the relationship between molecular structure and biolog-
ical activity of platinum(II) compounds containing methylated derivatives of
1,10-phenanthroline (Figure 1.11) has determined that the position and num-
ber of methyl groups on the 1,10-phenanthroline structure influences biological
activity. In vitro cytotoxicity assays showed the following activity: [Pt(en)(5,6-
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Figure 1.11: Chemical structures of (a) [Pt(en)(phen)]2+; (b) [Pt(en)(4-
Mephen)]2+; (c) [Pt(en)(5-Mephen)]2+; (d) [Pt(en)(4,7-Me2phen)]2+; (e)
[Pt(en)(5,6-Me2phen)]2+ and (f) [Pt(en)(3,4,7,8-Me4phen)]2+ [42].
Me2phen)]Cl2 >[Pt(en)(5-Mephen)]Cl2 > [Pt(en)(phen)]Cl2 with IC50 < 10µM
against the L1210 cell line. The complexes [Pt(en)(4-Mephen)]Cl2, [Pt(en)(4,7-
Me2phen)]Cl2 and [Pt(en)(3,4,7,8-Me4phen)]Cl2 were inactive (IC50 >50µM).
The induced circular dicroism studies of the complexes with DNA were con-
sistent with an interaction and indicated that some small, but different, struc-
tural/conformational changes result when these compounds interact with DNA.
Also, viscometry and linear dicroism experiments indicated that all the plat-
inum(II) complexes intercalate into the base pair stack at a [Complex]/[DNA] ra-
tio of 0.25. Finally, 1D and 2D 1H NMR studies with the hexamer d(GTCGAC)2
were used to probe the location and orientation of the binding interaction. For
each of the metal complex studied with d(GTCGAC)2, intermolecular NOE data
and observed changes in chemical shift suggested that the Pt(en)(Menphen)]Cl2
complexes bind the hexanucleotide by intercalation from the minor groove, and
predominantly, between the T2-A5 and C3-G4 base-pairs. [Pt(en)(phen)]Cl2 re-
sulted to be the most efficient intercalator of the platinum(II) complexes investi-
gated.
Another group of platinum(II)-based DNA intercalators developed in Aldrich-
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Wright laboratories are of the type [Pt(IL)(AL)]2+ where IL is an intercalating
ligand (similar to the ones seen above) and AL is an ancillary ligand (Figure 1.12)
[43]. Some of these have demonstrated significant potential against human cell
lines in vitro, including those that show resistance to current chemotherapeutic
agents. It was shown that the type and chirality of the ancillary ligand, along
with functional group substitution on the intercalating ligand, play an important
role in cytotoxic activity [44].
Figure 1.12: Chemical structures of platinum(II)-based DNA intercalating com-
plexes. Stereocenters are indicated by (*) and are either S or R. Charges (2+ for
all complexes) have been omitted for clarity; counterions are chloride or perchlo-
rite [44].
An interesting structural feature of these new cytotoxic platinum complexes
is the absence of anionic ligands (e.g., chloride) that serve as leaving groups in
traditional platinum antitumour agents that act by platination of DNA. Instead,
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the coordination spheres of these platinum complexes are filled with four relatively
stable, bound nitrogens of two chelating ligands. Thus, it would not appear that
covalent binding between the platinum complex and DNA is responsible for their
potent cytotoxicity.
The cytotoxicity of compounds 1-7 (as perchlorate salts) (Figure 1.12) in a
variety of cell lines has been studied [45], as well as the cytotoxicity of the water-
soluble compounds in the murine leukemia (L1210) cell line [46]. Among these
compounds, 5 results to be the most effective displaying cytotoxicity up to 100-
fold greater than that of cisplatin in the L1210 cell line. The compounds 8 and
9 with the ancillary ligand 1,2-diphenylethanediamine and the compounds 10,
11 and 12 with fluorinated derivatives have been used to mimic the synthetic
estrogens diethylstilbestrol and hexestrol in an attempt to target the estrogen
receptor system.
The biological activity of these compound has been tested in seven human
cancer lines. The compounds 1-7 have a lower IC50 value than cisplatin and
[Pt(rac-dach)Cl2] in all but one (HL60) of the cell lines. Compound 5 incorpo-
rating the 1S, 2S -diaminocyclohexane ancillary ligand resulted more active than
the comparable compounds containing 1S, 2S - diphenylethanediamine (8) and
rac-1,2-bis(4-fluorophenyl)-1,2-ethylenediamine (12) in the 5637 cell line.
The stereochemistry of the ancillary ligand has an effect on the overall activity
of the metal complex, with the S, S enantiomers often being more active than the
R, R compounds (e.g, 1 and 2, 5 and 6), although this trend is not observed with
all ancillary ligands (e.g., 8 and 9). Furthermore, preliminary in vivo studies on
compound 1 have shown low toxicity and reduced tumour growth, demonstrating
the potential of this class of compounds [47].
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1.2.3 Polymer nanoparticles for the delivery of platinum
drugs
Metal-based anticancer drugs, in particular platinum-drugs, have been investi-
gated for the treatment of cancer for the last 50 years. A small set of platinum-
based drugs have meanwhile received FDA approval for the treatment of various
cancer. Cisplatin and its relatives are currently one of the most widely used anti-
cancer drugs. The use is however associated with significant side effects and rising
drug resistance. To combat these problems, drug delivery carriers have been de-
veloped to increase the protection of the drug and increase efficacy. Metal-based
drugs represent a rather unique drug delivery challenge. Most anticancer drugs
are either physically encapsulated into a polymer matrix or they can be conju-
gated to the polymer via a degradable linker. While both pathways are possible
for metal-based drugs, the conjugation to the polymer can be carried via labile
or permanent ligands. In addition, the prodrug strategy using the drug in the
higher oxidation state is a common approach that has been widely tested for
platinum drug. The delivery of platinum drugs is now a mature field and the
various conjugation techniques have been combined with a range of drug carri-
ers including dendrimers, micelles and solid polymer nanoparticles. Hybrids of
macromolecular metal complexes with inorganic nanoparticles have been tested
in recent years to combine the ability to deliver the drug with imaging properties.
An emerging trend is the surface decoration of the polymeric nanoparticles with
targeting ligands such as folates. The advanced state of this field is evident by
the fact that some macromolecular platinum drugs even advanced to the clinic.
Strategies for the design of drug delivery systems for metal-complexes
The reasons mentioned above have motivated researchers to focus on the design
of carriers able to load, transport and deliver the drugs in a controlled manner.
Drug delivery using polymers is now is an established approach for traditional
anticancer therapies. Typically these drugs are either physically encapsulated
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into the polymer matrix or they are bound to the polymer as drug conjugates,
often via a degradable linker. The researchers can, in theory, choose from either
physical encapsulation or drug-conjugation when developing a drug carrier for
platinum complexes (Figure 1.13). However, their often unique solubilities and
the chemistry can limit some of the approaches while opening up new opportu-
nities in the area of polymer-drug conjugates. While physical encapsulation is
common for many drugs, it is rarely explored for metal complexes. Physical en-
capsulation strongly depends on the compatibility of the drug with the host and,
considering the polar nature of many platinum drugs, that can be a challenging
task. Only a few delivery systems, where the metal is not conjugated to the
polymer matrix, have been described in the literature. Besides polymeric nano-
and micro-particles, the encapsulation into liposomes was found to be particu-
larly promising. Polymer-drug conjugation is by far the dominant approach in
this field. Covalent attachment can be a useful tool to delay and even trigger the
release once the drug carrier reaches its target [48].
To understand the different pathways, the structures of metal-complexes need
to be considered. The metallodrugs may have higher or lower oxidation states
that are either inactive or too toxic. The active oxidation state for platinum
and ruthenium is +2, while gold-complexes have the oxidation state +1. These
metal ions are surrounded by ligands, which can be typically divided into two
groups: the permanent ligands, often amines or phosphines, are permanently
bound, while labile ligands, which are often halogenides or carboxylates, tend to
leave the complex. This labile ligand is often the key to the success of the drug
since the replacement of this ligand by water activates the drug. An elegant way
of conjugating metal-drugs to polymer is via prodrug strategies that employs the
inactive, oxidized state of the metallodrug. In a reductive environment, such as
the one present in the intracellular matrix, the drug is reduced to its active coun-
terpart and simultaneously cleaved from the polymer.
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Figure 1.13: Pathways to drug delivery systems for platinum drugs.
All four approaches have been widely used for the delivery of platinum drugs.
Conjugation strategies of other metal-drugs have undergone some initial explo-
rations by our group, but the field is still in its infancy. The next section discusses
the recent developments in the design of drug carriers for platinum drugs are dis-
cussed. Finally, advancements in the conjugation of other metal drugs will be
briefly summarized.
Very often, no distinction between physical encapsulation and chemical bind-
ing can be made. A polymer may be designed to only encapsulate the metallo-
drug, but functional groups within the polymer may also act as efficient ligands,
affecting loading and release. An important contribution to the interaction be-
tween synthetic and natural polymer and a metal-based drug, in this case cis-
platin, has been published by Schechter et al [49]. The authors mixed various
polymers with cisplatin and tested the in vitro and in vivo activity. Their study
highlighted that only a window of opportunity exists where the drug is protected
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without being inactive. They study emphasized the importance of the interplay
between drugs and polymers. The following groups were identified amongst others
[49]:
(a) The drug forms a highly stable complex with the polymer, which does not
permit drug release and are consequently totally inactive against tumour cells
both in vitro and in vivo (example: cisplatin with DNA);
(b) Low-capacity complexes that bind limited amounts of drug, only part of
which is reversibly bound (example: cisplatin with protein);
(c) Low-affinity complexes of relatively low drug content, the activity of which
is not different from that of free cisplatin (example: hyalorunic acid (HA));
(d) Moderately stable complexes of relatively high content of releasable drug,
this group has the best in-vitro and in-vivo outcome. Examples include: car-
boxymethyl dextran (CM-dex), poly(L-glutamic acid) (P(Glu)) and poly(L-aspartic
acid) (P(Asp)).
1.2.4 Physical encapsulation
Physical encapsulation of drugs into a carrier is a commonly applied strategy. In
general, drug loading and release is determined by the compatibility of the drug
with the surrounding matrix: the more compatible drug and polymeric matrix
are, the higher is the loading capacity and the slower the release. In the case of
a non-degradable polymer matrix with no stimuli-responsive features, the rate of
release is usually determined by the concentration gradient of the drug and its
diffusion rate. Other factors that influence the release profile of the drug are:
size, type, geometry and stability of the delivery system; type of polymer and its
interaction with the drug; ratio between drug and polymer; temperature and pH.
Different delivery systems have been employed as host for platinum drugs in-
cluding liposomes (also known as vesicles), polymeric nano- and micro-particles
which can host the platinum drug via supramolecular chemistry. Liposomes are
usually based on low-molecular weight surfactants and are not related to poly-
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mers. However, they have been included in the discussion here for completeness.
Liposomes
Liposomes, or vesicles, are lipid bilayers spherical membranes with an internal
aqueous volume. Their structure makes them a universal carrier system for hy-
drophilic, lipophilic and amphiphilic drugs [50]. The incorporation of Pt(II) based
drugs in liposomes is limited by its poor water solubility and low lipophilicity
which leads to a very low drug-lipid ratio and to an unstable liposomal system
especially when injected into the blood stream [51]. Drug-lipid ratio can be in-
creased by taking advantage of the limited solubility of Pt(II) drugs in water. In-
deed, a dry lipid film composed of equimolar amounts of dioleoyl phosphatidylser-
ine (DOPS) and dioleoyl phosphatidylcholine (DOPC) can be hydrated in a
buffered solution (pH=7.4) with 5mM cisplatin followed by 10 freeze-thaw cycles
and removal of free cisplatin by centrifugation. To facilitate the encapsulation
of Pt(II) drug into a liposome one can also use negatively charged phospholipids
which will establish electrostatic interactions with positively charged aquo species
of cisplatin. This will force the drug to form aggregates surrounded by a lipid
bilayer [52]. This kind of systems has been shown to have a cytotoxicity about
three order of magnitude higher than free cisplatin [53].
Cis-bis-neodecanoato-trans-1R,2R-diaminocyclohexane platinum(II) (NDDP),
a structural analogue of oxaliplatin (Figure 1.14), was incorporated into a mixture
of dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylgycerol
(DMPG) at a molar ratio of 7:3. This liposomal formulation is called aroplatin,
also known as L-NDDP. During phase II clinical trial of L-NDDP in patients with
advanced colorectal cancer (CRC) L-NDDP was well tolerated by patients and
45% of them was able to receive an elevated dose of 375mg/m2 during the course
of treatment. However, 40% of patients experienced shortness of breath along
with back or chest pain of grade 1-3 severity. The trial results obtained using
aroplatin are comparable to reported response rate of single-agent oxaliplatin in
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metastatic CRC patients [54].
Figure 1.14: Cis-bis-neodecanoato-trans-1R,2R-diaminocyclohexane plat-
inum(II) (NDDP) structure.
One of the weaknesses of liposomes is the lack of stability. Coating the surface
of the liposome with a biocompatible hydrophilic polymer such as poly-[ethylene
glycol] (PEG) increases the stability of the delivery system. PEGylated lipo-
somes, also known as Stealth liposomes, are able to avoid detection by the body's
immune system, specifically, the cells of reticuloendothelial system (RES) and
they have a prolonged circulation time thus allowing the accumulation on the
tumour tissues via the EPR effect [55, 56, 57]. A Stealth liposome formula-
tion, identified as SPI-077, encapsulates cisplatin in the aqueous core of sterically
stabilized liposomes made of hydrogenated soy phosphatidylchlorine (HSPC),
methoxypolyethyleneglycol-distearoyl phosphatidyl-ethanolamine (PEG-DSPE)
and cholesterol in a molar ratio of 51:5:44 [51]. The SPI-077 has a half-life of
30 to 40 h in animals and 40 to 50 h in humans. In tumour bearing mice it
shows a superior antitumour activity compared to the same cumulative dose of
cisplatin in murine colon and lung cancer models. In addition, it has been shown
that mice can tolerate a single intravenous SPI-077 dose of 100mg/kg without
mortality whilst the highest tolerated single dose LD50 of cisplatin is 12mg/kg
[51, 53] but SPI-077 has also been reported to be inactive to squamous cancers
of the head and neck [58]. Despite the promising properties of SPI-077, more
research is needed to determine its ability to carry and locally release cisplatin
into tumourous tissue. Difficulties arise when determining the kinetics of the local
release of drug as it is problematic to distinguish between liposomal encapsulated
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drug and free drug in solid tissue [59].
Another formulation of Stealth liposomes is Lipoplatin, composed by 8.9% cis-
platin and 91.1% lipids. The lipid component consists in dipalmitoyl phosphatidyl
glycerol (DPPG), soy phosphatidyl choline (SPC-3), cholesterol and polyethylene
glycol-distearoyl phosphatidtylethanolamine (mPEG 2000-DSPE) [60]. In phase
I and II clinical studies, using a combination of lipoplatin and gemcitabine, there
was no observation of nephrotoxicity, neutrotoxicity, hepatoxicity or ototoxicty
[61]. Results obtained from ongoing phase III clinical studies suggested that
lipoplatin has a higher therapeutic index than cisplatin treatment of non-small
cell lung cancer [62, 63].
Nano- and micro-particles
Nanoparticles can be used for the delivery of various classes of drugs such as
anticancer agents, antihypertensive agents, and macromolecules such as nucleic
acids, proteins, peptides, and antibodies. The nanoparticles used for drug de-
livery have a size range generally between 10-1000 nm and their performance in
vivo depends on morphology, surface chemistry [53] and molecular weight. As
highlighted above, the physical encapsulation of platinum drugs into a polymer
matrix is often challenged by the nature of the drug. The high solubility of the
drug in polar solvent often results in low compatibility of the drug with the poly-
mer matrix. As a result, the platinum drugs explored for physical encapsulation
often carry hydrophobic ligands to increase their oil-solubility.
Nanospheres
Solid nanoparticles can be prepared with various methods including emulsion
polymerisation, interfacial polymerisation, desolvation, solvent evaporation and
solvent deposition [64]. These conventional methods suffer from low encapsulation
efficiency. The new double emulsion solvent diffusion technique is a combination
of double emulsion solvent evaporation technique with partially water miscible
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organic solvent. This technique offers better encapsulation yield of hydrophobic
drugs in nanoparticles [65]. The biocompatibility and pharmacokinetics of en-
capsulated cisplatin in PLGA-mPEG nanoparticles have been tested. The size of
the particles vary between 110 to 150 nm and, with a drug loading efficiency of
only 0.5-1% (w/w), the rate of in vitro degradation, in PBS at pH=7.4, is de-
pendent upon the ratio of poly(D,L-lactic-co-glycolic acid) (PLGA) and methoxy
poly(ethylene glycol) (mPEG) segments. The rate of degradation increases when
the mPEG:PLGA ratio increases [66]. In tumour bearing mice, 5mg/kg of cis-
platin loaded PLGA nanoparticles showed a higher activation of apoptosis in
tumour compared to the free drug [67].
Chitosan is a modified natural biopolymer derived from crustacean shells such
as crabs, shrimps and lobsters which can be used for drug delivery due to its
biocompatible and biodegradable properties [68]. Nano-sized glycol chitosan par-
ticles (300-500 nm) were modified with hydrophobic cholanic acid to form aggre-
gates which can encapsulate cisplatin in their hydrophobic cores. The release of
the drug occurs in a sustained manner for a week but the cytotoxicity is inferior
to free cisplatin however, in vivo studies on tumour bearing mice confirmed their
targeting ability and prolonged circulation time [69].
An effective approach to enhance the specificity and uptake of the carrier is
targeting of the nanoparticle surface with specific ligands. Tumour cells over-
express transmembrane protein that can be receptor for biomolecules such as
peptides segments, proteins or sugar molecules. These bioactive groups can be
integrated in the polymeric carrier as targeting moieties. In this regard, apo-
ferritin, a protein found in the intracellular fluid that stores iron and releases it
in a controlled manner, can help to enhance the localisation and uptake of drug
towards the tumour tissues [70, 71].
Recent years saw a push to develop systems for the co-delivery of two drugs.
To enhance the activity of Pt(IV) drugs, multifunctional system, which combine
the platinum drug with an inhibitor, have been developed to overcome drug re-
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sistance. Although this new generation of Pt(IV) drugs show better cytotoxicity
than cisplatin and its analogous in different cell lines, they present the same kind
of solubility, transport and specificity of the approved platinum drugs [72, 73].
Nevertheless, the idea of combining platinum drugs with inhibitors has not been
abandoned; in contrast, the attention has been moved to platinum-inhibitor drugs
which can be loaded into polymeric delivery systems. Aryal et al. [74] has re-
cently developed a paclitaxel-cisplatin(IV) conjugate where Pt(IV) is also con-
nected to paclitaxel, a mitotic inhibitor, on its 20-position (Figure 1.15). This
system has been successfully encapsulated into a lipid polymer hybrid nanopar-
ticle with controllable drug loading yield and drug release profile. The cyto-
toxicity of the paclitaxel-cisplatin(IV) drug conjugate loaded nanoparticles was
investigated against human ovarian cancer cells and compared to that of the free
drug conjugates. It was found that the cellular cytotoxicity of the paclitaxel-
cisplatin(IV) drug conjugate is significantly improved after being encapsulated
into the nanoparticles.
Figure 1.15: a) Schematic illustration of a lipid-coated polymeric nanoparticle en-
capsulating paclitaxel-Pt(IV) conjugates; b) chemical structure of the paclitaxel-
Pt(IV) conjugate. Adapted from [74].
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Microspheres
Biodegradable microsphere can also be employed to encapsulate chemotherapeu-
tics with the advantage of a controlled and prolonged release of the drug and
a good acceptability from the patients [75]. The drug distribution in the mi-
crosphere depends on the ratio between poly(D, L-lactic acid) (PLA) and PLGA
resulting in two different morphologies: a) microspheres with drug located in
the core of the particle covered by non-drug layer, and b) microsphere with the
drugs located in the shell [76] (Figure 1.16). Therefore, the drug release rate
at a steady state depends on the structural integrity of the drug containing and
drug-free layer of the microspheres.
Figure 1.16: Localisation of drug powder in either the internal (PLGA) core or
outer (PLA) layer [76].
The techniques generally used for the synthesis of microspheres include: sol-
vent evaporation, phase-separation, and spray-drying; among these, the most fre-
quently used method is the solvent evaporation of oil-in-water emulsion. These
methods, however, result in low encapsulation efficiency and thus produce in an
initial burst of drug from the microspheres. Mastumoto et al. have developed a
new polymer-alloy method to prepare PLA and PLGA microspheres where the
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drug is distributed in the internal layer with an encapsulation efficiency of almost
100% resulting in an overall 10% drug loading capacity [77]. The initial burst-
release of drug was prevented improving the drug release profile and systemic
administration. Moreover, polylactic acid based microcapsules with an albumin
have demonstrated linear release kinetics [78], after a 30min lag phase, due to
the inhibitory effect caused by the crosslinking between the albumin coated mi-
crospheres and the proteins [79].
Micelles
Polymeric micelles have been successfully employed for the encapsulation of Pt(IV)
prodrugs. The versatility of the chemistry of Pt(IV) drug is an advantage: the
modification of the axial ligand with esters allows a better oil-solubility and thus
better loading in micelles. Thanks to their biocompatibility and biodegradabil-
ity, PLA, PLG (poly(glycolide)) and PLGA have been extensively explored to
formulate nano- and micro-particles suitable for drug delivery [80].
Dhar et al. employed nanoparticles of PLGA-PEG with prostate-specific
membrane antigen to deliver Pt(IV) drugs to prostate cancer cells (Figure 1.17).
The anticancer activity of the Pt(IV)-encapsulated targeted nanoparticles was
found to be superior to that of free cisplatin and similar to that of the non-
targeted nanoparticles [15].
Another hydrophobic drug, cis-bis(cyclohexylamine) dinitratoplatinum(II),
(cis-(cha)2Pt(NO3)2), was encapsulated by macromolecular micelles self-assembled
from an amphiphilic cyclotriphosphaze with the formula [N=P(X)(Y)]3 prepared
by stepwise substitutions of cyclic chlorophosphazene [N=PCl2]3 with equimolar
hydrophilic (X) and hydrophobic (Y) nucleophiles in cis-non-geminal arrange-
ment (Figure 1.18) [81, 82]. In particular, these tripodal amphiphiles with mPEG
as the hydrophilic group and a linear oligopeptide as the hydrophobic group self-
assemble into stable spherical micelles with a mean diameter of 7.4 to 13.9 nm
[83].
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Figure 1.17: Encapsulation of Pt(IV) drugs into polymeric micelles with prostate-
specific membrane antigen on the micelle surface. Scheme adapted from [15].
Figure 1.18: Conceptual diagram for micelle-encapsulation of cis[(cha)2Pt(NO3)2]
using an amphiphilic cyclotriphosphazene [NP(mPEG750)(GlyPheLeu)2Et]3
(CP750) in aqueous solution. Scheme adapted from [81].
These tripodal amphiphiles can completely change the pharmacokinetics and
tumour selectivity of hydrophobic platinum drugs. They exhibit good pharma-
cokinetics in rats by showing long blood circulation and much larger systemic ex-
posure (AUC=43.5µg h/mL) compared to the carboplatin (AUC=4.32µg h/mL).
Biodistribution studies using male Sprague-Dawley rats showed excellent tumour
to tissue ratios of 4.03 at 2 h post injection and 4.67 at 24 h post injection. Fur-
thermore, this micellar platinum(II) compound exhibited more than six times
higher cellular uptake in human cervical (HeLa) and lung (A549) tumour cells
compared with the free platinum compound. The micellar platinum(II) com-
pound also displayed high cytotoxicity specifically against the stomach tumour
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cells (SNU638), which are among the least responsive to chemotherapeutic agents
currently in clinical use. The acute toxicity study showed that the LD50 values of
free and the micellar cis [-(cha)2Pt(NO3)2] are approximately 70 and 90mg/kg,
respectively. The loading efficiency of cisplatin alone can be increased by using
block copolymers that favourably interact with the drug such as poly[2-(N,N -
dimethylamino)ethyl methacrylate] (PDEA). Micelles based on PDEA can con-
tribute to the fast release of the drug in acidic conditions. Once the micelles
enter the cell via endocytosis, the micelles disassemble in the acidic endosomes
of lysosomes releasing the drug. For example, PDEA-PEG nanoparticles were
observed to disassemble at pH=6 while the protonation of the carrier further
accelerates the release by lowering the interaction with the drug [84].
The set-back of physical encapsulation is the limited drug retention in the
polymer matrix. The release of platinum drugs is in general rather fast, often with
an initial burst release. The early leakage of drug decreases the specificity and the
efficacy of the drug itself. Cross-linking of micelle is one option to delay release
by creating a network structure within the core or the shell. Brush copolymers
were created from macromonomers based on poly(ε-caprolactone) (PCL) and hy-
drophilic PEG or PDEA. Self-assembly of the resulting brush structure resembled
a micelle system that is crosslinked on the interface between the hydrophilic shell
and the hydrophobic core. The crosslinking, together with the positive charge
of the PDEA block, improves the internalisation process giving cisplatin loading
efficiency of approximately 90% and a much higher cytotoxicity compared to free
cisplatin [84].
β-cyclodextrins
Cyclodextrins are theoretically the perfect candidates to host drugs. β-cyclodextrin
(β-CD) has been extensively studied for its drug delivery properties since it pro-
vides individual and reversible encapsulations of the drug [85]. It has been proven
that the association of metal complexes in β-cyclodextrins significantly decreases
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the rate of diffusion and degradation with other proteins [86]. The β-cyclodextrins
offer a quite broad chemistry that allows specific modification and thus conjuga-
tion with polymers. Unfortunately, it seems that the affinity between cyclodextrin
and cisplatin is rather low and thus to date few examples have been reported.
It was previously investigated the use of β-CD as an anchor point to crosslink
micelles while the Pt-containing crosslinker acts simultaneously as anti-cancer
drug [87]. Crosslinking of micelles has been shown to have a range of benefits
including enhanced cellular uptake [88] and prolonged circulation in the blood
stream [89, 90]. However, permanent crosslinking can result in the accumulation
of nanoparticles in the organs of the reticuloendothelial system (RES) [20, 91] and
it is therefore desirable to introduce functional groups that can be cleaved once
the drug has been released. A range of approaches are indeed available that al-
low the degradation of crosslinking units of the micelle [76]. The pathway chosen
[87] was to introduce a Pt(IV) pro-drug based on bile acid as axial ligand. Bile
acid is known to form a host-guest complex with β-CD [92], but it is also known
to be a cholesterol metabolite that is produced in the liver. Block copolymers
with pendant β-CD groups are therefore synthesized by a combination of RAFT
polymerization and click chemistry [87]. The resulting water-soluble polymer un-
dergoes self-assembly once the host-guest complexation with the hydrophobic bile
acid-based Pt(IV) drug takes place. With a combination of RAFT and click chem-
istry an amphiphilic block copolymer with poly(ethylene glycol) methyl ether
methacrylate (PEGMEMA) as hydrophilic block and poly(propargyl methacry-
late) (PMA) as hydrophobic block has been successfully synthesized. To this,
6-azide-6-deoxy-β-CD (N3-β-CD) was clicked creating a hosting environment for
a hydrophobic small molecule platinum pro-drug (Figure 1.19).
Oxoplatin, the oxidized version of cisplatin, has been modified on its axial lig-
and introducing cholic acid groups through esterification. This modified cisplatin
forms a host-guest complex with β-CD that has been characterised via NMR
spectroscopy. The host-guest interaction that the drug established with the β-
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Figure 1.19: Synthesis of block copolymer and Pt-drug crosslinker [87].
CD grafted copolymer drove the self-assembly into nanoparticles of a diameter of
266 nm able to physical encapsulate the platinum-based drug. In the presence of
ascorbic acid, 70% of the pro-drug is released over a period of 24 h. Cytotoxicity
assays on ovarian cancer cells show that the polymer carrier improves the cyto-
toxicity of the platinum pro-drug. The IC50 value decreases from 37.7mM with
the pro-drug to 20.4mM when the pro-drug is encapsulated into the polymer
carrier. This is due to the fact that the uptake of the polymer carrier is up to 6
fold higher than the significantly smaller pro-drug by itself [87].
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Polyamidoamine (PAA) polymers containing pendant cyclodextrins and ad-
ditional binding sites for the conjugation of cisplatin were prepared creating a
delivery device with chemical bonding and physical entrapment of cisplatin [93].
PAA-platinated polymers are generally less toxic than free cisplatin with an IC50
of 2-5µg/mL depending on the cell line. A quantum dot/pseudopolyrotaxane
supramolecules have been shown to be suitable delivery systems for cisplatin [94].
Pseudopolyrotaxanes (Ps-PR) consisting of β-CD, polyethylene glycol axes and
end triazine groups were assembled in a supramolecular structure through host-
guest relationship between the triazine end groups and β-CDs conjugated onto
the surface of quantum dots (β-CD-graft-QDs). Stability of the supramolecules
depends on the efficiency of the host-guest relationships between the triazine end
groups of Ps-PR and β-CD-graft-QDs through which release of β-cyclodextrins
from the polyethylene glycol axes is controlled. The efficacy of the supramolecules
as drug delivery systems has been proved conjugating cisplatin and folic acid, a
tumour-recognition module, to their QDs. The supramolecules were subjected
to the receptor-mediated endocytosis and release inside murine colon adenocarci-
noma tumour C26 cells and the cytotoxicity studies show an IC50 of 35.2µM for
the macromolecules compare to an IC50 of 40.12µM for the free cisplatin [94].
1.2.5 Polymer-drug conjugation
In Pt-polymer conjugates the platinum drug is bound to the polymer chain via a
coordinative bond. Figure 1.13 outlines the different approaches that can be used
to attach platinum drugs to a polymer chain. Regardless of the approach used,
the goals remain the same: to increase stability during the circulation period
in the blood stream, to avoid the leakage of drug before reaching the target,
and to release the drug specifically into or in the proximity of the tumour cells.
There are three ways in which the platinum drugs can be chemically bound to a
polymer backbone: via a leaving ligand such as carboxylate ligating groups; via
a permanent ligand through amino ligating groups; or via the axial position of a
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Pt(IV) complex.
Pt(II)-polymer conjugate via leaving ligands
Linear polyme rs and micelles
The conjugation of the Pt(II) drug to a polymer carrier is usually inspired by the
drug carboplatin, which carries carboxylate ligands as leaving ligands. Polymers
with pendant carboxy-functionalities are readily available for Pt-drug conjuga-
tion. Carboplatin is less reactive but is more stable in the blood stream than
cisplatin because of the reduced binding to plasma proteins [95]. As a result, the
coordination of the platinum drug to the polymer via carboxylate ligands can be
an approach to obtain prodrugs structurally similar to carboplatin. The prodrug
is strongly bound to the polymer but can be released via hydrolytic cleavage of
the COO− leaving groups [96] (Figure 1.20).
Figure 1.20: Polymer-platinum conjugation through leaving ligands, here biden-
tate carboxylato groups [96].
When conjugating a platinum drug to a polymer containing carboxylate groups:
monofunctional conjugation, bifunctional conjugation, and/or crosslinking of poly-
mer chains can be obtained [96]. The bifunctional conjugation leads to the forma-
tion of ring structure between polymer and platinum, as depicted in Figure 1.21.
Moreover, one can explore different polymer structures such as homopolymer,
statistical copolymer or block copolymer.
It is also necessary to take in account that the presence of platinum drug
on a polymer can change the properties of the polymer itself. The solubil-
ity of the conjugated system can decrease because of inter-polymer crosslink-
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ing and the increased cohesive force between conjugates themselves [97]. Also,
the often hydrophilic carboxylate-containing polymers can transform into a hy-
drophobic polymer-platinum conjugates with increasing platinum coordination
[49, 98]. Conjugation of cisplatin to hydrophilic polymers such as poly(aspartic
acid) P(Asp) [97, 99, 100] or poly(L-glutamic acid) P(Glu) [96, 101, 102] affects the
polarity of these polymers turning them from water-soluble to hydrophobic poly-
mer. This increase in hydrophobicity can induce micelle formation when these
polymers are combined with a second hydrophilic block such as poly(ethylene
glycol) (Figure 1.21).
Figure 1.21: Chemical structures of CDDP and PEG-P(Glu) block copolymers,
and schematic illustrations of CDDP-incorporated micelles and the hypothesized
behaviour of the micelles in physiological saline at 37 ◦C. The CDDP-incorporated
micelles are spontaneously formed via a ligand exchange reaction of Pt(II) from
the chloride to the carboxylates in the copolymers in distilled water, and the
micelles dissociate accompanied with the sustained release of CDDP via an inverse
ligand exchange reaction of Pt(II) from the carboxylates in the copolymer to the
chloride ions in the surroundings in physiological saline. Scheme adapted from
[96].
Initial studies into the delivery of platinum drugs via this route employed
polymers with carboxylic acids that could efficiently conjugate cisplatin and re-
lated platinum drugs in a non-specific geometry. Platinum was coordinated either
by one or two COO− groups to the polymer backbone, or acted as crosslinker.
Nishiyama et al. demonstrated that the conjugation of cisplatin and PEG-P(Asp)
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block copolymer in an aqueous medium results in the spontaneous formation
of cisplatin-incorporated micelles with varying size ranging from 20 to 100 nm
[97, 99, 100, 101]. The micelle size depends on the ratio between hydrophobic
block and hydrophilic block. The loading efficiency depends on the feed ratio
between cisplatin and Asp residue in the block copolymer [97]. The micellar
formulation reduced nephrotoxicity, increased accumulation of drug in tumour
tissues, and demonstrated equivalent cytotoxicity compared to cisplatin, against
Lewis lung carcinoma bearing mice [99, 101]. Moreover, platinum-incorporated
micelles down-regulate many genes with tumour invasion, metastasis, and angio-
genesis whilst free cisplatin up-regulates such genes [101].
PEG-β-P(Glu) polymeric micelles, carrying cisplatin with a size of 30 nm in
diameter (NC-6004), have been developed and widely investigated. The ototoxi-
city of NC-6004, which is a common side effect of high-dose cisplatin therapy, has
been studied in guinea pigs and compared with that of cisplatin. The auditory
brainstem responses (ABRs) of the pigs to 2, 6, 12, 20, and 30 kHz sound stim-
ulation were measured before and 5 days after the administration of NC-6004.
Groups treated with NC-6004 showed no apparent ABR threshold shifts, whereas
groups treated with cisplatin showed dose-dependent threshold shifts particularly
at the higher frequencies. Consistent with the ABR results, groups treated with
NC-6004 showed excellent hair-cell preservation, whereas groups treated with
cisplatin exhibited significant hair-cell loss. Synchrotron radiation-induced X-ray
fluorescence spectrometry imaging demonstrated that the platinum distribution
and concentration in the organ of Corti were significantly reduced in guinea pigs
treated with NC-6004 compared with those treated with cisplatin. The findings
indicate that micellization of cisplatin reduces its ototoxicity by circumventing
the vulnerable cells in the inner ear [100]. Furthermore, in-vitro antitumour ac-
tivity was assayed in four oral squamous carcinoma cell lines to investigate the
antitumour and nephrotoxic effects of NC-6004 in nude mice bearing OSC-19.
The in vitro growth-inhibitory effect of NC-6004 was significantly less than that
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of cisplatin. However, both NC-6004 and cisplatin showed equivalent antitumour
effects in vivo. Mice injected with cisplatin developed renal cell apoptosis, how-
ever, those injected with NC-6004 were almost free of renal cell injury. Moreover,
in an orthotopic tongue cancer model using OSC-19, NC-6004 reduced the rate
of sentinel lymph node [103]. NC-6004 is currently on phase II of clinical trials
[104].
Dichloro(1R,2R-diaminocyclohexane) platinum(II), shown in Figure 1.22, was
also employed to generate micelles with a diblock copolymer PEG-b-P(Glu) [105].
The micelles formed are around 40 nm in size and have a significant stability with
no change in size being observed after 24 h. The system was optimized for superior
tumour targeting and antitumour activity and it was found that shorter P(Glu)
chains lowered accumulation in the liver and spleen.
Figure 1.22: Dichloro(1R,2R-diaminocyclohexane) platinum(II) structure.
Crosslinking of polymers is a distinguishing feature of platinum conjugation
to P(Asp) and P(Glu). The platinum drug cannot differentiate between adjacent
carboxylic groups and reactive groups located on other polymer chains. This
causes crosslinking, which facilitates micelle formation. It is difficult to obtain
a single polymer chains with pendant platinum drugs without any evidence of
crosslinking. To address this, polymers were designed to drive the formation of
stable six-membered rings. This was accomplished by creating discrete biden-
tate ligands along the polymer chain. One of the earliest and most successful
example, that uses this approach are carboxylate-containing HPMA polymers
(Figure 1.23). The polymer contained additional amino functionalities, which
facilitates the formation of five-membered rings with the platinum [106]. pH
sensitive peptides were introduced in the HPMA side chains to provide ligating
37
groups for platinum complexes. This design retains the platinum while in the
blood stream, prolonging the half-life circulation time and because of the com-
promised vasculature the polymer accumulates in the tumour before releasing
the platinum drug [89]. This polymer design was further modified to contain
glycine-phenylalanineleucine-glycine side chains and an aminomalonic acid ter-
minated group, to become AP5280 (Figure 1.23) [107, 108, 109]. Although good
platinum loading was obtained, this design exhibited dose limiting toxicity, ex-
pressed as nausea and vomiting, in phase I clinical trials [107]. A HPMA-based
polymer (AP5346) with triglycine side chains and an aminomalonic acid termi-
nal group was designed and synthesised to deliver more platinum to the tumour
[107, 110, 111, 112]. Superior cytotoxicity in numerous cell lines, compared to the
parent drug (oxaliplatin) [111], facilitated its progress through to phase I clinical
trials with the maximum tolerated dose, safety and pharmacokinetics, determined
[107, 112]. This platinum-polymer conjugate, ProlindacTM , is currently in phase
II clinical trials.
Figure 1.23: Development of HPMA-based polymers as platinum drug carriers
[106, 107, 112].
Other investigations using a similar approach in regards to Pt-drug conju-
gation, but with a different polymer structure, were published around the same
time. Polyphosphazene was functionalized with amino acids such as aspartic acid
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or glutamic acid, that contain bidentate dicarboxylic ligands as pendant groups
for effective platinum complexation and the formation of 7-8 membered rings
[113, 114, 115]. Polyphosphazene functionalized with glutamate was observed to
degrade, releasing the platinum, forming glycine, phosphoric acid, and aqueous
ammonia as side products that can be easily cleared from the body. This system
showed a higher in vivo antitumour activity than free cisplatin [114].
Different versions of polyphosphazene based polymers functionalised with as-
partic acid and glutamic acid and conjugated to 1,2-diaminocyclohexane plat-
inum(II) were found to be effective on various cancer cell lines [113, 115]. Song
et al. have functionalized both chlorines of polyphosphazene to yield polyphosp-
hazene with PEG chains and hydrophobic glycyl-L-glutamate as side groups [116].
The polymer, conjugated to 1,2-diaminocyclohexane platinum(II), preferably ac-
cumulates in tumour tissue and has enhanced in vivo cytotoxicity compared to
free cisplatin.
At this point in time, two different types of polymers with pendant platinum
drugs have been successfully investigated in clinical trials. While NC-6004 has a
micellar structure, AP5346 is a linear water-soluble polymer. Both approaches
led to reduced tumour growth while reducing side effects.
Inspired by the success of these polymers, further investigations have been
undertaken to look at alternative routes to introduce the ligand for the drug
or to understand how the underlying polymer architecture affects toxicity. The
different behaviour between statistical and block copolymers based on poly-(2-
hydroxyethyl methacrylate) (PHEMA) and poly[(ethylene glycol) methylether
methacrylate] (PEGMEMA) was analysed. The copolymers were modified with
4-pentenoic anhydride or 4-oxo-4-(prop-2-vynyloxy)butanoic anhydride to gener-
ate polymers with pendant vinyl or acetylene, respectively. Subsequent thiol-ene
or thiol-yne reaction with thioglycolic acid or 2-mercaptosuccinic acid leads to
polymers with carboxylate functionalities, which were coordinated to cisplatin.
Only the polymers modified with 2-mercaptosuccinic acid resulted in the forma-
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tion of soluble, well-defined polymers with no gel formation. This confirmed the
hypothesis that the formation of a stable ring-structure will lead to geometri-
cally defined structures while crosslinking is absent. It was originally envisaged
that a seven-membered ring would be formed, however NMR evidence suggested
that the thioether, which was formed as a result of the thiol-ene reaction, par-
ticipated in the complex formation with Pt. As a result, a six-membered ring
with a thiol-ligand was created. Due to the hydrophobicity of the drug, the block
copolymers took on an amphiphilic character leading to micelle formation, addi-
tion of crosslinking further stabilizes their structure. The cellular uptake by the
A549 lung cancer cell line was determined for Pt-containing statistical copolymer,
micelles, and crosslinked micelles with the last polymer showing superior uptake.
The highest cytotoxicity, however was observed with the statistical copolymer
due to the more efficient Pt release [117].
Thiol-ene chemistry, which introduces thioethers into the polymers, was iden-
tified as a less ideal ligand due to the strong complex formation between Pt
and sulphur. Malonic acid, which can form six-membered rings with Pt, can
easily be converted into a reactive monomer using the well-known reaction of
Michael-Addition of malonic acid. Block copolymer consisting of PEGMEMA
and a polymer based on 1,3-dicarboxylate functional groups were synthesized.
The monomer was prepared by the Michael-Addition using malonate esters and
ethylene-(MAETC), butylene-(MABTC), and hexylene (MAHTC) glycol dimethacry-
late, respectively (Figure 1.24).
In this way, three different block copolymers (BP-E80, BP-B82, and BP-H79)
with similar numbers of repeating units, but various spacer lengths as distin-
guishing features, have been generated. Conjugation with platinum drugs cre-
ated macromolecular platinum drugs resembling carboplatin. The amphiphilic
natures of these Pt-containing block copolymers led to the formation of micelles
in solution. The effect of linker length, between the dicarboxylate ligand and the
polymer backbone, has been assessed [118].
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Figure 1.24: Block copolymer micelles with pendant bifunctional chelator: study
of the influence of spacer length. Reprinted from [118, 119].
The rate of drug release in a buffer saline solution (0.9%) of all micelles was
similar, but the distinguishing feature of the three micelles was their stability
against disassembly. Longer, more hydrophobic linkers led to a higher micelle
stability, which translated into a better cellular uptake and therefore higher tox-
icity against A549, OVCAR3, and SKOV3 cancer cell lines which exceeded the
activity of carboplatin. The clonogenic assay revealed that micelles loaded with
platinum drugs, in contrast to low molecular weight carboplatin, have not only
better activity within the frame of a 72 h cell viability study, but also display a
longer lasting effect by preventing the colony formation A549 for more than 10
days.
The same system has been studied to understand the influence of the block
ratio on the performance of the drug carrier [119]. Three block copolymer sys-
tems were prepared, using PEGMEMA as macroRAFT agent with fixed length
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for chain extension with MAETC but with three different block lengths (Figure
1.22). Subsequent conjugation to platinum resulted in amphiphilic block copoly-
mers, which can generate micelles. The length of the core block had a significant
influence where the micelle size increased with an increase of the hydrophobic
block length. After conjugation with the platinum drug, the micelle with the
shortest PMAETC block length was found to have the highest toxicity with an
IC50 value of 23.5µM, which may be due to the fastest cisplatin release when
compared to the longer PMAETC block lengths.
A similar study, based on degradable polymers, has been carried out with
PEG-graft-α,β-poly[(N -amino acidyl)-aspartamide]. Two amino acids (Glu: glu-
tamic acid; and Asp: aspartic acid) or potassium aminomalonate (Ami) were used
to attach a bidendate ligand to the polymer to avoid crosslinking [17]. The Pt(II)
drug is attached to the carboxylic groups of the peptides which form micelles with
a typical diameter size of 105 nm while carrying folate end functionalities. The
micelles showed a sustained drug release profiles over 40 h and their accumulative
drug release was ranked in the order of FA-PEG-γ-PAsp-Ami-CDDP <FA-PEG-
γ-PAsp-Glu-CDDP <FA-PEG-γ-PAsp-Asp-CDDP, depending on the category of
amino acid used. Cellular uptake, and thus cytotoxicity, of folate conjugated
micelles was found to be higher than that of the non-conjugated counterparts
because of folate receptor mediated endocytosis.
The stability of the micelle was identified as one key element to high cellular
uptake, especially at lower concentrations [88]. Further work therefore focused
on the effect of crosslinking on the toxicity of the drug loaded carrier. Two dif-
ferent crosslinkers were employed to stabilize the structure: an acid degradable
and a non-degradable prepared from triblock copolymers of poly(oligo(ethylene
glycol) methyl-ether methacrylate)-β-poly(N -hydroxysuccinic methacrylate)-β-
poly(1,1-di-tert-butyl 3-(2-(methacryloyloxy)ethyl) butane-1,1,3-tricarboxylate)
(PEGMEMA-β-PNHSMA-β-PMAETC).
Both crosslinked micelles showed high cellular uptake at low concentrations,
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which translated into higher toxicities, thus lower IC50 values. There is no signif-
icant difference in cytotoxicity of crosslinked platinum polymeric micelles using
various crosslinkers (permanent and acid cleavable) after 72 h of exposure, how-
ever the difference is noticeable after 24 h of incubation. Micelles with a perma-
nent crosslinker demonstrate an IC50 value of 80µM whilst the micelles with an
acid cleavable crosslinker exhibit an IC50 value of 35µM after 24 h, due to faster
drug release of the acid-degradable micelles. Upon entry via endocytosis, the
crosslinks could be depleted in the slightly acidic endosomes and lysosomes re-
sulting in an accelerated drug release. Thus, acid degradable linkers ensure high
cellular uptake compared to uncrosslinked micelles but also lead to a faster drug
action in comparison to a permanently crosslinked micelle [120]. The improved de-
livery using stable micelles has recently been demonstrated using shell-crosslinked
micelles [121].
Although the strong focus on linear polymers and micelles in the literature
is evident, other self-assembled aggregates have been tested. Recently, a diblock
copolymer was prepared by Ring Opening Metathesis Polymerisation (ROMP).
While one block carried water soluble PEG moieties, the other block, which was
prepared from oxanorbornenyl anhydride, was used to attach cisplatin. Interest-
ingly, these polymers led to the formation of vesicles that allowed the sustained
release of cisplatin over several days [122].
Cholesterol has been observed to be the driving force to vesicle structures. γ-
shaped block copolymers of ω-cholesteroyl-poly(L, glutamic acid) and two-armed
poly(ethylene glycol) (PEGasus-PLGA-Chole) conjugated to a Pt(II) drug spon-
taneously forms vesicles, coined metallosomes owing to the presence of metal
complexes, with uniform size of about 100 nm (Figure 1.25). Circular dichroism
spectrum measurements revealed that the PLGA segment forms an α-helix struc-
ture within the metallosomes, suggesting that secondary-structure formation of
metallocomplexed PLGA segment may drive the self-assembly. These metallo-
somes can encapsulate water-soluble fluorescent macromolecules into their inner
43
aqueous phase and eventually deliver them selectively into tumour tissues in mice,
leading to the prolonged blood circulation [123].
Figure 1.25: Schematic diagram of the self-assembly of metallosomes through the
formation of a metal complex between a Pt(II) drug and the carboxylic moiety
of PLGA segment. Reprinted from [123].
Dendrimers
Dendrimers are well-defined, globular, synthetic polymers with multiple surface
groups, have also been investigated as a mean to deliver platinum drugs. Den-
drimers have unique structural properties such as high molecular weight, and
lymphatic dysfunction that make them particularly suitable for biological appli-
cations especially for drug delivery. Dendrimers show good localization, enhanced
EPR effect and good permeability into hyper-permeable vasculature. Two meth-
ods are commonly used to prepare dendrimers: convergent, divergent method, or
a combination of the two [124, 125].
Poly(amidoamine) (PAMAM) dendrimers are attractive drug carriers for an
array of drugs including cisplatin [126]. In early studies, Malik et al. investi-
gated a highly water soluble dendrimer-platinate obtained by the conjugation
of third generation PAMAM dendrimers with terminated carboxylic acid groups
and cisplatin [127]. There are three modes for cisplatin to coordinate to a den-
drimers: through a single leaving group (monofunctional), through two leaving
groups (bifunctional), and by crosslinking between two dendrimers (Figure 1.26
a). This design allows high platinum loading but the crosslinking between den-
drimers generates large aggregates. Moreover, the release profile is extremely slow
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with less than 1% of the platinum cleaved after 72 h in a biological medium and
thus a similar release rate would be expected in the blood plasma. Furthermore,
the platinum-dendrimer conjugates are 3 to 15 fold less toxic than free cisplatin.
However, a disadvantage of dendrimeric drug delivery systems is that the release
of the drug seems to be pH independent which makes it unable to discern between
tumour tissue (slightly acidic) and healthy tissue [128]. The reason for the slow
release may be found in the structure of the platinum complex: the terminal car-
boxylic acid and internal amine functional groups can be both readily conjugated
to platinum drugs through the O,O ligands or O,N ligands (Figure 1.26 b). Co-
ordination via O,N ligands may be more stable than that of O,O and is expected
to have a moderate release rate. This hypothesis, is supported by a study that
employed polyester dendrimers of two generations (G1 and G2) and carboxylic
acid groups on the surface. Although drug release was accelerated, full release
could not be achieved. Better release translated directly into higher toxicity. The
G2 dendrimer was found to be more efficient while displaying at the same time
lower hemolysis compared to cisplatin [129].
Figure 1.26: a) possible pathways to conjugate cisplatin to dendrimers; b) con-
jugation of cisplatin to internal amine groups [128].
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The low drug release from PAMAM did not necessarily result in an inactive
carrier. Cisplatin was conjugated to G3.5, G4.5, G5.5 and G6.5 [130]. None of
the carrier allowed the full release of the drug. Nevertheless, in-vivo studies using
an A2780 tumour xenograft model showed a high efficiency of the G6.5 PAMAM
dendrimer and a higher tumour size reduction compared to free cisplatin [131].
Third generation dendrimers with terminal carboxylic acid groups were recently
reported by Chen et al. [132]. The combination of thiol-yne and esterification
reaction allowed the efficient generation of dendrimers in only a few steps. Al-
though no in vitro or in vivo experiments were done, the dendrimers showed a
high platinum loading efficiency of 86%. Dendrimers with a phtalocyanine centre
andsurface conjugated cisplatin were process together withblock copolymers into
nanoparticles that generated singletoxygen upon laser light irradiation [133].
Solid nanoparticles
Cisplatin has been loaded into solid poly(γ, L-glutamic acid) nanoparticles, which
were modified with citric acid for Pt-drug conjugation [γ-PGA-CA-CDDP] re-
sulting in particles with a diameter of 107± 6.3 nm [134]. The nano-conjugate
delivery system released platinum in a sustained manner in PBS at 37 ◦C with
an initial burst release during the first 8 h and 50% cumulative release within
48 h. Both in vitro and in vivo studies showed that the toxicity of γ-PGA-CA-
CDDP nano-conjugate was significantly decreased compared to free CDDP. Also,
the maximum tolerated dose of γ-PGA-CA-CDDP nano-conjugate was about 38
versus 8mg/kg for cisplatin, in contrast, no apathy or acute adverse reactions
were observed with the γ-PGA-CA-CDDP nano-conjugate groups while mice ex-
pressed apathy at all dose levels with cisplatin treatment. Near-infrared fluo-
rescence imaging demonstrated that γ-PGA-CA-CDDP nanoconjugate gradually
accumulates at the tumour site within 15min post injection and exhibits pro-
longed retention for more than 8 h (Figure 1.27).
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Figure 1.27: Typical in vivo non-invasive NIR fluorescence images of real time
distribution of γ-PGACA-CDDP conjugate obtained at different time point on
H22 allograft tumour in SPF mice and ex vivo images of dissected tissues after
8 h. Reprinted from [134].
Hybrid nanoparticles
Hybrid nanoparticles are obtained by mixing two different materials, which are
either chemically linked or physically mixed. Very often this definition is applied
to the combination of metal-based material or other inorganic material with poly-
mers. Superparamagnetic iron oxide nanoparticles (SPIONs) were loaded into mi-
celles based on amphiphilic poly(ε-caprolactone)-b-poly-(propargyl methacrylate-
click-mercaptosuccinic acid-co-poly(ethylene glycol) methyl ether methacrylate)
(PCL-β-P(PMA-click -MSA-co-PEGMA)) to deliver the platinum(II) drug to blad-
der cancer cells (UMUC3) and to image the nanoparticles in the bladder at the
same time [135]. The block copolymers were synthesized by a combination of ring-
opening polymerization, reversible addition fragmentation chain transfer (RAFT)
polymerization, and thiol-yne "click" reaction. The hydrophobic PCL core can
load SPIONs, while the pendant dicarboxylic groups in the hydrophilic shell co-
ordinate cisplatin. SPIONs-loaded cisplatin-conjugated polymeric nanoparticles
(PtFePNs) are superparamagnetic at room temperature and are mucoadhesive,
these properties enable the localization of the nanoparticles on the bladder wall.
When the nanoparticles are dialysed against artificial urine at 37 ◦C, 30% of cis-
platin is released from PtFePNs in the first 4 h followed by a slow sustained release
over 4 days. PtFePNs can effectively induce cytotoxicity against UMUC3 bladder
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cancer cells with IC50 values of 32.3µM [135].
Recent work from Adeli et al. [136] described a hybrid nanomaterial-based
drug delivery systems (HNDDSs) consisting of carbon nanotubes and linear den-
dritic copolymers where the anticancer drug is linked through the leaving ligands.
Multi-walled carbon nanotubes (MWCNTs) were solubilized and functionalized
by poly(citric acid)-poly(ethylene glycol)-poly(citric acid) (PCA-PEG-PCA) lin-
ear dendritic copolymers through non-covalent interactions. Cisplatin, coordi-
nated to the carboxyl functional groups of the dendritic blocks of PCA-PEG-PCA
interacts non-covalently with the MWCNTs to produce HNDDSs. The cytotox-
icity of HNDDSs has been tested on murine colon adenocarcinoma tumour C26
cancer cells. The HNDDSs show improved cytotoxicity compared to PCA-PEG-
PCA as well as MWCNTs, MWCNTs/PCAPEGPCA and free cisplatin.
A very similar approach has been employed using gold nanoparticles (AuNP).
The active component of the platinum anticancer drug oxaliplatin was tethered
to the surface of a 20 nm AuNP via a thiolated PEG linker. Binding of oxaliplatin
via labile linker to the AuNP increases cytotoxicity, compared with oxaliplatin
alone [137]. Attachment of platinum to the AuNP surface through a PEG linker
exhibits an increase in the drug loading with increasing particle size. Thus, the
active component of cisplatin was tethered to 25, 55, and 90 nm AuNPs, with
the nanoparticles being almost spherical in nature, demonstrating good batch-to-
batch reproducibility and a significant improvement in size distribution [138].
Nanodiamonds (NDs) are also highly promising drug delivery systems due to
their biocompatibility, manipulable surface chemistry, and non-bleaching fluores-
cence. Cisplatin has been incorporated via direct attachment to the ND surface,
physical adsorption within a PEGMEMA surface coating, and complexation to
MAETC groups of a PEGMEMA-st-PMAETC surface layer. In the last two cases
the polymer layers were introduced by grafting from RAFT-functionalized NDs
(Figure 1.28). The three ND systems displayed lower IC50 values than free cis-
platin in A2780 and A2780cis ovarian cancer cells. Furthermore, the two polymer
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coated systems outperformed their "naked" counterpart, with the PEGMEMA-
coated particles the most cytotoxic, displaying an IC50 of 1.5µM, more than an
order of magnitude lower than that of cisplatin. The enhanced cytotoxicity is
attributed to promotion of cellular uptake by the hydrophilic surface polymer
[139].
Figure 1.28: Increasing of effectiveness against ovarian cancer cells using nanodi-
amonds coated with polymers [139].
Solid Microspheres
Although the physical encapsulation of platinum drugs into microspheres is more
common, the chemical attachment has found to be superior. The rate of release
was measured to be between few hours when using hydrophilic chitosan and up
to 30 days with hydrophobic polylactide spheres. However, release studies were
mainly carried out in buffer solution, which does not take into account the po-
tentially fast degradation of polylactide in an environment rich of enzymes. One
report described the chemical binding via complexation to partially succinylated
glycol chitosan, although the size of the spheres was in the nanometer range
[140]. Conjugation of cisplatin to microspheres with malonic acid or other car-
boxylic acid functionalities could create a carrier for sustained release over several
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weeks. The extended release allows the potential use of these microspheres for
the treatment of liver cancer via transarterial chemoembolization [117].
Pt(II)-polymer conjugate via permanent ligands
A different pathway to conjugate the cisplatin to polymers is via permanent amine
ligands. The resulting structure is subject of debate. The permanent conjugation
of the drug leads to the formation of a macromolecular drug and therefore a new
type of drug and not a drug carrier has been generated. However, it has been
hypothesized that these polymers are only active if the polymer can break down
into sufficiently small platinum containing molecules, which then act similarly
to cisplatin in the cells. A second hypothesis is that the whole macromolecular
complex enters the cell nucleus through the nuclear pores and binds to DNA.
Although nuclear pores have diameters of around 100 nm, the transport into the
nucleus is controlled by a regulatory system. It is estimated that only molecules
of sizes well below 10 nm can freely diffuse in and out. Larger polymer constructs
therefore may not be able to enter the nucleus supporting the hypothesis that
polymers need to be able to break down to a certain extent. A range of studies
indeed confirmed that degradable groups are necessary to achieve a high drug
activity, which is usually reflected by a high toxicity [141, 142, 143, 144, 145,
146, 147, 148, 149]. Several approaches can be used to permanently attach the
platinum drugs to the polymer, these are summarized in Figure 1.29.
Neuse and co-workers investigated a large library of polymer structures, di-
viding them into groups depending on the site of the degradable group and the
structure of the platinum drug (Figure 1.29). In all cases, the degradable groups,
which are indicated by the red bars, need to be cleaved to liberate the platinum.
Potassium tetrachloroplatinate (K2PtCl4) was employed to form complexes
with amine ligands. As depicted in Figure 1.30 the conjugation results in mono-,
di-, tri- and tetra-bounded platinum complexes and even crosslinking between
polymer chains was observed under suitable conditions [95].
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Figure 1.29: Pathways to conjugate platinum drugs to polymers through perma-
nent ligands [141, 142, 143, 144, 145, 146, 147, 148, 149, 150].
Figure 1.30: General structural formula of mono-, di-, tri- and tetra-bounded
platinum complexes and crosslinking between polymer chains.
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The importance of having structures that are degradable, to some extent,
was highlighted when using poly(aminoethyl methacrylates-co-methyl methacry-
lates), which was processed into particles with high platinum-loading efficiency
(>85%) (Figure 1.31). The non-degradable polymer displays little or no toxicity
[150] probably due to the high stability of the hydrophobic polymer particle in
an aqueous environment. It is therefore crucial to generate polymers that can
either fully degrade or at least degrade into strands that are small enough to
allow entry into the nucleus. It was found to be sufficient to include ester func-
tionalities embedded into a rather hydrophilic polymer to promote drug release.
A study that employed two types of polymers, a statistical and a micelle forming
block copolymer, showed no difference in cytotoxicity (Figure 1.31). Although
the micelle is potentially big to enter the nucleus, the measured IC50 values of
both polymers were similar suggesting the degradation of the ester functionality
[151].
Figure 1.31: Macromolecular platinum drugs prepared from highly crosslinked
polymer [149], block copolymers or statistical copolymer [151].
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Recently, a new acid-degradable polymer-platinum conjugate was prepared
by post-modification of a PEGMEMA-β-PHEMA block copolymer. A hydrazone
linkage, susceptible to hydrolytic cleavage, was formed by reaction of the carbonyl
group of a diamino ligand with the hydrazide-modified copolymer. NMR kinetic
studies showed that the degradation of the hydrazone bond is 10 times faster at
pH=5.5 than at pH=7.4. This is an important feature considering the low pH
of tumour cells. The platinum was coordinated via the diamino sites using the
copolymers and subsequently self-assembled. Short conjugation times produce
micelles with a diameter of 27 nm with the platinum drug safely encapsulated in
the core. In vitro experiments revealed a high cytotoxicity for these micelles com-
pared to the polymer before conjugation as well as an IC50 value superior to the
low molecular weight drug (IC50=10.5µM). Longer conjugation times produces
crosslinking and particles of more than 1000 nm which do not show any toxicity
as their size prevents uptake by cells by endocytosis. However, endocytosis and
the subsequent location of the micelles in the acidic endosomes or lysosomes are
necessary to trigger the release of the toxic platinum drug while large particles
that reside in the cell growth media at pH=7 only do not release any drugs [152].
Dendrimers with their compact size may be able to circumvent the size ex-
clusion effect of the nuclear pores. Bellis et al. [153] synthesized dendrimers
with amino end-groups on the surface, which promptly form complexes with plat-
inum(II) chloride species. Diamino butane poly(propyleneimine) dendrimers with
different generations (1-3) were prepared (Figure 1.32) and subsequently conju-
gated to platinum (II) chloride. The resulting complexes were highly insoluble in
water, alcohols and in organic solvent including DMF and DMSO. Interestingly,
thermogravimetric measurements showed that the platinum coordinates with the
amino groups on the surface as well as internal tertiary nitrogen donors. Partial
conjugation between platinum(II) chloride and dendrimers gave soluble products.
Another study was carried out on the 1,2-diaminoethane-terminated dendrimers.
They typically accumulate in MCF-7 cells with clathrin-dependent pathways and
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target the platinum moieties at the nucleus compartment. A high intracellular
platinum concentration and DNA binding with these platinum dendrimers were
observed [154].
Figure 1.32: Dendrimer containing terminated amine [153].
Pt(IV)-polymer conjugate
Octahedral Pt(IV) complexes represent an attractive alternative to Pt(II) com-
pounds for two main reasons. Firstly, the ligands on the axial axis of the Pt(IV)
drug can be used in a quite wide range of chemistry facilitating the conjugation
with the polymer. The axial axis is usually a hydroxyl ligand where one can
introduce functional groups such as carboxyl groups which can then readily be
conjugated to polymers. Moreover, Pt(IV) drugs are more stable than Pt(II)
drugs in the biological environment. Indeed, Pt(IV) compounds are less suscepti-
ble to deactivation due to attacks of proteins in the blood. This inertness results
in fewer side effects compared to Pt(II) based drugs. However, Pt(IV) compounds
are considered to be prodrugs since they need to be reduced to the more active
Pt(II) species in the intra- or extra-cellular fluid by biological reductants such as
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glutathiol, ascorbic acid or cysteine to be able to bind to the DNA. Reduction
of Pt(IV) to Pt(II) breaks the bond to the polymer releasing the active drug,
although one has to take into account that modification of the axial ligand will
affect the redox potential of the Pt(IV) compound and therefore its availability
in the Pt(II) active form. As Pt(IV) compounds represent an inert alternative to
Pt(II), they have attracted the interest of researchers working on the preparation
of polymeric drug delivery systems for platinum based drugs. It is noticeable that
most recent research activity in the area of platinum drug delivery took place in
the area of Pt(IV)-polymer conjugates.
Micelles
Duong et al. have developed core-crosslinked micelles by clicking bifunctional
Pt(IV) anticancer agent with isocyanates to enhance the stability in blood streams
[155]. Two amino groups were introduced on the two axial ligand of the Pt(IV)
pro-drug that now can act as a crosslinker stabilizing the micelles structure by
connecting the self-assembled polymer chains. The micelles so obtained have a di-
ameter of 36 nm and are very stable in aqueous media. In a reducing environment
the Pt(IV) crosslinker reduces to cisplatin opening up the now non-crosslinked
micelles (Figure 1.33).
Figure 1.33: Micelles before and after release of Pt(IV). Reprinted from [155].
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However, the drug release rate is slow with 82% of the drug being released over
22 days. This slow release was improved by replacing the hydrophobic environ-
ment of the micelle with the hydrophilic poly(methacrylic acid) PMAA. Conjuga-
tion of oxoplatin introduced hydrophobic properties to the water-soluble PMAA,
which initiates the micelle formation. Folate conjugation via boronic esters led to
improved uptake, although the correlation between folate conjugation and drug
delivery was only visible when using small micelles. The high hydrophilicity of the
core of the micelle produced a much faster release of the drug which consequently
led to higher bioactivity. However, the micelle also succumbed to fast disassem-
bly due to the nature of the core. Core-crosslinking led to more stable structures
with a better cell uptake and therefore higher toxicity [16]. As briefly discussed
in the paragraph for physical encapsulation, the conjugation of platinum-drugs to
other active drugs can create effective chemotherapeutic treatments. Oxoplatin
has been conjugated to dichloroacetate (DCA), an inhibitor of glycolysis, in the
equatorial plane to the leaving ligands and connected to methoxyl-poly(ethylene
glycol)-β-poly(ε-caprolactone)-β-poly(L-lysine) (mPEG-β-PCL-β-PLL) polymer
carrier through a succinic spacer. The polymer self-assembles in micelles of diam-
eter of ca. 150 nm containing 30wt% of DCA-Pt(IV). A similar polymeric system
was then prepared using carboplatin instead of DCA-Pt(IV). The cytotoxicity
studies showed that the DCA-Pt(IV) drug loaded polymer carrier has a much
lower IC50 value than the free DCA-Pt(IV) and the carboplatin loaded polymer
carrier. Furthermore, the DCA-Pt(IV) drug loaded polymer carrier shows a bet-
ter biodistribution to the tumour tissue compared to the other drugs analysed
[156, 157].
Stimuli-responsive features are a potential way to trigger the release of the
drug once the drug carrier reaches a certain site. In particular the cleavage of
bonds in acidic surroundings, as found in cancerous tissue or inside the endosomes
or lysosomes after uptake by endocytosis, has been an increasingly attractive ap-
proach [158]. This pathway can be applied to platinum drugs as demonstrated
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using Pt(II) drugs as discussed above [120, 152]. The axial ligand allows easy
modification of Pt(IV) drugs to enable the introduction of an acid-labile hydra-
zone linker. The Pt(IV) drug can then be conjugated to the end functionality of
an amphiphilic block copolymer, Bi(PEG-PLA) to create a micellar drug delivery
system that releases the drug only low pH values (Figure 1.34) [159].
Figure 1.34: Schematic illustrations of the structure of polymercisplatin prodrug
conjugate, the formation of Bi(PEG-PLA)-Pt(IV) NPs through self-assembling,
and acid-responsive drug release from the NPs [160].
Hybrid nanoparticles
Carbon nano-tubes (NTs) have emerged as attractive tools for drug delivery.
The most common NTs used as drug carriers are single-walled carbon nano-
tubes (SWNTs) which can internalize various cargos into cells such as fluorescent
molecules, plasmid DNA, proteins, and other substances that would not otherwise
be taken up, with no apparent side effects. It has been found that naked SWNTs
do not circulate well in biological systems due to their poor solubility. In contrast,
surface-modified SWNTs have a half-life of a few hours in the blood stream and,
when taken up by the reticuloendothelial RES, are cleared slowly by the biliary
pathway and in faeces without any obvious in vivo toxicity. The surface of SWNTs
can be functionalized through oxidation obtaining oxygen-containing functional
groups such as alcohols or carboxylic acid that can be used to attach water soluble
side-chains. In their soluble version, SWNTs can efficiently cross cell membranes
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and be taken into the cytosol by endocytosis carrying inside different sizes and
types of drugs.
Dhar et al. [161] showed that SWNTs conjugated to Pt(IV) compounds can
be utilized as "longboat delivery system" to transport Pt(IV) pro-drugs into cells
via clathrin-dependent endocytosis. The Pt(IV) compound is attached to the sur-
face of an amine-functionalized SWNT through one of the axial functional group,
whilst on the other axial group it contains a folate derivative. The presence of
folic acids on the surface of the delivery system is a way to target cancer cells
that overexpress folate receptor (Figure 1.35).
Figure 1.35: Delivery of SWNTs decorated with Pt(IV) to endocytosis. Reprinted
from [161].
Another type of hybrid nanoparticles are the gold base AuNPs. These are
bioinert, non-toxic, easy to synthesize and functionalize. AuNPs can be used to
load, transport and deliver Pt(IV) compounds to cancerous cells. Dhar et al.
assembled AuNPs with polyvalent oligonucleotide to which a Pt(IV) compound
can be conjugated (Figure 1.36) [162].
PEGylated gold nano-rods have also been used as platforms for the deliv-
ery of Pt(IV) pro-drugs, demonstrating enhanced cellular uptake and superior
cytotoxicity compared with cisplatin [163].
Nanoparticles based on NaYF4: Yb3+/Er3+ have been employed not only as
targeted drug delivery systems but at the same time as diagnostic systems. The
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NaYF4: Yb3+/Er3+ nanoparticles were coated with branched polyethyleneimine
to which the Pt(IV) drug is attached. Subsequent PEGylation with the occasional
functionalization of some chains with folic acid (FA), promoted the receptor-
mediated endocytosis. Upon uptake of the drug delivery system into the cell, the
drug is released by reduction [164].
Figure 1.36: Construction of Pt-DNA-Au NP. Reprinted from [162].
Layer-by-layer assembly
Poly(L-lysine) (PLL) was used as the reactive polymer for Pt(IV), which was then
co-assembled with poly(glutamic acid) (PGA) through a layer-by-layer approach
on colloidal silica templates. After removal of the templates, biodegradable PGA-
PLL-Pt(IV) multilayer capsules with a diameter of 0.5µm and 10µg of platinum
incorporated into each bilayer were obtained [165]. The capsules demonstrated a
higher release at pH=5.0 then at pH=7.4 (Figure 1.37). Furthermore, in vitro
evaluation showed that the PGA-PLL-Pt(IV) multilayer microcapsules displayed
higher cytotoxicity (IC50=3.5µg/mL) against colon cancer cells CT-26 than that
of free cisplatin (IC50=8.6µg/mL). This enhanced cytotoxicity was attributed to
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the effective uptake of the capsules by the cancer cells, which was observed by
confocal laser scanning microscopy (CLSM) imaging.
Figure 1.37: Schematic illustration of the structure of PGA/PLL-Pt(IV) micro-
capsules and intracellular release of cisplatin(II) [165].
1.2.6 Platinum based nanosystems transferred to the clinic
There are currently three platinum based nanosystems in clinical trials. NC-6004
NanoplatinTM is a system made of PEG-P(Glu) to which CDDP is conjugated
through the leaving ligands invented by Kataoka et al. at the University of
Tokyo. The technology was licensed in from TOUDAITLO Ltd. and is currently
in phase II clinical trial in USA and Phase I clinical trial in Japan. NC-4016,
which has been developed by the same team, is similar to NanoplatinTM with
the CDDP substituted by oxaliplatin. NC-4016 is currently in phase I clinical
trial. LipoplatinTM , invented by Stathopoulos et al., is a system made of liposome
that physically encapsulates CDDP. It is currently in phase II/III clinical trials
sponsored by Regulon. ProlindacTM is a DACH (1R,2R-diaminocyclohexane)
platinum polymer prodrug currently in phase II clinical trials sponsored by Ac-
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cess Pharmaceuticals. In Table 1.1, the IC50 values of NC-6004 in a range of cell
lines are compared with those of CDDP. The IC50 values of ProlindacTM have also
been analysed on a wide spectrum of cell lines. The reader can refer to "Platinum
and Other Heavy Metal Compounds in Cancer Chemotherapy, Cancer Drug Dis-
covery and Development" 2009, pp. 41-47, for an overview on the cytotoxicity
of ProlindacTM . Table 1.2 shows the main pharmacokinetic parameters of the
nanoparticles currently in clinical trials compared with cisplatin. The table does
not include NC-4016 as no parameters are yet available.
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Table 1.1: IC50 values of NC-6004 in different cell lines compared to the ones of CDDP
IC50 (µM)
Cell lines 48 h 72 h
CDDP NC-6004 CDDP NC-6004
Neck [103] OSC-19 28.3 129.3 17.6 117.0
OSC-20 22.4 398.4 18.4 113.9
Head [103] HSC-3 11.2 110.5 10.2 71.7
HSC-4 16.5 118.9 20.5 119.3
Bladder [102] Ej-1 2.46 25.45 1.86 18.44
J82 2.78 42.89 2.42 20.27
MBT-2 15.88 >100 5.67 71.67
Colon [102] Colo201 34.77 >100 28.52 >100
Colo320 16.32 >100 9.71 81.15
HT-29 14.44 >100 8.83 >100
Lung [102] A549 21.43 >100 20 >100
EBC-1 >100 >100 9.36 84.78
PC-14 16.81 >100 8.73 87.11
Gastric [102] MHN-28 >100 >100 8.23 76.81
MHN-45 7.12 68.36 6.94 43.81
Breast [102] MCF-7 12.78 >100 5.71 54.71
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Table 1.2: Pharmacokinetic parameters for CDDP, NC-6004, LipoplatinTM and ProlindacTM in rats and humans. Cmax: maximum
concentration detected; T1/2: half-life; CL: clearance; DLT: dose limiting toxicity; MTD: maximum tolerated dose.
CDDP NC-6004 LipoplatinTM ProlindacTM
Rat
Administration Single injection [102] Single injection [102] N/A N/A
Dose mg/Kg 5 [102] 5 [102] N/A N/A
Cmax (µg/mL) 11.67± 0.57 [102] 89.90± 4.29 [102] N/A N/A
T1/2 (h) 34.50± 16.14 [102] 6.43± 0.55 [102] N/A N/A
CL (mL/(h Kg) 70.67± 20.34 [102] 3.77± 0.21 [102] N/A N/A
DLT (mg/m2) N/A N/A N/A N/A
MTD (mg/m2) N/A N/A N/A 625 [166]
Human
Administration Single injection [167] Escalation [168] Escalation [169] N/A
Dose (mg/m2) 100 [167] 120 [168] 125 [169] N/A
Cmax (µg/mL) 2.9± 0.63 [167] 84.6± 8.1 [168] 5.65± 2.67 [169] N/A
T1/2 (h) 93.6± 66.9 [167] 87± 37 [168] 81.53 [169] N/A
CL (L/h m2) 0.53± 0.35 [167] N/A 0.49 [169] N/A
DLT (mg/m2) N/A 90 [168] 125 [169] N/A
MTD (mg/m2) N/A 120 [168] 100 [169] 640 [166]
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1.2.7 Conclusions
The field of metal-drug delivery has significantly matured in the last 10 years.
While only a few reports were available more than 10 years ago, the literature
is now filled with creative approaches to deliver mainly metal-drugs that are
based on platinum. The preference for Pt-drugs can be easily understood con-
sidering that the parent drug, cisplatin, has obtained FDA approval around 40
years ago. Alternative drugs based on other transition metals such as ruthenium,
cobalt, gold, osmium and other are still in their infancy although some drug
have made it into clinical trials. More than 96% of all reports in the literature
that deal with the delivery of metal based drugs therefore focuses on the deliv-
ery of various Pt-drug. Initially, simple physical encapsulation strategies were
explored. This has now shifted mainly to drug conjugation where the drug is
chemically bound to the polymer and slowly cleaved depending on the type of
conjugation. Whereas non-metal based drugs are mostly physically encapsulated
into nanoparticles, polymer-drug conjugation is the most common approach for
Pt-drugs. Researchers have a wide range of options in conjugating Pt-drugs to
nanoparticles obtaining several advantages. The polymer-drug chemical bound
improves the stability of the nanoparticle and reduces the leaking of drug from
the nanoparticle. It is also a useful tool to delay and trigger the release of the
drug once the nanoparticle reaches its target. The last few years have seen the
design of systems that can deliver two drugs. In addition, simultaneous imaging
of the drug carrier seems to be of interest as well as the attachment of targeting
ligand to the surface. Folic acid and aptamers are the most reported targeting
ligands in the literature, however other targeting ligands such as sugar and pep-
tide moieties have considerable potential in this field. It is noticeable that the
type of water-soluble polymer is mostly based on PEG. This choice is probably
expected since the interactions between metal-based drugs and PEG are limited
facilitating the overall design of the drug carrier. The main challenge in mak-
ing platinum-based nanosystems is the ability to develop an efficient preparation
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method which leads to standardized and simple systems. Most examples found
in the literature are in fact complicated structures which require several synthetic
steps and are therefore difficult to transfer to commercial production. However,
these nanoparticles provided valuable lessons on how nanoparticles can increase
the activity of the drug and these structures therefore represent highly valuable
contributions to the discussion. More investigations however are warranted on
the particle stability. The stability of the nanosystems is crucial for a possible
future clinical application. Some nanosystems can only be synthesized at low
concentrations and scaling up at higher concentrations can lead to their agglom-
eration and precipitation. Other type of nanosystems can even change size and
shape during the storage period. If the nanoparticles are stored as a dried powder
they may not be able to be dispersed in water again for administration. At the
same time, it may not be possible to store the nanoparticles in solution for long
time. Finally, another difficulty is to predict in vivo behaviour of nanoparticles
from in vitro studies. Some nanosystems that are currently in clinical trials had
shown higher IC50 values than cisplatin in cancerous cell lines, but better results
have been obtained in in vivo studies or even on human patients. The area is
now reasonably mature as evidenced by the number of polymer-drug conjugates
in clinical trials.
1.3 Aim of the thesis
The aim of this thesis is to design, prepare and study polymer nanocarriers for the
delivery of anti-cancer platinum-based drugs. Platinum-based drugs are among
the most common chemotherapeutics used in the clinic today. However, like
many other anti-cancer drugs, they present several limitations including poor
solubility in aqueous media, poor stability in the blood stream, high toxicity and
non-specificity unless purposely modified causing severe side effects to patients.
They will therefore highly benefit from the use of polymer nanocarriers as delivery
vehicles.
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This work is divided into three parts. In the first part, an alternative to
targeting ligands such as folic acid, antibodies or peptides is explored to by-
pass the accumulation of the PNs in the RES. This alternative is represented by
carbohydrate based polymers. Nanocarriers made of glycopolymers are readily
internalised by cancer cells which overexpress sugar receptors without the need
to add any other targeting moiety. In this thesis, PNs based on glycopolymers
are applied to a platinum-based drug and studied in vitro on cancer cell lines.
As discussed in the previous section, the size, shape and surface characteristics
are the features generally taken into account when designing the PN. In the
second part of this thesis, the extent of platinum drug loading is explored as a
new feature that needs to be taken into consideration because of its influence on
the morphology of the PN, which has an important role in its interaction with
cells, thus affecting its efficiency.
Finally, a platinum complex will be combined with paclitaxel, another cancer
drug, in a single carrier to improve their biological activity through the synergistic
effect between the two chemotherapeutics.
1.4 Flow of the thesis
The thesis includes ten chapters. Beyond the Introduction, the reader will find
an extensive literature review in Chapter 1 which will give a general overview on
the state of art around drug delivery systems for platinum-based drugs. First, the
mechanism of action of platinum-based drugs will be described followed by the
evolution of new generations of drugs. Subsequently, the most relevant examples
of drug delivery systems applied to platinum drugs found in the literature will
be reported grouped according to the pathway used to encapsulate the platinum
drug into the polymeric delivery system.
Chapter 2 will describe the two main polymerization methods used to synthe-
size the block copolymers in this work: Radical Addition-Fragmentation Transfer
(RAFT) polymerization and N -Carboxyanhydride Ring Opening Polymerization
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(NCA-ROP). Chapter 3.10 reports the methods for biological evaluation of drugs
and nanocarrier, whereas in Chapter 3 the reader will find the details of tech-
niques and instruments used in this work.
In Chapter 4, the targeting effect of different sugars making the outer shell
of polymer micelles on the efficiency of a platinum-based chemotherapeutic was
studied. Four different sugars (glucose, galactose and two isomers of fructose)
were used to synthesize the glycopolymers to which a platinum drug was con-
jugated and self-assembled into micelles. The sugar-based outer shell of these
micelles affects the cellular uptake with fructose showing good targeting proper-
ties towards breast cancer.
In Chapter 5, the changes in internal morphology of fructose-based micelles
when highly or poorly loaded with a platinum complex were put in relationship
with their biological behaviour. The study gave important insight into an impor-
tant aspect that seems to have been neglected in the literature so far.
In Chapter 6, a fluorescent platinum complex was prepared for probing the
internalization of the nanocarrier into cells, and the release of the drug from
the polymer to finally target the DNA. In particular, this fluorescent probe will
be used to compare fructose based glycopolymer and neutral synthetic block
copolymer made nanocarriers to investigate whether their mechanism of action
differs.
In Chapter 7, a platinum complex was combined with paclitaxel into vesicles
made of a polypeptide-base triblock copolymer. The efficiency of the dual-drug
delivery system was tested on 3D cancer spheroids.
In Chapter 8 the reader will find conclusions and final remarks of the thesis.
Lastly, there will be an Appendix with abbreviations and the Bibliography.
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Chapter 2
Synthesis of block-copolymers
Block copolymers consist of two or more chemically homogeneous polymer blocks
joined together by covalent bonds. The simplest case is a linear diblock (AB)
made of two monomers: A and B. However, linear multiblock copolymers (e.g.
ABA or ABC), branched or star-block copolymers can also be prepared. The
blocks that form a block copolymer can have different solubility properties and
thus can undergo self-assembly in block-selective solvents. For example, a diblock
copolymer self-assembles in block-selective solvents which solubilize one, but not
the other block, forming micelles of various shapes [170, 171, 172]. If the soluble
block is predominant, the insoluble block aggregates to produce spherical micelles.
As the length of the soluble block is decreased relative to the insoluble block,
cylindrical micelles or vesicles are formed (Figure 2.1).
Many different synthetic methods can be employed to prepare block copoly-
mers and the choice of method depends on the type of monomers and the final
scope of the copolymer. In this thesis, Radical Addition-Fragmentation Transfer
(RAFT) polymerization and Ring Opening polymerization (ROP) were employed
to prepare amphiphilic block copolymers.
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Figure 2.1: Cross-sectional view of chain packing in diblock copolymer (a) spher-
ical, (b) cylindrical, (c) vesicular and (d) tubular micelles.
2.1 Radical Addition-Fragmentation Transfer poly-
merization
Most conventional polymers can be obtained by a Free Radical Polymerisation
(FRP) process. Radical chain polymerization is a chain reaction consisting of a
sequence of three steps: initiation, propagation, and termination. The initiation
step is involves two reactions. The first is the production of free radicals. The
usual case is the homolytic dissociation of an initiator species I to yield a pair
of radicals R•. This is usually achieved by exposing the initiator in a thermal
or ultraviolet environment, but it can also be done through irradiation or redox
chemistry
I
kd−−→ 2R•.
The decomposition rate of the initiator is described by the following expres-
sion:
d[R]
dt = 2fki [I2]
where R is the radical concentration, [I2] is the initiator concentration, t is the
time and ki is the rate constant of decomposition, typically around 10−1 to
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10−6s−1, f is the initiator efficiency defined as the fraction of radicals formed
in the step of the initiation which successfully starts the polymerization process.
The second part of the initiation involves the addition of this radical to the first
monomer molecule to produce the chain-initiating radical M•1
R• + M
ki−−→M •1 .
Propagation consists of the growth of M•1 by the successive additions of large
numbers of monomer molecules. Each addition creates a new radical that has the
same identity as the previous, except that it is larger by one monomer unit. The
successive additions may be represented by
M •n + M
kp−−→M •n+1.
At some point, the propagating polymer chain stops growing and terminates.
Termination with the annihilation of the radical centres occurs by bimolecular
reaction between radicals. Two radicals react with each other by combination or
by disproportionation, in which a hydrogen radical that is beta to one radical
centre is transferred to another radical centre. This results in the formation of
two polymer molecules: one saturated and one unsaturated. The two different
modes of termination can be represented in general terms by:
M •n + M
•
m
ktc−−→Mn+m
M •n + M
•
m
ktd−−→Mn + Mm
where ktc and ktd are the rate constants for termination by coupling and dispro-
portionation, respectively. One can also express the termination step by
M •n + M
•
m
kt−−→ dead polymer
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where the particular mode of termination is not specified and
kt = aktc + (1− a)ktd
where a and (1− a) are the fractions of termination by coupling and dispropor-
tionation, respectively. The term dead polymer signifies the cessation of growth
for the propagating radical. The propagation reaction would proceed indefinitely
until all monomer molecules in a reaction were exhausted if it were not for the
strong tendency toward termination. Typical termination rate constants are in
the range of 106-108 L/(mol s) or orders of magnitude greater than the propaga-
tion rate constants. The greater value of kt (whether ktc or ktd) compared to kp
does not prevent propagation because the radical species are present in very low
concentrations and because the polymerization rate only depends on the one-half
power of kt.
Living Free Radical Polymerization (LFRP), now preferably called Reversible
Deactivation Radical Polymerization (RDRP), provides a solution to the irre-
versible termination of FRP; enabling a greater control over the weight of macro-
molecules and the synthesis of complex polymer architectures [173, 174]. RDRP
with reversible termination generally proceeds as follows:
R− Z −−⇀↽− R• + Z• (1)
where R• is the reactive radical and Z• is the stable radical,
R•
M−−⇀↽− RM •n Propagating radical (2)
RM •n
Z•−−→ RMn − Z Dormant species (3)
RM •n −−⇀↽− Bimolecular termination (4)
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The initiator R−Z undergoes homolytic bond breakage to produce one reac-
tive and one stable free radical. The reactive radicals quickly initiate polymeriza-
tion, while the stable radicals are too stable to do so. Technologically important
living systems are those in which all the initiator decomposes at once or in a very
short time so that all propagating radicals grow for very close to the same time.
Fast initiation is important, but it is the fast equilibrium between the propagat-
ing radical and dormant species with an appropriate equilibrium constant that
determine the living characteristics of these reactions. The equilibrium constant
must be low but not too low: the concentration of propagating radical must be
sufficient to achieve a reasonable propagation rate but not so high that normal
bimolecular termination becomes important.
The concentration of propagating and stable radicals are equal at the start,
but there is a rapid and drastic change over time. The most important feature
of living radical polymerization is a build-up in the concentration of the stable
radicals because of their stability, the normal termination of initiating and prop-
agating radicals in the early stage of polymerization, and the irreversible addition
of monomer to the initiating radicals. The equilibria (1), (3) and (4) are shifted
to the right toward the dormant species. Overall, the concentration of stable
radicals increases to at least four orders of magnitude than the concentration
of propagating radicals. The concentration of propagating radicals is about the
same or somewhat lower than that in traditional (non-living) radical polymer-
izations. The stable radical acts as a controlling or mediating agent because
it is sufficiently reactive to couple rapidly with propagating chains to convert
them reversibly into dormant, non propagating species. The dormant species are
in equilibrium with propagating radicals. The equilibrium favours the dormant
species by several orders of magnitude. The concentration of dormant species is
about 6 orders of magnitude greater than the concentration of propagating rad-
icals. Typically, the propagating radical concentrations are 10−7-10−8 M while
the concentration of dormant species is 10−1-10−3 M. The overall result is that,
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with the introduction of the dormant state the bimolecular termination of living
polymers is suppressed and the average lifetime is increased by at least four or-
ders of magnitude. The stable radical is often called the persistent radical, and
its suppression of bimolecular termination between living polymers is called the
persistent radical effect (PRE). The persistent radical effect with its suppression
of bimolecular termination of living polymers coupled with the reversible reac-
tion of propagating radicals with the persistent radicals form the basis for living
radical polymerization [175].
When monomer conversion is complete, a second batch of a different monomer
can be added to form a block copolymer. If the second batch of monomer is not
added quickly and the reaction conditions not altered to preserve the dormant
species, there will be a continuous deterioration of the reaction system's ability to
form block copolymers because of bimolecular termination between propagating
radicals since no other competitive reaction is possible in the absence of monomer.
The equilibrium between dormant species and radicals will be pushed toward the
propagating radicals and their subsequent irreversible bimolecular termination.
RDRPs include Atom-Transfer Radical Polymerization (ATRP), Stable Free-
Radical Polymerization (SFRP) which proceed through reversible termination
and Reversible Addition-Fragmentation Transfer (RAFT) which proceeds through
reversible chain transfer. In this work, RAFT polymerization was used to syn-
thesize most copolymers.
Reversible Addition Fragmentation Chain Transfer (RAFT) Polymerisation
[173] uses chain transfer in order to control the propagation during the polymeri-
sation and to limit, although not completely remove, termination pathways. This
is achieved by employing a thiocarbonyl compound known as the RAFT agent.
Various sulphur containing compounds can be used as RAFT agents. In this work
dithioesters were used as RAFT agents (Figure 2.2). The RAFT agent consists
of two functional groups: the Z group is a stabilizing group which determines
the stability and reactivity of the thiocarbonyl group towards the addition and
73
fragmentation process; the R group is a leaving group which cleaves from the
RAFT agent to form a more stable radical which can initiate the polymerisation
of monomer units to form a propagating chain [176].
Figure 2.2: Typical structure of a dithioester RAFT agent.
The mechanism of RAFT starts similarly to the conventional FRP process,
but with a slightly different propagation mechanism, Figure 2.3:
Figure 2.3: Mechanism of RAFT polymerization using dithioester RAFT agent.
The propagating chains (P •m) react with the RAFT agent to form an interme-
diate radical. The equilibrium here favours the loss of the R group resulting in a
dormant mode where the propagating process is temporarily stopped. The leaving
group, R•, reacts with other monomer units to form a propagating chain P •n . That
propagating chain P •n then reacts with the RAFT agent capped macromolecule
to form a second intermediate radical resulting in the loss of the first propagating
chain P •m. For different polymerisation processes the Z and R groups need to be
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changed to suit the reaction, as their reactivity towards different monomer units
varies. The stability of the R group is important in determining the rate of cleav-
age from the RAFT agent and the reattachment to the macroRAFT molecule.
The RAFT agent generally acts in much the same way as a conventional transfer
agent, but retardation is observed in some polymerizations because of coupling
between the intermediate dithioester radical and a propagating radical [177]. Re-
tardation may also be due to slow fragmentation in the transfer reactions. The
RAFT agent affects the number of polymer chains formed. The number of chains
is determined by the amount of RAFT agent consumed and the amount of con-
ventional initiator decomposed [178]. The degree of polymerization depends on
the monomer conversion and the number of polymer chains according to
X¯n =
p[M ]0
(p′[RAFT ]0+2fp′′[I])0
where [M ]0, [RAFT ]0 and [I]0 are the initial concentrations of monomer,
RAFT transfer agent, and initiator. p, p′, and p′′ are the fractional conversions
of monomer, RAFT agent, and initiator, respectively. The fraction of polymer
molecules with dithioester end groups is maximized (compared to chains termi-
nated by normal bimolecular termination) by maximizing the amount of chain
transfer. This is accomplished by using high concentrations of RAFT agents rel-
ative to initiator and RAFT agents with large chain-transfer constants. Many
dithioesters have chain transfer constants exceeding 1000. Under these condi-
tions, the RAFT agent is consumed within the first few percent of monomer
conversion (p′ = 1) and the number of polymer chains due to initiator decom-
position is small (p′ [RAFT ]02fp
′′ [I])0). The degree of polymerization is given
by
X¯n =
p[M ]0
[RAFT ]0
RAFT polymerization proceeds with narrow molecular weight distributions
as long as the fraction of chains terminated by normal bimolecular termination
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is small. This occurs when a RAFT agent with high transfer constant is used
and the initiator concentration decreases faster than the monomer concentration
does. Dispersity (Ð) increases when new chains are initiated over a longer time
period.
A significant advantage of RAFT is that it works with a wider range of
monomers than NMP and ATRP. Block copolymers can be obtained by the
RAFT polymerisation process which involves the polymerisation of one monomer
followed by the introduction of a second type of monomer. In detail, the first
monomer propagates to form polymer chains which have the R group on one
end of the molecule and the Z group on the other end. These groups can be re-
activated and propagation can be continued with the introduction of an additional
monomer. Many factors need to be taken into consideration for the production
of block copolymers. Firstly, the leaving property of the macromolecule leaving
group must be considered for the proper use of RAFT mechanism. Therefore,
a sensible choice of the first type of monomer is vital. For example, when mak-
ing poly(methylmethacrylate) and poly(styrene) block copolymers, the methyl-
methacrylate must be polymerised first as it is a better leaving group when com-
pared to styrene. Secondly, the choice of solvent is also very important, as it
can reduce side reactions such as chain transfer. Finally, the amount of initiator
used for the block copolymer synthesis is critical. A low initiator concentration
is desired in order to limit the amount of homopolymer impurity [179].
2.2 Ring opening polymerization
A wide variety of cyclic monomers have been successfully polymerized by Ring-
Opening process. These include N -carboxy-α-amino acid anhydrides. The single
most important factor that determines whether a cyclic monomer can be con-
verted to linear polymer is the thermodynamic factor, that is, the relative sta-
bilities of the cyclic monomer and linear polymer structure. Polymerization is
favored thermodynamically for all except the 6-membered ring. Ring opening
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polymerization of 6-membered rings is generally not observed.
Ring Opening Polymerization (ROP) is a chain polymerization consisting
of a sequence of initiation, propagation, and termination. Many ring opening
polymerizations proceed as living polymerizations: polymer molecular weight in-
creases linearly with conversion and the ratio of monomer to initiator.
N -Carboxy-α-amino acid anhydrides are polymerized by bases and transition
metal complexes. The polymerization proceeds with simultaneous decarboxyla-
tion to produce a polyamide:
The polyamide is a substituted nylon-2 derived from an α-amino acid, the
same type used in living organisms to produce polypeptides. NCA polymeriza-
tions have been used to synthesize polypeptides, both homopolymers and copoly-
mers, that may be useful in biotechnology applications such as artificial tissues,
drug delivery, and biosensors. Primary aliphatic amines, which have a high nu-
cleophilicity relative to basicity, polymerize N -carboxyanhydrides by the amine
mechanism involving nucleophilic attack by nitrogen at the C-5 carbonyl of NCA
with evolution of carbon dioxide:
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The polymerization rate is directly dependent on the concentrations of monomer
and amine. Most NCA polymerizations have similar but not exactly the same
characteristics as living polymerizations. The degree of polymerization is pro-
portional but not always equal to the monomer/amine ratio, and the dispersity
(Ð) is usually broadened or bimodal. The overall lack of control is attributed
to termination, transfer, and other side reactions. Polymerization by aromatic
primary amines, which are weaker nucleophiles, proceeds with considerable molec-
ular weight broadening due to the slower rate of initiation relative to propagation.
In this work, a primary amine will be used to initiate the reaction via a nucle-
ophilic attack to the ring.
2.3 Self-assembly of amphiphilic block copolymers
in solution
Independently of the method of synthesis, block copolymers can be considered as
formed by the union of two or more chemically homogeneous polymer fragments
(blocks) joined together by covalent bonds. Two distinct monomers, convention-
ally named A and B, can give a linear diblock (AB), a triblock (ABA or BAB),
a multiblock, or star-block copolymers. The building blocks should contain all
the necessary information to direct their self-assembly, thus, their design is the
keystone of nanofabrication. The morphology of the final aggregate is strongly
correlated to intrinsic parameters of the copolymer, such as the interaction pa-
rameter between the two blocks, the molecular weight, the block ratio, the dis-
persity, and the thermomechanical properties. Moreover, same polymers can give
different structures depending on the preparation process [9, 10]. Finally, the
targeted morphologies will be completely different if the copolymer is pure (bulk)
or diluted in a solvent system.
Amphiphilic block copolymers are generally characterized by a hydrophilic
block and a hydrophobic block. Water will preferentially dissolve one part of
78
a polymer over the other. It is more entropically favorable for the hydrophobic
segments to pack together in the core of the aggregate than for water to order itself
around each one separately in solution. The hydrophilic segments, however, prefer
to dissolve in water. This is because the interaction between hydrophilic parts
would lead to short range repulsion whilst there is an enthalpic compensation
from forming hydrogen bonds with water molecules. The balance between these
forces drives the formation of nanostructures [180]. The geometry and degree of
order of these architectures depends on the concentration and the volume ratio
between insoluble and soluble blocks: the so called insoluble-soluble ratio (ISR)
[181].
At very dilute concentrations, the soluble block compatibility with the host
solvent is sufficient to maintain the copolymer as dissolved molecules. At a certain
concentration, called the critical aggregation concentration (CAC), block copoly-
mers start to self-assemble to separate the insoluble blocks from the solvent. As
the molecular mass and the ISR increase, the CAC decreases. At concentrations
higher than CAC, block copolymers self-assemble into dispersed isotropic phases.
Knowing the CAC, one can obtain the stability of the aggregates from the
thermodynamics. The free energy change is:
∆G0agg = −RTln(Kc) = RTln(CAC)
where T is the temperature of the system, R is the gas constant and Kc is
the association number of unimers to form the aggregate. The typical CAC
for amphiphilic block copolymers is generally higher the the one of low molecular
weight surfactants. Hence, aggregation of block copolymers is thermodynamically
favoured compared to aggregation of low molecular weight surfactants. Well-
defined amphiphilic block copolymers undergo self-assembly in aqueous solution
in order to minimize energetically unfavourable hydrophobe-water interactions.
The various reported morphologies are primarily a result of the inherent molecu-
lar curvature and how this influences the packing of the copolymer chains: specific
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self-assembled nanostructures can be targeted according to a dimensionless pack-
ing parameter p:
p = va0d
where v is the volume of the hydrophobic chains, a0 is the optimal area of the
head group, and d is the length of the hydrophobic block. The packing parameter
is the ratio between the insoluble chain molecular volume and the volume actually
occupied by the copolymer in the assembly. As a general rule, spherical micelles
are formed when p ≤ 1
3
, cylindrical micelles are formed at 1
3
< p ≤ 1
2
and
membrane structures such as vesicles, also know as polymersomes, arise when 1
2
<p ≤ 1 (Figure 2.4) [182].
Figure 2.4: Different geometries formed by block copolymers in selective solvent
conditions [181].
If the two blocks have the same solubility the aggregates can still be produced
by the in situ formation of multiple cross-linking points. When the two blocks
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have different solubility the aggregate formation is triggered using a selective sol-
vent. In this case, the copolymer is dissolved in a good solvent for both blocks,
followed by a controlled change in the solvent composition, for example, by grad-
ually adding a solvent selective for one of the blocks. An alternative route is the
replacement of the good solvent by a selective solvent through a dialysis set-up.
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Chapter 3
Methods and Instruments
3.1 Nuclear Magnetic Resonance (NMR)
Spectroscopy
3.1.1 Solution Nuclear Magnetic Resonance (NMR)
Spectrometry
For 1H and 13C experiments the following spectrometers were used: Bruker DPX
(300MHz), Bruker AVANCE III with (400MHz) Prodigy probe, Bruker AVANCE
III (400MHz), Bruker AVANCE III (600MHz) Cryo probe, and will be specified
case by case. Samples were dissolved in the suitable deuterated solvent and the
experiments run at room temperature unless otherwise specified. All chemical
shifts are stated in ppm (δ) relative to tetramethylsilane (δ=0ppm), referenced
to the chemical shifts of residual solvent resonances. 195Pt NMR spectra were
recorded using a Bruker AVANCE III (400MHz) and Bruker Prodigy (400MHz)
and calibrated using a K2PtCl4 standard in D2O (δ=-1617 ppm).
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3.1.2 Solid-State Nuclear Magnetic Resonance (NMR)
Spectroscopy
1D 13C and 2D 1H-13C heteronuclear correlation and 1H-1H homonuclear correla-
tion spectra were obtained at 16.4T (1H and 13C Larmor frequency of 700MHz
and 175MHz respectively) using a Bruker Avance III NMR spectrometer and
4mm or 1.3mm magic angle spinning (MAS) double resonance probes. For the
13C and 1H-13C correlation experiment, ∼30mg of sample was centre packed in
4mm zirconia MAS rotors with kel-f caps and spun to 14 kHz MAS. Both spectra
were acquired with 100 kHz 1H spinal-64 decoupling scheme during acquisition.
1H to 13C Hartman Hahn cross polarization was achieved via a 3ms contact pulse.
The contact pulse amplitude on the 1H channel was ramped from 70 to 100% to
minimize variation in transfer efficiency due to mismatch of the Hartman Hahn
condition. The 2D dataset was acquired by collecting 32 transients in the indirect
domain with increments of 50µs in the 1H evolution time. For the 1H-1H corre-
lation spectra, approximately 5mg of sample was packed in a 1.3mm MAS rotor
for measurement. The spectra were acquired at 60KHz MAS with temperature
regulation to offset the MAS heating effects, which yielded a sample temperature
of approximately 55 ◦C. The 1H 90◦ pulse width was 1.7µs. The 2D 1H-1H SQ-
SQ correlation experiments (2D exchange) were acquired with 1H spin diffusion
mixing times of 100ms to 1 s. Where needed, 4ms 1H-1H-T2 filter period was
inserted to spectrally edit out the rigid components prior to the 1H evolution in
the indirect domain. The data set was acquired by collecting 256 transients in
the indirect domain with increments of 80µs in the 1H evolution time.
3.2 Gel Permeability Chromatography (GPC)
Gel permeation chromatography (GPC) measurements were carried out with
a Shimadzu modular system, comprising of an auto-injector, a Phenomenex
Phenogel 5.0mm bead-size guard column (50× 7.5mm), four linear Phenomenex
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columns (105, 104, 103 and 500 ), and a differential refractive index detector. The
eluent used was N,N -dimethylacetamide (DMAc) (0.05% w/v LiBr, 0.05% w/v
BHT) at 50 ◦C with a flow rate of 1mL/min. The apparent molecular weights
(MwGPC and MnGPC) and dispersities (Mw/Mn) were determined with a cali-
bration based on linear PS standards ranging from 162 to 2× 106 g/moL. Addi-
tionally, water GPC (water containing 0.02% w/v NaN3) was performed using
a Shimadzu modular system comprising a DGU-12A solvent degasser, an LC-
10AT pump, a CTO-10A column oven, and a RID-10A refractive index detector
(flow rate: 0.8mL/min). The system was equipped with a Polymer Laboratories
5.0mm bead-size guard column (50× 7.8mm2) followed by three 300× 7.8mm
linear PL columns (30, 40 and 50 respectively in type). Calibration was conducted
with PEG standards ranging from 500 to 500,000 g/moL.
3.3 Dynamic Light Scattering (DLS)
Dynamic Light Scattering (DLS) measurements were used to study size and z-
potential of the nanoparticles and were conducted using a Malvern Instruments
Zetasizer Nano ZS instrument equipped with a 4mV He-Ne laser operating at
λ=633 nm, an avalanche photodiode detector with high quantum efficiency, and
an ALV/LSE-5003 multiple tau digital correlator electronics system. The par-
ticles were analysed at a concentration of 1mg/mL in an aqueous medium and
filtered with a micropore filter (0.45µm) to remove dust. Dynamic light scatter-
ing was also used to study the critical micelle concentration (CMC) measuring
the count rate (kcps) at fixed attenuation.
3.4 Transmission Electron Microscopy (TEM)
The sizes and morphologies of the nanoparticles were observed using a trans-
mission electron microscope JEOL1400 TEM consisting of a dispersive X-ray
analyzer interfaced to the column and a Gatan CCD and an accelerating voltage
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of 100 kV. Samples were prepared by casting a 1mg/mL particle aqueous solution
onto a copper grid. The grids were air-dried and stained with phosphotungstic
acid or uranyl acetate, details will be reported case by case in following chapters.
3.5 Thermal Gravimetric Analysis (TGA)
Thermal gravimetric analysis (TGA) was used to measure the amount of platinum
complex loaded into the polymeric carriers. TGA was recorded using a TG5000
Thermogravimetric Analyzer. The sample (≈ 3mg) was placed on a thermo-
balance and heated from 25 to 800 ◦C at 20 ◦C/min and held isothermally at
100 ◦C for 10 min under an air atmosphere.
3.6 Fourier Transform Infra-Red (FT-IR) Spec-
troscopy
Transmission spectra were acquired by a Bruker IFS 66/S single-beam spectrom-
eter. The instrument has been equipped with a mid-infrared lamp and diffuse
reflectance sampling accessories. A minimum of 32 scans were performed for each
sample at a resolution of 4 cm−1.
3.7 Inductively Coupled Plasma Mass Spectrom-
etry (ICP-MS)
A Perkin-Elmer ELAN 6000 inductively coupled plasma-mass spectrometer (Perkin-
Elmer, Norwalk, CT, U.S.A.) was used for quantitative determinations of plat-
inum either to measure the drug release from a carrier or the amount of platinum
conjugated onto a polymer when TGA analysis was not available. All measure-
ments were carried out at an incident ratio frequency power of 1200W. The
plasma argon gas flow of 12 L/min with an auxiliary argon flow of 0.8 L/min was
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used in all cases, and the nebulizer gas flow was adjusted to maximize ion inten-
sity at 0.93 L/min as indicated by the mass flow controller. The element/mass
detected was 195Pt and the internal standard used was 193Ir. Replicate time was
set to 900ms and the dwell time was set to 300ms. Peak hopping was the scan-
ning mode employed and the number of sweeps/readings was set to three. Ten
replicates were measured at normal resolution.
3.8 Fluorescence spectroscopy
Fluorescence measurements were performed on an Agilent Cary Eclipse Fluores-
cence Spectrophotometer with xenon a flash lamp using a 1 cm path length and
a 4-sided quartz cuvette. All measurements were obtained at room temperature.
Further details will be specified in each chapter.
3.9 Optical Microscope
The optical microscope Leica DM IL inverted was used to obtain images of crys-
tals or cells .
3.10 Biological evaluation
3.10.1 Cell culture and viability
2D evaluation
In this thesis, 2D cell models were used to test cellular uptake and viability of
drugs and drug carriers. Several cell lines were used: human ovarian carcinoma
(A2780), human non-small cell lung carcinoma (A549) and human prostate car-
cinoma (LNCaP) cell lines were cultured using Roswell Park Memorial Institute
(RPMI-1640) media containing 10% Foetal Bovine Serum (FBS), sodium pyru-
vate and antibiotics (plasmocin); human breast carcinoma (MCF-7 and MDA-
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MB-231) cell lines were cultured using Dulbecco's Modified Eagle's medium (DMEM)
containing 10% FBS and antibiotics (plasmocin). Cells were grown in a ventilated
tissue culture flask T-75, incubated at 37 ◦C under a 5% CO2 humidified atmo-
sphere and passaged when monolayers reached about 80% confluence. To screen
the antitumor drugs and drug carriers standard sulforhodamine B colorimetric
proliferation assays (SRB assay) were performed [183].
The cells were seeded at a density of 4,000 cells per well in 96-well plates
containing 200µL of growth medium and incubated for 24 h. The medium was
then replaced with fresh medium (200µL) containing various concentrations of
the material being tested. Figure 3.1 shows a typical 96-well plate for cytotoxicity
evaluation. Three wells were dedicated to each concentration, from highest (dark
green) to lowest (light green). The outer wells were not seeded with cells and
filled with 200µL of MilliQ water to keep the moisture level inside the plate
homogeneous. As a control, a minimum of 9 wells were seeded with cells and
left untreated. Three wells were dedicated to a fixed concentration of cisplatin
(50µM) to make sure that the cells had not developed resistance to platinum.
Moreover, if DMF or DMSO were employed to dissolve the tested drug, 3 wells
were dedicated to the highest concentration of the organic solvent to ensure that
it did not effect cellular growth.
Figure 3.1: Diagram of a typical 96-well plate used for the cytotoxicity assays.
The shades of green represent the different concentration of therapeutic: from
highest (darker green) to lowest lighter green).
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After 72 h incubation, the medium was removed and cells were fixed with
trichloroacetic acid 10% w/v (TCA) before washing, then incubated at 4 ◦C for
1 h. Cells were then washed five times with MilliQ water and air dried. TCA-fixed
cells were stained for 30min with 0.4% (w/v) SRB dissolved in 1% acetic acid.
At the end of the staining period, SRB was removed and cultures were quickly
rinsed five times with 1% acetic acid to remove any unbound dye. The cultures
were then air dried until no conspicuous moisture was visible. The bound dye
was dissolved by adding 200µL of 10mM Tris Buffer (0.6055 g of Tris (Sigma
T1053) in 500mL of MilliQ H2O). The 96-well plate was shaken for 30 s and the
optical density (OD) at 490 nm was measured using a microtiter plate scanning
spectrophotometer Bio-Rad BenchMark microplate reader. All experiments were
repeated three times. Dose-response curves were plotted (values were expressed
as the percentage of control, medium only) and IC50 inhibitory concentrations
were obtained using the software Graph Pad PRISM 6.
3D evaluation
Cells within the human body interact with neighboring cells and extracellular
matrix (ECM) components to establish a unique 3D organization. Cell-cell and
cell-ECM interactions form a complex communication network of biochemical and
mechanical signals, which are critical for normal cell physiology. As a result, when
cells are grown in 2D monolayer cultures there is a loss of tissue-specific properties
[184]. To better mimic the 3D organization of tumours in the human body and the
interactions between tumour cells, 3D Multi Cellular Tumour Spheroids (MCTS)
can be grown and used to evaluate the properties of drug delivery systems.
MCTS were employed in Chapter 7 to evaluate the toxicity and penetration of
nanoparticles into a 3D cell structure. Lung cancer cell line A549 were grown in a
ventilated tissue culture flask T-75, incubated at 37 ◦C under a 5% CO2 humidified
atmosphere and passaged when monolayers reached about 80% confluence. The
cells were cultured using RPMI-1640 media containing 10% FBS, sodium pyruvate
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and antibiotics (plasmocin). To prepare spheroids, cells were seeded into a 96-
well suspension culture plate (Corning 7007) at a cell density of 1× 104 cells/mL
suspended in 200µL of medium. The outer wells were filled with 200µL of water
to keep the moisture inside the plate homogeneous. The 96-well plate was then
centrifuged for 5 min at 500 g and incubated for 4 days until spheroids formed,
as observed by optical microscope the MCTS had a diameter of about 400µm.
Viability of the MCTS treated with free drugs or drug loaded nanoparticles was
measured via acid phosphate (APH) assay and the change in morphology was
observed using a optical microscope.
3.10.2 Microplate reader
Microplate readers are designed to detect biological, chemical or physical events
of samples in microtiter plates. The microplate reader used in this work was a
Bio-Read microplate reader with a single wavelength at 490 nm. The microplates
used were 96-well (8 × 12 matrix) plates with a typical reaction volume of 200µL
per well.
3.10.3 Laser Scanning Confocal Microscopy (LSCM)
Typically, cells were seeded in 35mm Fluorodishes (World Precision Instruments)
with a density of 2× 10 5 cells per well in 2mL of medium. Nanoparticles were
labelled with fluorescein isothiocynate (FITC), loaded to the cells at a working
concentration of 100µg/mL and incubated in a humidified incubator (5% CO2,
95% air atmosphere at 37 ◦C) for 6 h. After incubation, the cells were washed
three times with PBS. The laser scanning confocal microscope system (Zeiss LSM
780) consisted of an argon laser (excitation wavelengths 405 nm) connected to a
Zeiss Axio Observer.Z1 inverted microscope (oil immersion × 100/1.4 NA or
× 20/1.4 NA objective) was used for observation. Zen2011 imaging software
(Zeiss) was used for imaging acquisition and processing. MCTS were cultured
for 4 day until complete formation. Drug loaded vesicles labelled with fluorescein
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isothiocynate (FITC) were loaded to the MCTS at a working concentration of
250µg/mL and incubated in a humidified incubator (5% CO2, 95% air atmosphere
at 37 ◦C) for 2 h. After incubation, the MCTS were transferred into a glass-
bottomed dish and carefully washed with PBS several times. The penetration of
the vesicles into the spheroids was observed under a Zeiss LDM 880 laser scanning
confocal microscope system equipped with an argon laser connected to a Zeiss
Axio Observer.Z1 inverted microscope (× 10/1.4 NA objective) was used for
observation. Zen2011 imaging software (Zeiss) was used for imaging acquisition
and processing.
3.10.4 Flow cytometry
Cells were seeded into 6-well tissue culture plates at a density of 5× 105 cells per
well and cultured for 2 days. Micelles were loaded into the wells at a working
concentration of 100µg/mL and incubated in a humidified incubator (5% CO2,
95% air atmosphere at 37 ◦C) for 6 h. After incubation, the cells were washed
three times with cold PBS. The cells were treated with trypsin, centrifuged and
resuspended in cold serum free medium before measurement. Flow cytometry
assays were performed with a BD FACSCanto II Analyzer (BD Biosciences, San
Jose, USA).
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Chapter 4
Modulating the cellular uptake of
platinum drugs with glycopolymers
The therapeutic potency of platinum-based anticancer drugs can be substantially
improved through the use of polymeric nanocarrier systems to target cancer cells
efficiently. Here, a series of glyco-block copolymers with three different sug-
ars able to self-assemble into nanoparticles when conjugated with (1S,2S )-trans-
1,2-diamino cyclopentane platinum(II) ([Pt((1S,2S )-dacp)Cl2]) were synthesised.
The polymers are based on glucose, galactose, and two isomers of fructose. They
are all readily taken up intracellularly by the breast cancer cell lines MCF-7 and
MDA-MB-231 and the ovarian cancer cell line A2780. All cell lines expressed
a high preference for the fructose coated nanoparticles. The nanocarriers were
themselves non-toxic, but exhibited high cytotoxicity and increased efficacy when
conjugated with the [Pt((1S,2S )-dacp)Cl2] drug.
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4.1 Introduction
Cisplatin is one of the most widely used metal-containing anticancer drugs in the
treatment of a variety of tumour cells. However, its extremely toxic side effects
restrict its clinical use. Many attempts have therefore focused on improving
cisplatin analogues capable of avoiding its side effects [25] and significant progress
has been made in delivering platinum drugs using nanoparticles [185]. The success
of these nanoparticles is evident by their progression into clinical trials, examples
include NanoplatinTM , LipoplatinTM , and ProlindacTM discussed in Chapter 1.
These successful drug delivery systems are all based on neutral water-soluble
polymers. Targeting of low molecular weight platinum drugs by replacing one
of the ligands with a bioactive ligand such as estrogen or galactose has been a
very common approach [186] while active nanoparticle targeting strategies are
just emerging.
In recent years, targeting ligands were introduced to the surface of the nanopar-
ticles to enhance the accumulation of platinum drug containing drug carriers. Ex-
amples found in the literature [19, 18, 15, 16, 17, 20, 15] frequently use PEG-based
polymers. However, hypersensitivity and increased immune response have been
observed after a series of treatments with PEG based drug carriers [187]. Gly-
copolymers are alternative water-soluble polymers [188, 189, 190, 191]. They are
prepared from natural building blocks and additionally display high bioactivity
[192]. Carbohydrates play a pivotal role in cell recognition and communication
with many carbohydrates displaying selectivity towards certain lectins. This pre-
ferred interaction of carbohydrates with a selected set of lectins, which are often
overexpressed on certain cell types, can be employed to deliver drug carriers in
a targeted manner. This approach is already popular with galactose based gly-
copolymers, which can specifically deliver drugs to hepatocytes [193, 194]. Also
glycopolymers based on fucose were found to have a high affinity towards cancer
cell lines [195]. It has been recently shown that fructose can be selective towards
cells that overexpress the GLUT5 receptors, such as certain breast cancer cells
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[196]. However, in the past studies neither drugs were delivered nor was this
glycopolymer compared directly to other glycopolymers.
In this Chapter, well-defined glycoblock copolymers composed of metacrylic
acid (MAA) and protected-sugar monomers AcGlcMA, AcGalMA, iprFrucMA1,
and iprFrucMA3 were synthesized via reversible addition-fragmentation chain
transfer (RAFT) polymerization. After deprotection of the sugar blocks, the
copolymers were conjugated with the anticancer drug (1S,2S )-trans-1,2-diamino
cyclopentyl diaquo platinum ([Pt((1S,2S )-dacp)(H2O)2]) which gave amphiphilic-
ity properties to the copolymers and drove the self-assembly into micelles (Figure
4.1). In cancer therapy, such biocompatible and biomimetic glycopolymeric mi-
celles encapsulating a platinum drug might be promising carriers for anticancer
drug delivery systems and alternative nanotherapeutics affording superior anti-
cancer efficacy due to better targeting.
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Figure 4.1: Schematic representation of the synthesis of glyco-block copolymers
and their nanoparticle preparation.
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4.2 Results and discussion
The glycoblock copolymers scaffold was comprised of sugar moieties based on glu-
cose, galactose or two fructose isomers, respectively, with hydrophobic/hydrophilic
chain length ratio controlled by the copolymerisation with MAA, which serves
as ligand for platinum drug conjugation. Figure 4.1 shows the general synthetic
scheme of the four glycopolymers and drug conjugation. The sugar monomers
and glycopolymers used in this project have been synthesized by Dr. Aydan Dag.
For details on synthesis and characterization of glycopolymers please refer to "A.
Dag∗, M. Callari∗, H. Lu and M. H. Stenzel, Polym. Chem., 2016, 7, 1031" [197].
Table 4.1 summarises the monomer/RAFT/initiator ratios used to prepare
the homo and block copolymers, time of reaction, molecular weight and conver-
sion calculated by 1H NMR, molecular weight and dispersity obtained via GPC
analysis. The measured molecular weight of the protected block copolymers were
found to be significantly higher than the theoretical amounts obtained using NMR
analysis, which was probably caused by the interaction of these amphiphilic poly-
mers with the GPC column material. Interestingly, after deprotection the mea-
sured molecular weight is again close to the theoretical values. After removal of
the protective acetyl or isopropylidene groups from the sugar residues, the de-
protected diblock copolymers were conjugated with anticancer drug [Pt((1S,2S )-
dacp)(H2O)2] via metal complex formation to generate [Pt((1S,2S )-dacp)]-loaded
micelles. [Pt((1S,2S )-dacp)(H2O)2] was used in its aquo form prior to conjugation
to the glyco block copolymers using the carboxylic acid group as ligand (Figure
4.1).
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Table 4.1: Characterization of glyco-block copolymers before and after the deprotection reaction.
GPC
Polymer [M]/[RAFT]/[I] Time (h) Conv. ( %) Mn (g mol−1) Mw/Mn Mn,NMR (g mol−1)
P(AcGlcMA50) 75/1/0.125 7 67 16000 1.07 23300
P(AcGalMA50) 75/1/0.125 7 67 16000 1.08 23300
P(iprFrucMA144) 50/1/0.125 11 89 9400 1.08 14900
P(iprFrucMA334) 50/1/0.125 15 68 8900 1.17 11450
P(AcGlcMA50-b-MAA116) 150/1/0.125 8 77 89500 1.23 33300
P(AcGalMA50-b-MAA112) 150/1/0.125 8 75 74000 1.23 33000
P(iprFrucMA144-b-MAA116) 150/1/0.125 8 77 65000 1.22 24900
P(iprFrucMA334-b-MAA94) 150/1/0.125 8 63 56000 1.24 19550
P(GlcMA50-b-MAA116) (a) 3 >95 25000 1.08 24900
P(GalMA50-b-MAA112) (b) 3 >95 25000 1.07 24600
P(FrucMA144-b-MAA116) (c) 3 >95 18600 1.10 21400
P(FrucMA334-b-MAA94) (d) 3 >95 16000 1.09 16850
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The platinum drug was prepared in a separate step and analysed using 195Pt
NMR (4.7). Briefly, the platinum tetrachloride potassium salt was treated with
potassium iodine to exchange the chloride ligands with trans-directing iodine lig-
ands. (1S,2S )-trans-1,2-cyclopentanediamine dihydrochloride was added to this
platinum iodine potassium salt to give the diiodo derivate. Reaction with silver
sulphate removes the iodine ligands to give the diacqua specie. Prior to complex-
ation of the drug to the polymer, the polymers were deprotonated with NaOH
(2.5M) to generate fully water-soluble polymers. The subsequent conjugation
of the polymer with [Pt((1S,2S )-dacp)(H2O)2] complex was carried out at 37 ◦C
for 24 h followed by dialysis against MilliQ water to eliminate the unconjugated
[Pt((1S,2S )-dacp)(H2O)2]. The glycoblock copolymers showed a conjugation ef-
ficiency of around 60% based on TGA analysis (Figure 4.8). This number is
within the expected range considering that the conjugation of the bulky drug
will not only cause some steric hindrance, but also unfavourable chain stretching.
The calculated drug loading capacity, which is the ratio of the mass of loaded
drug over the overall weight of the drug carrier, is therefore 30% for P(GlcMA-b-
MAA/Pt), 28% for P(GalMA-b-MAA/Pt), 32% for P(FrucMA1-b-MAA/Pt) and
32% P(FrucMA3-b-MAA/Pt). This seemingly high drug loading capacity is the
result of the heaviness of the platinum drug itself. With the conjugation of the
hydrophobic drug, the diblock copolymers start to self-assemble into micelles.
The particles sizes and shapes were measured by DLS and TEM. TEM images
are shown in Figure 4.2. DLS results are summarised in the Table 4.2: the sizes of
P(FrucMA3-b-MAA)/Pt micelles were similar to that of P(FrucMA1-b-MAA)/Pt
micelles, all of which were smaller than 100 nm. The zetapotential is independent
from the type of glycopolymer while it is interesting to observe that the fructose
containing copolymers result in the formation of larger micelles most likely due
to the slightly shorter glycopolymer length.
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Figure 4.2: a) TEM images of the nanoparticles: a) P(GlcMA-b-MAA/Pt), b)
P(GalMA-b-MAA/Pt), c) P(FrucMA1-b-MAA/Pt), d) P(FrucMA3-b-MAA/Pt),
the images were obtained using PTA staining.
Table 4.2: Summary of nanoparticles size, PDI and zeta potential.
Nanoparticles Number mean (nm) PDI ζ (mV)
a 33±4 0.269 -21.8
b 44±4 0.266 -20.9
c 77±5 0.296 -22.5
d 70±4 0.245 -19.7
Since the resulting complexes will theoretically form an unfavourable seven-
membered ring, the occurrences of crosslinking events as depicted in Figure 4.1 is
highly likely. To test this hypothesis the polymers were analysed in DMF using
DLS before and after drug conjugation. The block copolymer is fully soluble in
DMF and appears as unimers with a hydrodynamic diameter of 7 nm. In contrast,
the crosslinked micelle is stable and swells in DMF to a hydrodynamic diameter of
more than 200 nm (Figure 4.3a). In addition, only a minor signal corresponding
to free block copolymer can be observed during GPC analysis indicating that
most block copolymer has been crosslinked into the micelle and filtered off before
GPC analysis (Figure 4.3b).
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(a) (b)
Figure 4.3: a) DLS analysis in DMF of block copolymers before and after drug
conjugation; b) DMAc GPC trace of P(FrucMA144-b-MAA116) after platination
indicating that most block copolymer has been crosslinked into the micelles.
The release of Pt from P(FrucMA1-b-MAA)/Pt micelles was studied at 37 ◦C
in pH7.4 PBS solution, which simulates the environment in plasma. The release
can be triggered by adding NaCl to the solution. The resulting ligand exchange of
the carboxylate ligand by chloride ligand will liberate the platinum complex from
the drug carrier. Release from the polymer is therefore favoured in the presence
of high amounts of chlorides, but not in chloride free buffers. According to ICP-
MS results, the drug was released from P(FrucMA1-b-MAA) micelles releases at
a slow rate with only 40% being released after 100 h, which highlights a high
colloidal stability in the blood stream (Figure 4.4).
Figure 4.4: Release profile of platinum from P(FrucMA144-b-MAA116)/Pt micelles
in PBS (pH=7.4) at 37 ◦C.
99
The cellular uptake behaviour of [Pt((1S,2S )-dacp)]-conjugated glyco-nanoparticles,
which were labelled with fluorescein isothiocyanate (FITC) at a similar con-
centration, was investigated using flow cytometry and LSCM. MDA-MB-231,
MCF-7 and A2780 cancer cells were incubated with FITC-labelled [Pt((1S,2S )-
dacp)]-conjugated P(GlcMA-b-MAA), P(GalMA-b-MAA), P(FrucMA3-b-MAA)
and P(FrucMA1-b-MAA) glyco-nanoparticles at the same polymer concentration
of 100µg/mL for 6 h. Figure 4.5 depicts the cellular uptake of these four nanopar-
ticles.
The enhanced delivery of fructose micelles, in particular the one based on
the 1-substitution, becomes evident. Flow cytometry complements these results
showing a high uptake of all nanoparticles into all tested cell lines, but with a
preference of fructose coated particles, in particular when fructose is conjugated
by the 1-position (Figure 4.6). The result obtained using flow cytometry can be
considered a better measure since LSCM only records a smaller sample size while
the effect of light can easily quench the light-sensitive fluorescent dye. This may
explain why one of the fructose-coated micelles does not show similar enhanced
uptake by MCF-7 using LSCM as with flow cytometry. It is crucial to understand
that although a cell line might have a preference for certain types of molecules, the
large array of receptors and transporters on the surface of each cell line enables
entry into the cells via different passages. Full selectivity can therefore barely
be achieved, at the very best a preference towards one cell line or carbohydrate
over another. Glucose transporters (GLUT) are widely abundant on the surface
of these cells [198], many of them overexpressed on cancer cells [199]. Currently,
twelve glucose transporters are known (GLUT1 to GLUT12), most of them with
an affinity for glucose, while GLUT5 has a higher affinity for fructose. GLUT1
and GLUT12, glucose transporters, are regularly overexpressed in breast cancer
cells, but so is GLUT5, which has a higher affinity to fructose. Interestingly,
GLUT5, that provides a transport mechanism for fructose, is less expressed when
the cell lines, such as here MDA-MB-231, is more invasive.
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Figure 4.5: Cellular uptake of glyco-nanoparticles observed by laser scanning
confocal microscopy. a) P(GlcMA-b-MAA/Pt); b) P(GalMA-b-MAA/Pt); c)
P(FrucMA1-b-MAA/Pt); d) P(FrucMA3-b-MAA/Pt).DIC, Differential interfer-
ence contrast images. Oil immersion × 100/1.4 NA objective.
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However, GLUT5 is still an attractive target for drug delivery as GLUT5 has
only been found in human breast cancer tissue, but not in normal breast tissue
[200]. At the same time galactose can be instrumental in a range of cell processes.
There are four known galactose-binding receptors of the C-type family. These C-
type are the Kupffer cell receptor, the macrophage galactose lectin, the scavenger
receptor C-type lectin and the asialoglycoprotein receptor on hepatocytes [201].
Galactose binding lectins from the S-type family are present in many cancer
cell lines such as ovarian cancer cell lines [202, 203] and some breast cancer cell
lines such as MCF-7, but not MDA-MB-231 [204]. Considering the underlying
theory, it is not surprising that all glyco-nanoparticles have a high affinity to these
cell lines. However, from Figure 4.6 it becomes apparent that fructose still has
the highest uptake in all three cell lines, which may indicate an overexpression
of GLUT5 on these cell lines. This preference is less obvious in the ovarian
cancer cell line A2780 indicating a preference of fructose for some breast cancer
cell lines. The uptake of the nanoparticles coated with 1-substituted fructose is
higher in MCF-7 cells than in MDA-MB-231, probably owing to the decline of
GLUT5 receptors in invasive cell lines [199]. Interestingly, there seems to be a
preference for the micelles with fructose attached in 1-position. This is in contrast
to earlier results where an indifference towards either fructose modification was
noticed. However, the nanoparticles here are larger and there might well be a
size-dependency that needs to be investigated in future studies [196].
Figure 4.6: Cellular uptake measurements via flow cytometry.
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Subsequently, the effect of higher cellular uptake on the effect of drug delivery
was investigated. The cell viability of MCF-7 cells incubated with polymer so-
lutions without any conjugated drugs was determined using the SRB assay. The
polymers did not show obvious cytotoxicity to cells even at high concentrations
(222µg/mL). However, when [Pt((1S,2S )-dacp)Cl2] was conjugated to the gly-
copolymers, the cell viability of A2780, MCF-7 and MDA-MB-231 decreased in
a concentration dependent manner. In addition, the free [Pt((1S,2S )-dacp)Cl2]
was investigated as control. The resulting IC50 values are then listed in Table 4.3.
It becomes evident that the drug carrier enhances the delivery of the drug in the
ovarian cancer cell line, independently of the type of glycopolymer. Although the
cell line seems to have an increased preference for fructose coated nanoparticles,
this does not translate into higher toxicity. The glucose and galactose coated
nanoparticle have a lower uptake into A2780, but display a higher toxicity than
one of the fructose coated nanoparticles. These results highlight that other fac-
tors such as release of the drug and penetration of the drug into the nucleus play
an critical role.
Table 4.3: Summary of IC50 values of [Pt((1S,2S )-dacp)Cl2]; a) P(GlcMA-
b-MAA/Pt); b) P(GalMA-b-MAA/Pt); c) P(FrucMA1-b-MAA/Pt); d)
P(FrucMA3-b-MAA/Pt) on MCF-7, MDA-MB-231 and A2780.
IC50 values (µM)
MCF-7 MDA-MB-231 A2780
[Pt((1S,2S )-dacp)Cl2] 5.8 5.08 11
a 20.1 15.9 2.8
b 16.8 23.9 3.4
c 13.7 22.1 8.1
d 7.3 4.8 2.5
More noticeable is the relationship between higher uptake and increased tox-
icity when analysing the results obtained using breast cancer cell lines. Now the
highest uptake using P(FrucMA3-b-MAA)/Pt also translates to the highest tox-
icity. It therefore seems that these fructose-based glycopolymers are specifically
beneficial for breast cancer.
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4.3 Conclusions
The cellular uptake of four different micelles prepared from glucose, galactose or
two fructose isomers was investigated. The cell lines tested, two breast cancer and
one ovarian cancer cell lines, showed a high cellular uptake of all nanoparticles
with a strong preference towards nanoparticles based on 1-substituted fructose.
The high cellular uptake was particularly pronounced in breast cancer cell lines.
Interestingly, the higher uptake did not automatically translate into higher tox-
icity of the loaded platinum drug. The ovarian cancer cell line, albeit showing a
higher uptake of the fructosylated micelles, was almost indifferent to the type of
delivery vehicle and resulted in similar toxicities across all micelles prepared. In
contrast, the high cellular uptake by breast cancer cell lines translated directly
into higher toxicities making these fructose coated micelles especially suited to
deliver drugs to breast cancer cell lines.
4.4 Experimental
4.4.1 Materials
All chemicals were used as received without further purification. Potassium
tetrachloroplatinate (K2PtCl4, 99%) was purchased from Precious metals on-
line. Potassium iodine (KI) and diethyl ether (Et2O, anhydrous, 99%) were
purchased from Ajax Finechem. (1S,2S )-trans-1,2-cyclopentanediamine dihy-
drochloride ((1S,2S )-dacp), silver sulphate (>99%), sodium chloride (99.8%) were
purchased from Sigma-Aldrich. Ethanol (>95%) was purchased from Merck Mil-
lipore. Dimethylsulfoxide-d6 (DMSO-d6) and deuterium oxide (D2O) were pur-
chased from Cambridge Isotope Laboratories. MilliQ water was produced inter-
nally and had a resistivity of 18.2mΩ/cm.
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4.4.2 Synthesis and procedures
Synthesis of [Pt((1S,2S)-dacp)(H2O)2]. 250mg (0.6mmol) of potassium
tetrachloroplatinate were dissolved in 400µL of water and placed to stir at 40 ◦C.
A solution of 600mg (3.61mmol) of KI in 1mL of warm water was added to
the platinum solution and the temperature was risen slowly to 70 ◦C, as soon
as the temperature was reached the mixture was cooled down to room temper-
ature. The solid impurities were filtrated and a solution of 102mg (0.589mmol)
of (1S,2S )-trans-1,2-cyclopentanediamine dihydrochloride in 1mL of water was
added. The mixture was stirred for 20min at room temperature and the yellow
crystalline compound was filtrated using a millipore filtration system, washed
with ice-cold ethanol followed by ether and air dry. (Yield: 219mg, 68%) 219mg
(0.399mmol) of the diiodo derivate was added in small portions to a solution of
243mg (0.779mmol) of silver sulphate in 15mL of water. The suspension was
heated, with stirring, at 75 ◦C for 15min. The mixture was filtered to separate
the AgI precipitated. The solution was freeze dried to obtain a pale yellow pow-
der (Yield: 98mg, 57%). The acquated species was used for conjugation to the
polymers. 195Pt NMR (85.84MHz, D2O, 25 ◦C) δ (ppm): -2745.
Attachment of [Pt(S,S -dacp)(H2O)2] onto glyco-block copolymers.
[Pt((1S,2S )-dacp)]-loaded micelles were spontaneously formed from the treat-
ment of the carboxylic moieties of copolymers with the platinum of [Pt((1S,2S )-
dacp)(H2O)2] in water. As a general procedure: 10mg of glycopolymer was
dissolved in water (5mL). [Pt((1S,2S )-dacp)(H2O)2] solution (1 eq. for two car-
boxylic acids) in 5mL of water was added to the solution via syringe pump at a
rate of 0.2mL/h . The sample was then purified by dialysing against water using
membrane dialysis (MWCO 3500) to remove unbound [Pt((1S,2S )-dacp)(H2O)2].
The water was replaced 3 times every 2 h.
Release profile. P(FrucMA1-b-MAA/Pt) micelles aqueous solution was
dialysed (MWCO=3500 g/mol) against pH 7.4 buffer solution at 37 ◦C. To this,
NaCl (0.9%) was added to trigger the platinum drug release. Aliquots (10µL)
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were taken from inside the dialysis membrane at regular intervals. The samples
were digested with aqua regia solution (2%) at 60 ◦C overnight and analysed via
ICP-MS.
4.4.3 Characterization
Figure 4.7: 195Pt NMR, [Pt((1S,2S )-dacp)(H2O)2] in D2O.
Figure 4.8: TGA traces of P(FrucMA334-b-MAA94)/Pt (black); P(FrucMA144-
b-MAA116)/Pt (red); P(GlcMA50-b-MAA116)/Pt (purple); P(GalMA50-b-
MAA11)/Pt (green).
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Chapter 5
When less is more: effect of drug
loading on the activity of polymer
nanocarrier
The shape, size and surface functionalization are the primary design factors that
are considered for controlling nanoparticle-cell interactions. In this Chapter, the
focus is on a new designing factor: the extent of drug loading and its influence
on the morphology of the drug carrier that can also have an important role in
the interactions between nanoparticles and cells. Using a glycopolymer, which
upon conjugation with a hydrophobic platinum drug self-assembles into micelles,
the effect of drug loading on the architecture and efficacy of the micelles was
studied. In vitro studies showed that the micelles with low drug loading (LL
micelles) had better cellular uptake and higher toxicity than the micelles with high
drug loading (HL micelles), despite having the same fructose-based outer shell.
These unexpected results are explained by the changes in internal morphology of
the micelles due to the different amount of loaded drug, as were observed by a
combination of microscopy, light scattering and solid state NMR analyses.
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5.1 Introduction
Polymer nanoparticles (PNs) can improve drug stability, solubility, biodistribu-
tion, specificity, prolong circulating half-life, prevent clearance by the reticulo-
endothelial system (RES), exert an enhanced permeation and retention (EPR)
effect as well as enable controlled "triggered" release of the drug payload [205,
206, 2]. The upshot is that PNs allow the use of reduced drug dose and therefore
minimise the debilitating side effects of anti-cancer drugs. While chemothera-
peutics have been encapsulated into a variety of PNs and some of these systems
have made it through clinical trials [207, 208, 185, 209, 210] micelles are the most
commonly used form of drug nanocarriers [211, 212, 104, 102]. It is implicitly
assumed that polymeric micelles have a well-defined core-shell morphology and
their bioactivity and cellular uptake is primarily dependent on external parame-
ters such as nanoparticle size, shape and surface chemistry [213, 214].
The parameters generally considered by researchers when designing are poly-
mer nanocarrier are size, shape, and the chemistry of the surface. It has been
shown that these parameters effect greatly how the carrier performs. Particle sizes
affect vascular dynamics, velocity, diffusion characteristics and adhesion proper-
ties [5] resulting in different uptake efficiencies [6, 7, 8]. It also influences the
degradation mechanism of the carrier [4]. If the PN is large enough rapid leak-
age in blood capillaries will be prevented. However, bigger PN are captured by
macrophages in the RES, such as the liver and spleen, causing fast clearance. Sev-
eral studies have shown that the PN shape also determines the carrier functions,
especially in biological processes, including internalization, transport through the
blood vessels and targeting diseased sites [9, 10, 11]. Lastly, it has been observed
that surface features can determine the lifespan of PNs during circulation in the
blood stream [12].
To improve the efficiency of PNs, researchers usually aim to increase the
amount of drug that the PN can load. It is commonly believed that the higher
the amount of drug contained by the PN the better would be the outcome. In
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fact, few highly loaded PNs can deliver a big amount of drug into the cancer
cell reducing the overall drug dose needed to be administrated. Loading a hy-
drophobic drug, such as platinum drugs, into the nanocarrier, however, can have
profound effects on the internal morphology and molecular dynamics of the car-
rier. Although few reports suggest that drug loading can enhance the stability of
the micelle against disassembly [215], it has so far been neglected in the literature
whether the internal morphology of the carrier has an effect in the interaction of
the PN with the cells. In this Chapter, the effect of drug loading on the mor-
phology and molecular dynamics of the nanocarrier were directly correlated to its
biological activity. As a model system, the morphology of fructose-based micelles,
loaded with different amounts of an hydrophobic platinum complex were studied
via solid state NMR analyses (Figure 5.1).
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Figure 5.1: Synthesis of the high and low loading drug-polymer conjugates.
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5.2 Results and discussion
RAFT polymerization was employed to generate the glycopolymer (Figure 5.1,
structure 1), consisting of a fructose hydrophilic block and a PMAA block which
will provide anchoring points for the platinum complex. The fructose macro-
RAFT was prepared using similar conditions to the ones described in Chapter 6,
however, a monomer/CPADB ration of 50:1 was used in this case. The degree of
polymerization (DP) was determined by 1H NMR spectroscopy by comparing the
integration of the backbone signals with those of the end group from CPADB. It
was calculated that the fructose macroRAFT is 46 units long. This was then chain
extended with the commercial monomer MAA using a monomer/macroRAFT ra-
tio of 150:1, using azobisisobutyronitrile (AIBN) as initiator and dioxane as the
solvent, yielding 111 repeating units of MAA. The fructose block was then de-
protected in acidic conditions. The 1H NMR and GPC traces of macroRAFT
agent, protected and deprotected glycopolymer are shown in Figures 5.12 and
5.13. The final block copolymer has the structure P(FrucMA46)-b-PMAA111 and
narrow dispersity , Ð=1.09.
The platinum complex, [Pt(phen)Cl2], consists of a platinum centre connected
to an aromatic intercalating ligand, 1,10-phenanthroline. Platinum tetrachloride
potassim salt was dissolved in a warm mixture of H2O and DMSO. The ligand
was then dissolved in warm DMSO and added to the platinum solution. The
resulting yellow precipitate was filtrated, washed and air-dried. [Pt(phen)Cl2]
was then treated with AgNO3 to replace the chlorides with water, centrifuged,
decanted and filtrated to remove any trace of precipitated AgCl. The final struc-
ture of [Pt(phen)(H2O)2] is shown in Figure 5.1, 2. Two conjugates with different
amounts of [Pt(phen)] per polymer chain were prepared using a feed ratio of 1:1
and 1:0.2 between the COOH groups of the PMAA block and [Pt(phen)(H2O)2],
to yield polymer-drug conjugates with high drug loading (HL) (Figure 5.1, 3) and
low drug loading (LL) (Figure 5.1, 4) respectively. After purification by dialy-
sis the conjugates were freeze dried and analysed by thermogravimetric analysis
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(TGA) (Figure 5.15) to measure the amount of platinum conjugated, which yield
values of x = 7 and y = 50. The amphiphilicity induced by the conjugation
of the platinum complex to the PMAA block leads to the self-assembly of the
glycopolymer in aqueous media into the HL and LL micelles. To prepare the
micelles, the dried conjugates were redissolved in a minimum amount of DMSO,
before water was dropped slowly to a final polymer concentration of 1mg/mL.
Finally, the micelle solutions were purified by dialysis against water.
The stability of the micelles was investigated using DLS in a certain concentra-
tion range (c <1mg/mL). The critical micelle concentration (CMC) was obtained
measuring the count rate (kcps) at fixed attenuation. The inflection point ob-
tained plotting kcps versus the micelles concentration represents the minimum
concentration at which the micelles are still stable (Figure 5.2). The high load-
ing micelles remain stable down to a concentration of 0.03mg/mL while the low
loading micelles lose their morphology at a concentration less than 0.06mg/mL.
Figure 5.2: CMC of (blue) HL micelles and (red) LL micelles.
Firstly, the bioactivity of the HL and LL micelles was evaluated on two cancer
cell lines: a breast cancer cell line (MDA-MB-231) and a lung cancer cell line
(A549). The cytotoxicity profiles for the two micelles and [Pt(phen)Cl2] alone
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were obtained and the IC50 values are summarised in Table 5.1. The higher drug
loading did not translate into better cytotoxicity, as the LL micelles showed lower
IC50 values compared to the HL micelles for both cell lines. To understand this
unusual effect, a detailed biological and structural analysis of the micelles was
undertaken.
Table 5.1: IC50 values of [Pt(phen)Cl2], HL and LL micelles.
IC50 (µM)
MDA-MB-231 A549
[Pt(phen)Cl2] 7.8 12.7
HL 11.2 11.8
LL 5.9 2.8
The drug release rate was obtained by dialysing the micelle solutions against
a saline solution over a period of 72 h. Samples were taken from the inside of
the dialysis membrane at given time points and analysed via ICP-MS. Figure
5.3 (a) shows that the LL micelles have a higher percentage (72%) of [Pt(phen)]
released compared to the HL micelles (55%) even though the LL micelles had
slower initial release during the first 24 h. However, this difference is not enough
to account for the significantly higher improvement in the activity of the LL
micelles, since overall, they have less than a third of the [Pt(phen)] compared
to the HL micelles. The better performance of the LL micelles may be due to
their significantly improved cellular uptake which was observed by laser scanning
confocal microscopy (LSCM) and flow cytometry. Using both measurements, the
micelles were labelled with a fluorescent dye (FITC) at the same concentration
and the cells were incubated with the FITC labelled HL or LL micelles at a
concentration of 100µg/mL for 6 h. The LSCM images (Figure 5.3 (c and d))
show that both cancer cell lines preferentially took up the LL micelles and this
is particularly evident for the breast cancer (MDA-MB-231) cell line. These
observations were confirmed by flow cytometry (5.3 (b)) which show that the
normalised fluorescence intensity of the LL micelles was ∼ 2 fold higher than
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the HL micelles for both the breast and lung cancer cell lines indicating a higher
internalization of the LL micelles into the cancer cells.
Figure 5.3: a) Release profile of HL (blue) and LL (red) micelles over time; b)
Flow cytometry on MDA-MB-231 and A549 cell lines; c) LSCM images of A549
cell line and d) LSCM images of MDA-MB-231 cell line. The fluorescence channel
(micelles) and the differential interference contrast (DIC) are overlapped (merge).
The caharacterization of the HL and LL micelles in aqueous solutions via
transmission electron microscopy (TEM) and dynamic light scattering (DLS)
(Figures 5.4 a and b and 5.14) showed that the HL micelles have an average
diameter of 105 nm with a compact core of 40 nm and a narrow size distribution,
while the LL micelles are three times larger with an average diameter of 330 nm,
with a core of 130 nm and wider size distribution. Moreover, the TEM, which was
taken without any staining so to observe the platinum in the micelles, showed that
the HL core has an uniform distribution of Pt while the LL micelles have an inner
core with a high concentration of Pt surrounded by a region of reduced Pt density.
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Figure 5.4: TEM images of HL a) and LL b) micelles. The size of the micelles
Dh and their polydispersity index (PDI) were determined by dynamic light scat-
tering (DLS). 1D 13C CPTOSS NMR of: c) pure [Pt(phen)Cl2] in the crystalline
state, d) the polymer and e) HL micelles. f) 2D 13C[1H] HETCOR of HL mi-
celles. Dashed lines are the guides to the eye. Signal marked by a dashed square
corresponds to the correlation peak between the aromatic drug and the methyl
protons of the polymer backbone, which confirm the conjugation of the [Pt(phen)]
to the polymer. The correlation signals in red, blue and orange correspond to the
MMA, fructose and [Pt(phen)Cl2] species respectively.
1D and 2D solid-state NMR spectroscopy yielded insight into the internal
structure and dynamics of the micelles. A comparison of the 13C NMR spec-
tra of [Pt(phen)Cl2] and the freeze dried HL micelles (Figure 5.4 c-e) shows
that upon conjugation the 13C NMR signals for [Pt(phen)Cl2] are significantly
broadened compared to the well resolved 13C NMR spectrum for the crystalline
[Pt(phen)Cl2]. The change in the NMR lineshape demonstrates that [Pt(phen)]
is in an amorphous state in the presence of the polymer matrix and has not
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precipitated into a native crystalline form. 2D 13C[1H] heteronuclear correla-
tion experiment provides direct evidence of formation of the platinum-polymer
complex (Figure 5.4 f), where the observation of a through-space correlation peak
from the polymer backbone-methyl protons to the aromatic carbons of [Pt(phen)]
confirms the formation of the conjugate. Importantly, a correlation peak between
the sugar OCH/COH protons and [Pt(phen)] carbon is not seen, which implies
that there is nanometer scale segregation between the [Pt(phen)] and the sugar
block in the HL micelles.
The morphological and molecular dynamics changes in the self-assembled mi-
cellar structures as a result of differential [Pt(phen)] loading can more sensitively
be measured by ultrafast MAS NMR. At a spin rate of 60 kHz MAS, the 1H-1H
dipolar couplings are sufficiently suppressed to yield "high resolution" solid-state
1H NMR spectra of the neat polymer and the polymer-platinum conjugates (Fig-
ure 5.5) which enables the 1H assignment of the different functional groups in the
synthesized materials. The key features of the 1H ultrafast MAS NMR spectra are
the absence of aromatic resonances in the neat polymer (Figure 5.5 a), their low
intensity in the LL sample (Figure 5.5 b) and their high intensity in the HL sam-
ple (Figure 5.5 c). It is important to note the presence of the large signal assigned
to water in the LL micelles. The retention of water in the lyophilized LL micelles
can be explained by the reduced hydrophobicity. The spectroscopic separation
of the [Pt(phen)], sugar, water and the backbone alkyl signals in the 1H NMR
enables probing of the [Pt(phen)] dispersion and dynamics in the self-assembled
structures via 2D 1H-1H exchange spectra. For the LL micelles (Figure 5.5 d),
at the relatively short mixing time of 3ms for 1H magnetization exchange, there
is a high signal intensity for the cross peak from the aromatic 1H to the sugar,
water and alkyl 1H species as seen in the horizontal slice extracted from the 2D
spectrum (Figure 5.5 d). The intensity of the cross peaks demonstrates that in
the case of the LL, the [Pt(phen)] is molecularly dispersed within the polymeric
matrix which results in an overall closer spatial proximity to the polymer. The
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presence of the aromatic [Pt(phen)] to H2O proton cross peak must be assigned
to a zone of intermediate hydrophobicity interposed between the hydrophobic
and hydrophilic regions where water exists in sub-nanometer proximity to the
[Pt(phen)]. This corresponds to the regions circled in green in TEM images (Fig-
ure 5.4 b). In contrast, for the HL micelles (Figure 5.5, e), for 3ms of mixing
time, there are negligible cross-peaks to the polymer backbone which points to
formation of conjugated [Pt(phen)] aggregates, potentially via pi-pi stacking, with
a reduced spatial proximity to the polymer backbone.
Figure 5.5: [Pt(phen)] dispersion and dynamics in the polymer nanocarriers. 1H
ultrafast NMR of the neat polymer and micelles at 60 kHz MAS. a) 1H NMR of
neat polymer; b) 1H NMR of LL micelles; c) 1H NMR of HL micelles; d) 2D
1H-1H exchange spectra with 3ms mixing times of the LL and e) HL. The 1D
spectra plotted on top are extracted at 8.5 ppm as indicated by the dashed line.
A spherical aggregate size of ∼ 1-3 nm for [Pt(phen)] is estimated based on
equilibration time for the magnetization exchange in the HL micelles. Figures
5.6 and 5.7 show the 1H-1H 2D correlation spectra of the neat polymer and the
HL micelles with varying spin diffusion times. The 1D spectrum in blue plotted
over each 2D spectrum is the 1D slice obtained at the dashed line corresponding
to the primary signal from the sugar moiety. The overlaid spectrum in red is the
full 1H signal of the polymer. At short tsd, the 1H magnetization from any site
(in the present case the sugar OCH protons) is located on the same site. For the
2D correlation experiment, such a condition generates a signal along the slope 1
diagonal meaning that the signal (for e.g. at 4 ppm) is only correlated to its self.
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For increased spin diffusion times, the magnetization "diffuses" form the original
1H site to the neighbouring 1H species and in the 2D experiment this is observed
as the appearance of off-diagonal "cross peaks".
Figure 5.6: 2D 1H-1H correlation NMR of pure polymer acquired at 60 kHz MAS
with varying 1H spin diffusion times (tsd).
Figure 5.7: 2D 1H-1H correlation NMR of HL micelles at 60 kHz MAS.
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If a 1D slice is taken through the 2D experiment for the short tsd, only a
single peak is observed corresponding to the position of the slice. In the present
case, the slice at 4 ppm at tsd=0.1ms yields a single signal at 4 ppm, plotted
in blue over 2D spectrum. With increased spin diffusion, the 1D slice shows the
signal of the 1H species, to where the magnetization has diffused from the initial
position. With a sufficiently long spin diffusion time, the magnetization from
each site fully equilibrates within the sample, so that a 1D slice through any of
the signals yields the same signal as the overall 1H spectrum. For a given strength
of 1H-1H dipolar coupling, which is the mechanism enabling spin diffusion, the
equilibration time is dependent on the distance/domain size of the system being
investigated. 2D 1H-1H correlation NMR of HL micelles at 60 kHz MAS, showing
equilibration of the magnetization at 100ms as opposed to 30ms observed in the
pure polymer indicating the HL micelles form segregated domains larger in size
than the native polymer. This result also demonstrates that while at the short
time scale, the structure forms "nanometer scale heterogeneous aggregates" over
all within the spin diffusion measurement, the signal is equilibrated and there
are no extended micellar domains as seen in the low loading systems. Contrary
to the HL micelles, aromatic 1H signal does not equilibrate with the polymer 1H
signal in the LL micelles even after 1 s of mixing time (Figure 5.8).
This demonstrates that there are regions within the micellar assembly that are
completely depleted of any [Pt(phen)] on the larger length scales (< 30 nm). We
hypothesize that for the LL micelles such areas would belong to the outer corona
layer which is completely hydrophilic with high molecular mobility (forming a so
called "soft" corona). This hypothesis was tested by a 2D 1H-1H NMR correlation
measurement with a 1 s mixing time, but with an additional filterprior to the
mixing time to select the most mobile species corresponding to the outer corona
(Figure 5.9).
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Figure 5.8: 2D 1H-1H correlation NMR of LL (without 1H-T2 filter) at 60 kHz
MAS. In comparison to the neat polymer and the HL micelles, even at 1 s of tsd,
equilibration is not observed, confirming presence of extended micellar structures,
with regions of low/no bound [Pt(phen)].
Figure 5.9: 2D 1H-1H correlation spectra of the low drug loading with a 4.2ms
1H T2 filter (before the first evolution period) and mixing time of 1 s.
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This allows to track the transfer of 1H magnetization from the outer soft
corona, in particular from the mobile water species towards the inner core. Un-
der these conditions, cross-peaks from the mobile water to only the polymer and
not to [Pt(phen)] can be seen, which confirms our model of a highly mobile (soft)
[Pt(phen)]-depleted coronal layer. In the HL micelles, [Pt(phen)] forms aggre-
gates which are uniformly distributed throughout the micellar core. A fraction of
the sugar moieties are also trapped within the hydrophobic core as seen by the
appearance of cross peaks to both the polymer backbone and the sugar sidechain
at similar time scales (i.e. after 10ms of 1H spin diffusion, Figure 5.7a. The
rigid nature of the micellar structure is implied by the absence of any differen-
tial mobility between the hydrophobic core and the hydrophilic sugar blocks as
measured by 1H-T2 relaxation (Figure 5.10, left).
Figure 5.10: left: 1H spin echo at 60 kHz MAS for the HL micelles to mea-
sure 1H-T2 relaxation. Relatively uniform 1H-T2 relaxation observed since after
2.26ms, the polymer backbone, [Pt(phen)] and sugar peaks all survive. Note
that the aromatic signals survive due to formation of the [Pt(phen)] aggregates
with reduced 1H-1H dipolar couplings, and consequently longer 1H-T2 relaxation
times. right: 1H spin echo at 60 kHz MAS for the high low loading micelles to
measure 1H-T2 relaxation. Differential 1H-T2 relaxation is observed particularly
after 2.26ms, where the [Pt(phen)] and significant portion of the rigid polymer
signals are suppressed. After 4.06ms of 1H-T2 relaxation, only the residual signal
of the mobile water and polymer backbone survives. This differential relaxation
enables to probe the environment of the highly mobile species.
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In the LL micelles, [Pt(phen)] forms a hydrophobic gradient. The core is
most hydrophobic, surrounded by an area of reduced hydrophobicity and finally
an outer corona with no [Pt(phen)] at all. The gradient in hydrophobicity means
that the micellar structure also has a gradient in mobility, with a rigid core at the
centre surrounded by increasingly mobile regions towards the outward corona. In
particular the regions of high mobility (and no [Pt(phen)]) can be selected based
on a 1H-T2 filter (Figure 5.10, right). The schematic for the HL and LL (Figure
5.11 a and b respectively) show the structural model derived from the NMR
analysis.
Figure 5.11: a) and b) schematics of the platinum-polymer assembly in the high
and low drug loading systems. Small orange circles represent individual drug
molecules, which are aggregated in the HL and dispersed in the LL material.
Blue lines represent the hydrophilic sections of the polymer chain and red lines
represent the hydrophobic areas of the polymer chain. Dark blue hexagons rep-
resent the sugar molecules and light blue circles represent water molecules.
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5.3 Conclusions
In summary, the structural analysis of platinum loaded micelles lead to funda-
mental insights that open up a shift in the current paradigm for maximizing the
drug loading of nanocarriers, i.e. in certain cases less can be more. For the
present case of platinum-loaded micelles, higher loading of the platinum complex
actually reduced cellular uptake, drug release and cytotoxicity. The reduced ef-
ficacy of the HL micelles can be assigned to a reduced potential for interaction
between the sugar in the smaller-hard micellar structure and the cell wall. At
the same time, these micelles show a slower release rate due to the formation of
[Pt(phen)] aggregates. In contrast, the increased efficacy of the LL micelles can
be related to the softer micellar structure with higher potential for interaction
between the sugar moieties and the cell wall. The lesson learned from this chapter
is not that less drug does increase the efficiency, as various system may behave
differently. However, the take-away message is that when studying the perfor-
mance of nanoparticles, a focus on size, shape and surface chemistry may not
be sufficient. Drug loading content and its effect on nanoparticles' morphology,
must be considered to improve the bioactivity of nanocarrier delivery vehicles.
5.4 Experimental
5.4.1 Materials
Unless otherwise specified, all chemicals were reagent grade and were used as
received, without further purification. Potassium tetrachloroplatinate (K2PtCl4,
99%) was purchased from Precious metals online. Methacrylic acid (MAA, 99%)
was passed through basic alumina column to remove inhibitor and stored at -
20 ◦C, dichloromethane (DCM, anhydrous, >99.8%), fluorescein isothiocyanate
(FITC), 1,10-phenanthroline (99%) and N,N dimethylacetamide (DMAc, HPLC
grade) were purchased from Sigma-Aldrich. Ethanol (>95%) was purchased from
Merck Millipore. 2,2′-azobis(isobutyronitrile) (AIBN, 98%) was purchased from
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Fluka and it was recrystallized from methanol. Acetone (HPLC grade), dimethyl
sulfoxide (DMSO, 99%), dioxane (99%,) purified by vacuum distillation and di-
ethyl ether (99%) were purchased from Ajax Finechem. n-hexane (95%) was
purchased from chem-supply. Dimethylsulfoxide-d6 (DMSO-d6) and chloroform-
d (CDCl3) were purchased from Cambridge Isotope Laboratories. MilliQ was
produced internally and had a resistivity of 18.2mΩ/cm. The synthesis of RAFT
agent 4-cyanopentanoic acid dithiobenzoate (CPADB) is described in Chapter 6.
5.4.2 Synthesis and procedures
Synthesis of iprFruc. iprFruc was prapared according to the literature proce-
dure [196]. To a flame-dried two necked 1L of round-bottomed flask was added
D-fructose (36 g, 0.199mol). It was dried under vacumm for 2 h. Then a cooled
solution of conc. sulfuric acid (35mL) in acetone (700mL) was added to the
flask and left to stir for 1.5 h at room temperature. After that, the reaction mix-
ture was cooled in an ice bath. The sodium hydroxide solution was prepared in
water and gradually added to the reaction mixture with stirring. Acetone was
evaporated and resulting solution was extracted with CH2Cl2. The extracts were
washed with water and dried by anhydrous sodium sulphate and evaporated to a
crystalline solid. (Yield: 39.10 g, 75%). 1H NMR (300.17MHz, CDCl3, 25 ◦C) δ
(ppm): 4.63 (dd, J=7.9, 2.6Hz, 1H), 4.36 (d, J=2.6Hz, 1H), 4.26 (ddd, J=7.9,
1.9, 0.8Hz, 1H), 3.94 (dd, J=13.0, 1.9Hz, 1H), 3.79 (dd, J=13.0, 0.8Hz, 1H),
3.78 - 3.62 (m, 2H), 1.56 (s, 3H), 1.50 (s, 3H), 1.42 (s, 3H), 1.37 (s, 3H). 13C
NMR (75.51MHz, CDCl3, 25 ◦C) δ (ppm): 109.08, 108.52, 103.07, 71.00, 70.79,
70.06, 65.54, 61.27, 26.45, 25.76, 25.33, 23.96.
Synthesis of iprFrucMA. A solution of iprFruc (3.0 g, 11.52mmol) in anhy-
drous dichloromethane (165mL), pyridine (6mL) and 4-dimethylaminopyridine
(1.0 g, 8.18mmol) at 0 ◦C was treated dropwise with a solution of methyl acrylate
anhydride (2.2mL, 13.25mmol) in dichloromethane (5mL). After it was stirred
for 48 h at room temperature, the mixture was poured into ice-cold saturated
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NaHCO3 solution (165mL), and the organic layer was withdrawn. The aqueous
layer was extracted with CH2Cl2, and combined organic layers were dried us-
ing MgSO4 and concentrated under reduced pressure. The product was purified
by flash column chromatography. (Yield: 3.21 g, 85%). 1H NMR (300.17MHz,
CDCl3, 25 ◦C) δ (ppm): 6.17 (dq, J=1.8, 0.9Hz, 1H), 5.62 (dd, J=1.9, 1.3Hz,
1H), 4.64 (dd, J=7.9, 2.7Hz, 1H), 4.50 (dd, J=11.9, 0.6Hz, 1H), 4.40 (dd,
J=2.7, 0.6Hz, 1H), 4.27 (ddd, J=7.9, 1.9, 0.8Hz, 1H), 4.17 (dd, J=11.9, 0.7Hz,
1H), 3.96 (dd, J=13.0, 1.9Hz, 1H), 3.79 (dt, J= 13.0, 0.8Hz, 1H), 1.99 (dt,
J= 1.6, 0.8Hz, 3H), 1.56 (s, 3H), 1.50 (s, 3H), 1.41 (s, 3H), 1.37 (s, 3H).
P(iprFrucMA)46. iprFrucMA (1 g, 3.045mmol), CPADB (17mg, 0.060mmol),
and AIBN (1.25mg, 7.613µmol) were dissolved in 1,4-dioxane (4.3mL), placed in
a schlenk tube and degassed by three freeze pump thaw cycles. The polymeriza-
tion was carried out at 70 ◦C for 11 h and quenched by introducing air and cooling
in an ice bath. The polymer was purified by precipitation into a large excess of
ether. The viscous polymer was dried under vacuum for 24 h. The conversion
of polymerization was determined by 1H NMR (92%, 46 units, MwNMR=15100,
MnGPC =9500, Ð=1.07).
P(iprFrucMA)46-b-PMAA111. The fructose macroRAFT Agent (100mg,
6.6× 10−3mmol), MAA (85.32mg, 0.99mmol), AIBN (0.21mg, 1.3× 10−3mmol)
were dissolved in 1,4-dioxane (1.5mL) in schlenk tube and degassed by three
freeze pump thaw cycles. The polymerization was carried out at 70 ◦C for 24 h
and quenched by introducing air and cooling the solution in an ice bath. The
polymer was precipitated in large excess of n-hexane. The viscous polymer was
dried under vacuum for 24 h. The conversion of polymerization was determined
by 1H NMR (74%, 111 units, MwNMR=24670, MnGPC =60000, Ð=1.21).
P(FrucMA)46-b-PMAA111. The deprotection of the acetyl groups was
obtained by hydrolysis in acidic conditions. The glycopolymer (0.100 g) was
dissolved in DCM and TFA/H2O mixture (2mL, 6:1 v/v) was added under
stirring at room temperature for 3 h followed by dialysis against deionized wa-
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ter (MWCO=3500). The polymer was then freeze dryer. (MnGPC =20000,
Ð=1.09).
[Pt(phen)Cl2]. K2PtCl4 (0.250 g, 0.602mmol) was dissolved in 2mL of H2O
and 5mL of DMSO and the solution was warmed to 60 ◦C till the paltinum salt
was completely dissolved. Meanwhile, 1,10-phenanthroline (0.108 g, 0.602mmol)
was dissolved in 10mL of DMSO and the solution was warmed up to 60 ◦C.
The phenanthroline solution was then dropped slowly into the platinum solution,
whilst keeping the temperature at 60 ◦C. A yellow precipitate could be observed.
The solution was cooled to room temperature and cooled at 4 ◦C for 72 h to allow
the product to precipitate completely. The final product was filtered and washed
with chilled HCl solution, H2O, ethanol and diethyl ether.
[Pt(phen)]-glycopolymer conjugates. Firstly, [Pt(phen)Cl2] was treated
with AgNO3 to remove the chloride groups and make the platinum available to
conjugate with the carboxylic groups of the glycopolymer. Pt(phen)Cl2 (10mg,
22.4µmol) was dissolved in 2mL of DMSO. AgNO3 (7.4mg, 43.7µmol) was dis-
solvend in 3mL of H2O and added to the platinum solution. The flask was
covered with alluminium foil and the reaction mixture let in a orbital shaker at
37 ◦C overnight. The solution was filtered ones with a 0.45µm filter and three
times with a 0.22µm filter to fully remove the AgCl, washing the filters with
minimum amount of water. To prepare the conjugates: the glycopolymer was
dissolved in water at a concentration of 2mg/mL, the [Pt(phen)(H2O)2] solution
(1mg/mL) was dropped into the polymer solution under stirring at a speed of
0.1mL/h using a syringe pump. The platinum-polymer conjugate solution was
then shaken overnight in an orbital shaker at 37 ◦C followed by dialysis against
H2O (MWCO=3500Da) and lyophilization. The conjugates were then analysed
via thermogravimetric analysis (TGA) to measure the platinum content. The
LL micelles contain 4.25% of platinum in weight which translate to 7.5 molecules
of [Pt(phen)] per polymer chain. The HL micelles contain 19.5% in weight of
platinum which equals to 50 molecules of [Pt(phen)] per polymer chain.
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Micelle preparation. In a general procedure toprepare the micelles: the
platinum-polymer conjugates were dissolved in minimum amount of DMSO and
water was dropped slowly using a syring pump (0.1mL/h) followed by dialysis
against H2O (MWCO=3500Da).
Release of [Pt(phen)] from micelles. The micelle solutions were dialysed
against a saline solution (0.9% NaCl) in a membrane with a MWCO=3500Da.
Aliquots of 10µL were taken in regular time intervals from the inside of the
membrane. The aliquots were digested with 70% HNO3 at 60 ◦C overnight. The
amount of released Pt was determined using inductively coupled plasma mass
spectroscopy (ICP-MS).
5.4.3 Characterization
Figure 5.12: 1H NMR spectra of a) P(iprFrucMA46) in CDCl3; b)
P(iprFrucMA46-b-MAA111) in DMSO-d6; c) P(FrucMA46-b-MAA111) in D2O af-
ter deprotection reaction.
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Figure 5.13: GPC traces of a) P(iprFrucMA46) and P(iprFrucMA46-b-MAA111)
and b) P(FrucMA46-b-MAA111).
Figure 5.14: Intensity mean curves of (left) high loading micelles and (right)
low loading micelles measured via DLS.
Figure 5.15: TGA analysis of low loading (red) and high loading (blue) freeze
dried micelles.
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Solid state NMR analysis. The micelles solutions were lyophilized prior
to analysis by solid state NMR. The solid state NMR experiments were carried
out on a standard-bore Bruker Biospin Avance III solids-700MHz spectrometer
operating at a frequency of 175MHz and 700MHz for the 13C and 1H nuclei re-
spectively. For the 13C NMR experiments, approximately 20mg of samples were
centre packed into 4mm zirconia rotors fitted with Kel-fR caps and spun in a
double resonance H-X probe head up to 14 kHz MAS (Magic Angle Spinning).
The 13C and 1H 90◦ radio frequency pulse lengths were optimized to 3.5µs and
2.5µs each. 1D 13C CPMAS, spectra were acquired with 2ms cross polariza-
tion contact time with a total suppression of spinning sidebands (TOSS) scheme,
followed by 1H decoupling at 100 kHz field strength using Spinal-64 decoupling
during 20ms of signal acquisition. For sufficient signal to noise, up to 1 k tran-
sients were acquired for each sample with recycle delays of 4.0 s in between to
ensure sufficient relaxation of the 1H magnetization. The 2D 13C1H spectra were
obtained acquired using the frequency-switch Lee Goldburg scheme at 100 kHz
for 1H homonuclear decoupling during a total of 1.3ms 1H evolution in the indi-
rect domain. The ultrafast 1D and 2D 1H NMR spectra were acquired using a
1.3mm H-X double resonance probehead. For these experiments about 3mg of
sample was packed into 1.3mm zirconia rotors fitted with Vespel caps wich were
spun to 60 kHz at the magic angle. The 1H 90◦ radio frequency pulse lengths were
optimized to 1.7µs. The 2D 1H-1H correlation spectra were acquired with a total
of 2.8ms of 1H evolution in the indirect dimension, incremented in steps of 35µs.
1H spin diffusion times of 0.0001 s to 1 s were inserted between the first evolution
period and the detection period to generate the 1H-1H correlation peaks.
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Chapter 6
Creating a fluorescent platinum
complex to probe drug uptake and
release when comparing
fructose-based to non-targeting
drug delivery systems
As seen in the Chapter 4, drug delivery systems which consist of carbohydrate
shells showed great affinity towards cancer cells. Among the sugar blocks studied
here, fructose appears to have the greatest potential in targeting cancer, in par-
ticular breast cancer. In this Chapter, the focus moved from comparing a drug
delivery system with a fructose outer shell to a similar system but with a neu-
tral, non-targeting hydrophilic shell made of poly(ethylene glycol) methyl ether
methacrylate (PEGMEMA). The aim of this Chapter is to study the differences
in the uptake process into breast cancer cells when using a targeting compared to
a non-targeting drug delivery system. Moreover, we want to understand the drug
release mechanism of these systems inside cells. For this purpose, a fluorescent
platinum complex was synthesised to probe drug release.
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6.1 Introduction
Interest in this field has grown rapidly with many studies reported in the litera-
ture. Most research into drug delivery systems for anti-cancer chemotherapeutics
focuses on the in vitro and/or in vivo evaluation of the cytotoxicity of the carrier
and how this compares to that of the free drug. Drug delivery systems are know
to improve cellular uptake thus increasing the amount of drug delivered to the
cancer cell. This leads to an improved efficacy and overall a reduced drug dosage
required. The cellular uptake of polymer nanocarrier into cells can be easily ob-
served by labelling the polymer with a fluorescent moiety which can be detected
by fluorescence microscopy. This allows the researcher to observe the timing and
sometimes the mechanism by which the PN is internalised by the cancer cells.
Once inside the cell, the PN degrades and this can be observed by the loss of
fluorescence and it is assumed that a this moment the drug is released. It is more
challenging, however, to know the pathway taken by the drug once it is released
from the polymer until it reaches its target. In the case of platinum based drugs it
is know that their mechanism of action involves the interaction with DNA, found
either in the nucleus or in the mitochondria. However, it is not known when and
how this happens. Moreover, it is not known whether the journey of the platinum
from the PN to its target depends on the type of polymer which constitutes the
carrier.
In this Chapter, a fluorescent platinum complex, [Pt(dafone)Cl2], was synthe-
sised with the aim of tracking the journey of the drug from the cellular uptake of
the PN, thorough the release mechanism from the polymer, to the interaction of
the platinum with DNA. The drug-model prepared was a platinum(II) complex
which can conjugate to amphiphilic block copolymers in a similar manner to cis-
platin. However, it is coordinated to a fluorescent ligand, 4,5-diazafluoren-9-one
(dafone), which allows the use of fluorescence microscopy to probe the platinum.
In Chapter 4, it was demonstrated that different sugar shells have different
effects on cancer cells. Among the sugars studied, glucose, galactose and the two
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isomers of fructose, it was evident that the 1-substituted fructose has a great
affinity for breast cancer cells MDA-MB-231. As a consequence, in this Chapter
the fructose shell was chosen to be compared with a neutral shell. In particular,
it is of interest to understand how the cellular uptake and drug release processes
within the cell differ between the two systems. [Pt(dafone)Cl2] was the fluorescent
tool used to perform fluorescence microscopy (Figure 6.1).
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Figure 6.1: The synthetic scheme.
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6.2 Results and Discussion
The two block copolymers (Figure 6.1, 1 and 2) comprise of a bidentate carboxy-
late monomer block and a fructose or a PEGMEMA block as the hydrophilic
part and were synthesised by RAFT polymerization. Pt(dafone)Cl2, Figure 6.1,
3, consists of a platinum(II) centre which coordinates to the fluorescent ligand.
[Pt(dafone)Cl2] can conjugate, once its chloride ligands leave, to the bidentate
carboxylate units of the block copolymers and drive the self-assembly into mi-
celles. The micelles will consist of a hydrophilic shell made of either fructose or
PEGMEMA and a hydrophobic core where the platinum complex is encapsulated.
The fructose monomer was synthesized according to a literature method [196].
Firstly, fructose was selectively protected in positions 2, 3, 4 and 5. The hydroxyl
group in position 1 was then coupled to methacrylic anhydride to obtain the
protected fructose monomer which was then purified by column chromatography
and characterised by NMR (Figures 6.12 to 6.14). The synthesis of the biden-
tate carboxylato monomer, MAHTC, was obtained via Michael Addition between
ethylene glycol dimethacrylate cross-linker and di-tert-butyl malonate in presence
of 18-crown-6 under anhydrous conditions as previously described in the literature
[119]. The MAHTC monomer was ultimately purified by column chromatography
and characterised by NMR (Figures 6.15 and 6.16). The effect of the length of
the cross-linker, and consequently the length of the final monomer, have on the
stability of cisplatin loaded micelles has been previously studied [118]. It was evi-
dent that longer spacers produce more stable micelles, higher cellular uptake and
better cytotoxicity profile. For this reason the 1,6-hexylene glycol dimethacrylate
cross-linker was chosen to synthesize the bidentate carboxylate monomer.
RAFT polymerization was employed to prepare the two block copolymers.
Both the synthesized fructose monomer and the commercial PEGMEMA were
polymerized using AIBN as initiator and CPADB as RAFT agent. The RAFT
agent was synthesised following a procedure found in the literature [216, 217].
First, the precursor di(thiobenzoyl)disulfide was prepared from benzyl chloride,
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elemental sulphur and sodium methoxide in anhydrous methanol, followed by
reaction with potassium ferricyanide. The precursor was then reacted with 4,4′-
azobis(4-cyanopentanoic acid) to give the final product which NMR characteri-
sation is shown in Figures 6.10 and 6.11. The polymerizations were carried out
in toluene at 70 ◦C using a monomer/CPADB ratio of 50:1. The PEGMEMA
was polymerized for 6 h yielding a polymer 40 units long and a dispersity of
Ð=1.16, whereas the fructose monomer was reacted for 10 h affording a poly-
mer that was 44 units long and Ð=1.15. The two macroRAFT agents were
then chain extended with MAHTC. A ratio MAHTC/macroRAFT of 100:1 was
used giving a conversion of about 70% in both cases. The final block copolymer
have the following composition: Fruc44-b-PMAHTC70 with dispersity Ð=1.17
and PEGMEMA40-b-PMAHTC70 with Ð=1.11. The two block copolymers were
deprotected in acidic conditions and purified by dialysis. The bidentate carboxo
group is now available for conjugation with a platinum complex, [Pt(dafone)Cl2]
(Figure 6.1, 3). Details of the synthesis of the block copolymers are reported
in Section 6.4.3. Molecular weight and polymerization conversions were calcu-
lated by 1NMR (Figures 6.17 to 6.20) whereas the dispersity of the polymers was
obtained by GPC analyses (Figures 6.21 and 6.22).
The synthesis of [Pt(dafone)Cl2] had previously been reported in the literature
[218]. However, attempts to reproduce the procedure from the literature did not
lead to acceptable yields (∼ 20%). Thus, another method was used to prepare
[Pt(dafone)Cl2] [41]. The platinum tetrachloride potassium salt was dissolved in
a mixture of H2O and DMSO and was warmed to ensure complete dissolution.
The fluorescent ligand dafone was dissolved in warm DMSO. When dropping the
dafone solution into the platinum solution it is important to avoid immediate
precipitation of the product. This, caused the free ligand to co-precipitated with
the desired product through pi-pi stacking. This effectively reduces the amount
of free ligand that is available to complex with platinum resulting in a reduction
in yield. After cooling slowly to room temperature, the volume of the solution
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was reduced to facilitate formation of the bright yellow product. The product
was filtered, washed and air-dried. The platinum(II) complex forms needle-like
crystals (Figure 6.2) with cell dimensions and crystal lattice, reported in Table
6.1, consistent with those of the unit cell parameters previously reported in the
literature [218].
Figure 6.2: Microscope images of Pt(dafone)Cl2 crystals.
Table 6.1: Crystal data and unit cell parameters obtained on Bruker APEX II
Single Crystal Diffractometer.
Results from [218]
Chemical formula C11H6Cl2N2OPt C11H6Cl2N2OPt
Formula weight 448.17 448.17
Crystal system Monoclinic Monoclinic
a (Å) 5.158(6) 5.1296(12)
b (Å) 16.748(17) 16.638(4)
c (Å) 12.882(13) 12.785(3)
β (◦) 98.01(2) 98.419(18)
V (Å3) 1102(3) 1079.4(4)
NMR characterization of [Pt(dafone)Cl2] was not reported in the previous
work [218]. 1H NMR of [Pt(dafone)Cl2] in DMSO-d6 can be seen in Figure 6.3,
t=0. The spectrum shows a set of three aromatic resonances at 7.52, 8.10 and
8.81 ppm which are the chemical shifts expected for the free ligand in DMSO-d6.
The resonances assigned to [Pt(dafone)Cl2] are shifted towards lower magnetic
field (7.71, 7.77, 8.27, 8.36, 9.20, and 9.30 ppm) and split into pairs confirming,
on the one hand, the coordination of dafone to the platinum, but indicating,
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on the other hand, a loss of symmetry. This can be explained by the replace-
ment of one chloride with a DMSO molecule to form the [Pt(dafone)Cl(DMSO)]
complex in solution. vestigate the conformation of the platinum compTo in-
lex in DMSO and why free ligand is present in the solution a set of 1H NMR
spectra were recorded at regular intervals (5min) for 4 h (Figure 6.3). The spec-
trum at t= 0 shows mostly [Pt(dafone)Cl(DMSO)] resonances, however, over
time these become less intense as the resonances of the free ligand become more
prominent. It is evident that [Pt(dafone)Cl(DMSO)] is not stable in DMSO
and the dafone ligand is replaced by DMSO over time. Plotting the integrals of
[Pt(dafone)Cl(DMSO)] and free ligand resonances over time (Figure 6.4) it can
be observed that most [Pt(dafone)Cl(DMSO)] has decomposed to give the free
dafone and a platinum/DMSO complex within 3.5 h.
Figure 6.3: 1H NMR of the platinum complex in DMSO-d6 from t=0 to 4 h.
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Figure 6.4: Normalised integral intensity vs time.
195Pt and 1H NMR in DMF/D2O mixture shows only one resonance at -
2793 ppm, which is consistent with platinum (II) coordinated to two nitrogen
and two chloride atoms [219] which confirms the purity of the platinum com-
plex (Figure 6.5). However, when DMSO-d6 is used as the solvent the 195Pt
NMR spectrum shows the appearance of multiple peaks, suggesting again that
a decomposition process is occurring. To investigate this process further a ki-
netic study was also performed using 195Pt NMR. [Pt(dafone)Cl2] was quickly
dissolved in DMSO-d6 and 195Pt NMR spectra were measured at regular inter-
vals (8min) over 4 h. In Figure 6.6 the 195Pt NMR spectra illustrate how the
resonance at -2793 ppm relative to [Pt(dafone)Cl(DMSO)] decreases in intensity
over time, whereas a second resonance at -3454 ppm, which it was believed to
represent the final platinum/DMSO complex accordingly to what is reported in
the literature [219], increases in intensity. This experiment confirmed that the
coordinated dafone is being displaced in DMSO. However, the experiment does
not provide information about the mechanism by which the displacement occurs.
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Figure 6.5: 195Pt NMR, 400MHz, DMF/D2O of [Pt(dafone)Cl2].
Figure 6.6: 195Pt NMR in DMSO-d6 of [Pt(dafone)Cl(DMSO)] from t=0 to 4 h.
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A final experiment was designed to investigate whether the decomposition
of [Pt(dafone)Cl2] goes through an intermediate. For this purpose, a saturated
solution of [Pt(dafone)Cl2] in DMSO-d6 was prepared. In the presence of solid
[Pt(dafone)Cl2] in the NMR tube, all species, including possible intermediates,
would be available and so they should be able to be observed in the spectrum.
The spectrum in Figure 6.7 shows the presence of at least one intermediate species
with a chemical shift of -2953 ppm. This does not exclude the presence of other
intermediates, however, their concentration is not sufficient to be observed clearly
in the 195Pt NMR spectrum. It is believed that the intermediate visible in the
spectrum is a platinum which coordinates with a chloride, two DMSO molecules
and one of the nitrogens from the dafone. This hypothesis is supported by the
observation of a third set of asymmetrical peaks in the 1H NMR with the same
coupling constant (J = 0.12 ppm) as the [Pt(dafone)Cl(DMSO)] (Figure 6.8) sug-
gesting that the intermediate is also an asymmetric species.
Figure 6.7: 195Pt NMR in DMSO-d6 of a saturated [Pt(dafone)Cl2] solution.
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Figure 6.8: 1H NMR of [Pt(dafone)Cl2] in DMSO-d6 at t=0 and enlargement of
the spectrum from 8.6 ppm to 9.6 ppm.
Biju et. al. evaluated the cytotoxicity of [Pt(dafone)Cl2] compared to cis-
platin on cervical cancer cell line (HeLa) and aneuploid immortal keratinocyte
cell line (HaCat) and reported that the cytotoxicity profiles were very similar,
however, cisplatin was slightly more efficient. As is commonly done with highly
hydrophobic drugs like [Pt(dafone)Cl2], Biju and co-workers used DMSO to sol-
ubilise [Pt(dafone)Cl2] before dilution in cell culture media. In light of the NMR
findings, it is highly probable that the IC50 values obtained by Biju et. al. are
relative to a platinum/DMSO complex and not [Pt(dafone)Cl2] itself.
In this work, the cytotoxicity of [Pt(dafone)Cl2] was tested using DMF in-
stead of DMSO. It was first confirmed that [Pt(dafone)Cl2] is stable under these
conditions. The 195Pt NMR spectrum in a mixture of DMF/RPMI/D2O shows
a single resonance at -2802 ppm and no changes where observed over time (Fig-
ure 6.23). Subsequently, the cytotoxicity was tested on the breast cancer cell
line MDA-MB-231 by dissolving [Pt(dafone)Cl2] in minimum amount of DMF
followed by dilution in medium (RPMI). The highest concentration of DMF used
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was also tested as a control since DMF is usually more toxic towards cells than
DMSO. [Pt(dafone)Cl2] exhibited no toxicity towards breast cancer cells at a con-
centration <100µM. This was explained by the fact that the hydrophobicity of
[Pt(dafone)Cl2] leads to formation of needle-like crystals with a size of 2 to 10µm
when the DMF solution is diluted in the medium (Figure 6.9).
Figure 6.9: a) microscope image of MDA-MB-231 after incubation with
[Pt(dafone)Cl2] for cytotoxicity test. [Pt(dafone)Cl2] forms needles-like crystals
which prevent cellular uptake. b) TEM image of [Pt(dafone)Cl2] crystal in water
solution.
Due to its instability in DMSO, [Pt(dafone)Cl2] would not be suitable for
conjugation onto the prepared polymers. In fact, it was hypothesised that it is
possible that the substitution of the chlorides by the carboxo would displace the
dafone from the platinum in a similar process to the one observed in DMSO. For
future works, a different fluorescent ligand is recommended to form a platinum
complex which is stable in DMSO solution, this would permit conjugation onto the
polymer. In particular, it is recommended that a fluorescent ligand which forms
a 6-atom ring when bound to the platinum centre is selected, as it is hypothesized
that the 5-atom ring formed when the dafone coordinates to the platinum is not
energetically favourable, which results in the instability of [Pt(dafone)Cl2].
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6.3 Conclusions
The aim of this Chapter was to track the fate of a platinum-based drug when
delivered into cancer cells by PNs with either a fructose-based or a PEGMEMA
hydrophilic shell. A fluorescent platinum complex was synthesized as probing
tool. NMR analyses demonstrated that [Pt(dafone)Cl2] decomposes when dis-
solved in DMSO in about 3.5 h and the reported cytotoxicity was not evident on
the cell lines tested here. The instability of [Pt(dafone)Cl2] makes the conjuga-
tion onto the block copolymers impractical because replacing the chloride groups
with the carboxo groups of the block copolymers would most likely lead to the
dafone release from platinum, similarly to what observed with DMSO. However,
at this stage, this has not been possible to be confirmed. Future work may include
looking at a different fluorescent ligand that is coordinatively stable in order to
obtain a stable platinum complex.
6.4 Experimental
6.4.1 Materials
Unless otherwise specified, all chemicals were reagent grade and were used as re-
ceived. Potassium tetrachloroplatinate (K2PtCl4, 99%) was purchased from Pre-
cious metals online. Di-tert-butyl malonate (98%), ethylene glycol dimethacrylate
(EGDMA, 98%), 4,5-diazafluoren-9-one (dafone, 97%), tetrahydrofuran (THF,
anhydrous, 98%), 18-crown-6 (99%), toluene (purum), N,N -dimethyl-acetamide
(DMAc, HPLC grade), 1,4-dioxane (99%), D-fructose (99%) and oligo(ethylene
glycol) methyl ether methacrylate (OEGMEMA, MW= 300 g/mol) which was
deinhibited by passing through a column of basic aluminum oxide, were pur-
chased from Sigma-Aldrich. Sulfuric acid (95-98%), diethyl ether (Et2O anhy-
drous, 99%), petroleum spirit (BR 40-60 ◦C, 90%), ethyl acetate (EtAc, 99.5%),
magnesium sulfate (70%) and dimethyl sulfoxide (DMSO, 99%) were purchased
from Ajax Finechem. Potassium carbonate (anhydrous) was purchased from Uni-
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var. O-phenylenediamine (O-PDA) was purchased from Hopkin and Williams.
2,2′-azobis(isobutyronitrile) (AIBN, 98%) was purchased from Fluka and was
purified by recrystallization from methanol. Dimethylsulfoxide-d6 (DMSO-d6)
and chloroform-d (CDCl3) were purchased from Cambridge Isotape Laborato-
ries. Deionized(DI) water produced by MilliQ water purification system has a
resistivity of 17.9mΩ/cm.
6.4.2 Synthesis and procedures
Synthesis of iprFruc. iprFruc was prapared according to the literature proce-
dure [196]. To a flame-dried two necked 1L of round-bottomed flask was added
D-fructose (36 g, 0.199mol). It was dried under vacumm for 2 h. Then a cooled
solution of conc. sulfuric acid (35mL) in acetone (700mL) was added to the
flask and left to stir for 1.5 h at room temperature. After that, the reaction mix-
ture was cooled in an ice bath. The sodium hydroxide solution was prepared in
water and gradually added to the reaction mixture with stirring. Acetone was
evaporated and resulting solution was extracted with CH2Cl2. The extracts were
washed with water and dried by anhydrous sodium sulphate and evaporated to a
crystalline solid. (Yield: 39.10 g, 75%). 1H NMR (300.17MHz, CDCl3, 25 ◦C) δ
(ppm): 4.63 (dd, J=7.9, 2.6Hz, 1H), 4.36 (d, J=2.6Hz, 1H), 4.26 (ddd, J=7.9,
1.9, 0.8Hz, 1H), 3.94 (dd, J=13.0, 1.9Hz, 1H), 3.79 (dd, J=13.0, 0.8Hz, 1H),
3.78 - 3.62 (m, 2H), 1.56 (s, 3H), 1.50 (s, 3H), 1.42 (s, 3H), 1.37 (s, 3H). 13C
NMR (75.51MHz, CDCl3, 25 ◦C) δ (ppm): 109.08, 108.52, 103.07, 71.00, 70.79,
70.06, 65.54, 61.27, 26.45, 25.76, 25.33, 23.96.
Synthesis of iprFrucMA. A solution of iprFruc (3.0 g, 11.52mmol) in anhy-
drous dichloromethane (165mL), pyridine (6mL) and 4-dimethylaminopyridine
(1.0 g, 8.18mmol) at 0 ◦C was treated dropwise with a solution of methyl acrylate
anhydride (2.2mL, 13.25mmol) in dichloromethane (5mL). After it was stirred
for 48 h at room temperature, the mixture was poured into ice-cold saturated
NaHCO3 solution (165mL), and the organic layer was withdrawn. The aqueous
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layer was extracted with CH2Cl2, and combined organic layers were dried us-
ing MgSO4 and concentrated under reduced pressure. The product was purified
by flash column chromatography. (Yield: 3.21 g, 85%). 1H NMR (300.17MHz,
CDCl3, 25 ◦C) δ (ppm): 6.17 (dq, J=1.8, 0.9Hz, 1H), 5.62 (dd, J=1.9, 1.3Hz,
1H), 4.64 (dd, J=7.9, 2.7Hz, 1H), 4.50 (dd, J=11.9, 0.6Hz, 1H), 4.40 (dd,
J=2.7, 0.6Hz, 1H), 4.27 (ddd, J=7.9, 1.9, 0.8Hz, 1H), 4.17 (dd, J=11.9, 0.7Hz,
1H), 3.96 (dd, J=13.0, 1.9Hz, 1H), 3.79 (dt, J= 13.0, 0.8Hz, 1H), 1.99 (dt,
J= 1.6, 0.8Hz, 3H), 1.56 (s, 3H), 1.50 (s, 3H), 1.41 (s, 3H), 1.37 (s, 3H).
MAHTC.MAHTC was synthesised via Michael Addition between 1,6-hexylene
glycol dimethacrylate (HGDMA) and di-tert-butyl malonate. A 500mL two-
necked round-bottom flask was flamed under vacuum and let cool. HGDMA
(17.78 g, 0.69mmol, 3 equiv), potassium carbonate (3.54 g, 0.25mmol, 1.1 equiv)
and 18-crown-6 (0.20 g, 7.68× 10−1mmol, 0.033 equiv.) were added to anhydrous
THF (80mL) in the two-necked round-bottom flask, and the mixture was cooled
to 0 ◦C in an ice bath before degassing under nitrogen for 45min. Di-tert-butyl
malonate (5.00 g, 0.23mmol, 1 equiv) was added dropwise with vigorous stirring.
The slurry suspension was stirred further for 30min while maintaining the tem-
perature at 0 ◦C, then stirred for further 48 h at 40 ◦C. The colorless solution
turns yellowish. Deionized (DI) water (80mL) was added into the slurry before it
was washed 3 times with diethyl ether (3× 156.5mL) using a separation funnel.
The diethyl ether phases were collected and evaporated under reduced pressure.
The residual oil obtained was purified by silica gel column chromatography using
n-hexane/ethyl acetate mixture as gradient eluent with the ratio changing from
20:1 to 8:1 v/v. The collected fractions were examined by TLC stained by per-
manganate solution (Rf =0.15). The purified product gave 64% yield. 1H NMR
(300.17MHz, CDCl3, 25 ◦C): δ (ppm): 6.12 (s, 1H, H1), 5.58 (s, 1H, H2), 4.25
(t, 2H, H4), 4.15 (t, 2H, H5, J=1.08Hz), 3.2 - 3.25 (dd, 1H, H11, J=6.45Hz,
J=8.91Hz), 2.45 - 2.57 (qq, 1H, H8, J=6.99Hz), 2.15 (dd, 1H, H10, J=6.54Hz),
1.9 (dd, 4H, H10 and H3, J=6.12Hz), 1.65 (m, 4H, H5 and H6), 1.43 (s, 18H,
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H12), 1.18 (d, 3H, H9, J=7.02 Hz). 13C NMR (75.48MHz, CDCl3, 25 ◦C), δ
(ppm): 176.5, 169.4, 169.2, 168, 136.5, 126.01, 81.50, 64.33, 61.99, 52.5, 37.5,
31.96, 28.5, 26, 19, 17.30.
CPADB. CPADB was synthesized as reported in the literature [216, 217].
The dithiobenzoic acid (DTBA) was firstly prepared using sodium methoxide
(30% solution in methanol, 45 g, 250mmol), elemental sulphur (8.0 g, 250mmol),
anhydrous methanol (60mL) and benzyl chloride (15.75 g, 125mmol). The re-
action mixture was heated in an oil bath at 67 ◦C for 10 h. The reaction mix-
ture was then cooled to 7 ◦C using an ice bath. The precipitated salt was re-
moved by filtration and the solvent removed in vacuum. The residue was dis-
solved in deionized water (125mL). The crude sodium dithiobenzoate solution
was acidified with 1.0M HCl (125mL) and extracted with diethyl ether (50mL).
Deionized water (75mL) and 1.0M NaOH (150mL) were added, and sodium
dithiobenzoate was transfered to the aqueous phase. The sodium dithioben-
zoate solution (87.5mL) and potassium ferricyanide (III) (8.23 g, 25mmol) were
mixed in deionized water (150mL) under vigorous stirring. The red precipitate
was filtered and washed with deionized water until the washings became colour-
less. The solid was filtered and dried in vacuum at room temperature overnight.
The product, di(thiobenzoyl) disulphide, was recrystallized from ethanol. 4,4′-
azobis(4-cyanopentanoic acid) (2.92 g, 11.5mmol) and di(thiobenzoyl)disulfide
(2.13 g, 7mmol) were dissolved in distilled ethyl acetate (40mL). The reaction
solution was heated at reflux for 18 h and ethyl acetate was removed in vacuum.
The crude product was isolated by column chromatography (silicagel 60Å, 70-
230mesh) using ethyl acetate hexane (2:3) as eluent. Fractions that were red
in colour were combined and dried over anhydrous sodium sulphate overnight.
The solvent mixture was removed in vacuum, and the red oily residue placed
in a freezer at -20 ◦C where upon it crystallized. The target compound was re-
crystallized with an acetate/hexane (2:3) mixture (Final yield 79%). 1H NMR
(300.17MHz, CDCl3, 25 ◦C) δ (ppm): 1.95 (s, 3H), 2.36 - 2.86 (m, 4H), 7.34 -
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7.95 (aromatic H). 13C NMR (75.51MHz, CDCl3, 25 ◦C) δ (ppm): 222.2, 177.2,
144.5, 133.1, 128.6, 126.7, 118.4, 45.6, 33.0, 29.6, 24.2.
PEGMEMA40. OEGMEMA (1 g, 3mmol), the RAFTagent CPADB (17.5mg,
0.6× 10−1mmol) and AIBN (1.9mg, 0.12× 10−1mmol were dissolved in toluene
(4mL) in a 10mL schlenk tube. The tube was then sealed and deoxygenated
through 3 freeze-pump-thaw cycles leaving the reaction vessel under argon. The
tube was then placed in an oil bath at 70 ◦C for 6 h. The reaction was quenched
in an ice bath and opening to air. The raw solution was analysed via 1H NMR
to determine the conversion. A 40 units long polymer was obtained. 1H NMR
(300.17MHz, CDCl3, 25 ◦C) δ (ppm): 4.4 - 4.2 (2nH, CH3COOCH2CH2O), 4.0 -
3.8 (11nH, CH2 of OEGMEMA monomer), 3.6 - 3.4 (3nH, CH3 of chain end of
OEGMEMA), 1.4 - 1.2 (3nH, CH3 of the main chain), 1.2 - 0.9 (2nH, CH2 of the
main chain); n is the degree of polymerisation (DPn) of PEGMEMA. The solu-
tion was concentrated under reduced pressure and the PEGMEMA precipitated
in petroleum spirit while stirring, decanted and dried in a vacuum oven at 40 ◦C.
(80%, 40 units, MnNMR=12000, MnGPC =11400, Ð=1.16).
P(iprFrucMA44). iprFrucMA (1 g, 3.045mmol), the RAFT agent CPADB
(17mg, 0.60× 10−1mmol), and AIBN (1.25mg, 0.76× 10−4mmol) were dissolved
in 1,4-dioxane (4.3mL) and placed in a Schlenk tube. Then the tube was degassed
by three FPT cycles. The polymerization was carried out at 70 ◦C and stopped at
11 h by cooling the solution in ice water. The polymer solution was poured into
a large excess of ether for precipitation. The viscous polymer was dried under
vacuum for 24 h. The conversion of polymerization was determined by 1H NMR.
(88%, 44 units, MnNMR=18800, MnGPC =16300, Ð=1.15).
PEGMEMA40-b-PMAHTC70. PEGMEMA40 macroRAFT agent was chain
extended with MAHTC. Polymerization of MAHTC using PEGMEMA macro-
RAFT agent was performed with a similar procedure as above. PEGMEMA40
(0.255 g, 2.13× 10−2mmol), MAHTC (1 g, 2.13mmol) and finally AIBN (0.69mg,
4.26× 10−3mmol) were dissolved in dioxane (3.5mL). The tube was degassed with
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3 freeze-pump-thaw cycles leaving the reaction under argon. The tube was then
placed in an oil bath at 70 ◦C for 5 h and the reaction was quenched in an ice bath
and opening to air. The solution was concentrated under reduced pressure and
the diblock copolymer was precipitated in petroleum spirit decanted and dried in
a vacuum oven. The final products were then analysed by 1H NMR to determine
the conversion. (70%, 70 units, MnNMR=44900, MnGPC =45000, Ð=1.17)
P(iprFrucMA44)-b-PMAHTC70. The fructose based macroRAFT agent
(100mg, 6.8× 10−3mmol), MAHTC (0.3 g, 6.8× 10−1mmol), AIBN (0.21mg,
1.3× 10−3mmol) were dissolved in 1,4-dioxane (1.5mL) in schlenk tube and de-
gassed by three freeze pump thaw cycles. The polymerization was carried out
at 70 ◦C for 24 h and quenched by introducing air and cooling the solution in an
ice bath. The polymer was precipitated in large excess of n-hexane. The vis-
cous polymer was dried under vacuum for 24 h. The conversion of polymerization
was determined by 1H NMR. (70%, 70 units, MnNMR=51700, MnGPC =52000,
Ð=1.11).
Deprotection. PEGMEMA40-b-PMAHTC70 (0.5 g, 1.1× 10−2mmol) and
P(iprFrucMA44)-b-PMAHTC70 (0.5 g, 0.96× 10−2mmol) were firstly dissolved in
dichloromethane (10mL) in a 25mL round bottom flask and trifluoroacetic acid
(12-equivalent compared to tert-buthyl group) was then added. The reactions
were stirred at room temperature for 72 h. The final mixtures were dialyzed
using dialysis membranes with a molecular weight cut off (MWCO) of 3500Da
against acetone-water (1:1) followed by MilliQ water. The solutions were then
freeze-dried. The deprotected copolymers were characterized by 1H NMR.
[Pt(dafone)Cl2]. K2PtCl4 (0.250 g, 0.602mmol) was dissolved in H2O (2mL)
and DMSO (5mL), the solution was warmed up to 60 ◦C till the paltinum salt
is completely dissolved. Meanwhile, dafone (0.073 g, 0.4mmol) was dissolved in
DMSO (10mL) and the solution was warmed up to 60 ◦C. The dafone solution
was then dropped slowly into the platinum solution keeping the temparature at
60 ◦C. A yellow precipitate could be observed. The solution was cooled to room
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temperature and placed in the fridge for few days to allow the product to pre-
cipitate completely. The final product was filtrated and washed with chilled HCl
solution, H2O, ethanol and diethyl ether. Yield (0.215 g, 0.48mmol, 80%). X-ray
quality needle shaped orange crystals were obtained by dissolving the platinum
complex in a DMF/H2O mixture with a ration of 4:1. The solution was placed
in a long tube at room temperature for few days. X-Ray: crystal system, mon-
oclinic; a (Å), 5.158(6); b (Å), 16.748(17); c (Å), 12.882(13); b (0), 98.01(2); V
(Å3), 1102(3). 195Pt NMR: (DMF/D2O, 85.84MHz, 25 ◦C) δ (ppm): -2793. 1H
NMR (400.13MHz, DMSO-d6) δ (ppm): 9.31 (d, J=5.7, 1H), 9.20 (d, J=5.7,
1H), 8.37 (d, J=7.69, 1H), 8.28 (d, J=7.69, 1H), 7.78 (dd, J=7.67, 1H), 7.71
(dd, J=7.67, 1H).
6.4.3 Characterization
Figure 6.10: 1H NMR, CDCl3, iprFruc.
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Figure 6.11: 13C NMR, CDCl3, iprFruc.
Figure 6.12: 1H NMR, CDCl3, iprFruc.
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Figure 6.13: 13C NMR, CDCl3, iprFruc.
Figure 6.14: 1H NMR, CDCl3, iprFrucMA.
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Figure 6.15: 1H NMR, CDCl3, MAHTC.
Figure 6.16: 13C NMR, CDCl3, MAHTC.
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Figure 6.17: 1H NMR, CDCl3, PEGMEMA40-b-PMAHTC70.
Figure 6.18: 1H NMR, CDCl3, deprotected PEGMEMA40-b-PMAHTC70.
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Figure 6.19: 1H NMR, DMSO-d6, Fruc44-b-PMAHTC70, crude.
Figure 6.20: 1H NMR, DMSO-d6, deprotected Fruc44-b-PMAHTC70.
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Figure 6.21: GPC traces of P(iprFrucMA44) and P(iprFrucMA44)-b-PMAHTC70.
Figure 6.22: GPC traces of PEGMEMA40 and PEGMEMA40-b-PMAHTC70.
Figure 6.23: 195Pt NMR, 85.84MHz, DMF/RPMI/D2O, [Pt(dafone)Cl2].
155
Chapter 7
Synergistic dual-drug delivery of
platinum drugs and paclitaxel in
vesicles
As already mentioned in Chapter 1.1 beside tailoring the physical, chemical and
mechanical characteristics of the drug delivery system, one strategy used to im-
prove the efficacy of platinum drugs is to co-deliver them together with a second
cancer inhibitor to take advantage of the synergistic effect that the two drugs
can show. Moreover, co-delivery of platinum with a second chemotherapeutic
can overcome the drug resistance that certain cancers can develop during plat-
inum therapy. In this Chapter a polymer vesicle was designed to co-deliver a
platinum(IV) drug and placlitaxel simultaneously.
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7.1 Introduction
Cancers can sometimes develop drug resistance over the course of chemotherapy
mainly due to genetic alterations which occur in cancer cells [220]. Combination
chemotherapy may be used to overcome drug-induced mutations and drug resis-
tance by combining two or more drugs which act on different stages of the cell
cycle and/or in the repair process. The attack on multiple fronts enhances the
apoptosis of cancer cells [221].
Cisplatin analogues such as oxaliplatin and platinum(IV) pro-drugs have shown
to be active in highly cisplatin-resistant cancer cells in the laboratory; however,
there is little evidence for their activity in the clinical treatment of patients with
cisplatin-resistant cancer [222]. Therefore, platinum drugs are often used in con-
junction with other therapeutics in the attempt to overcome drug resistance. In
recent years, multifunctional systems which combine a platinum(IV) drug with
an inhibitor have been developed and show promising results [73, 72, 223]. Ad-
ministration of platinum drugs with paclitaxel could overcome cisplatin-resistant
cancers, although the mechanism for this effect is not fully understood. Clinical
investigations suggest increased survival among patients with platinum sensitive
relapsed ovarian cancer when administered with paclitaxel in combination with
platinum drugs [224, 225]. Multi-drug combination therapy shows better efficacy
than cisplatin and its analogous alone. However, similar to the administration
of only one drug, dual-drug administration is greeted with the same issues such
low solubility, stability and tumour targeting. These shortcomings are widely
addressed by the use of nanoparticles to deliver platinum drugs [185, 226]. Drug
delivery systems can not only improve the solubility of the hydrophobic drug and
protect it from deactivation by proteins increasing the circulation in the blood
stream enabling the enhanced accumulation into the cancerous tissue. More-
over, drug delivery systems are able to passively target the tumour through the
enhanced permeability and retention (EPR) effect. This leads to a targeted ther-
apeutic approach decreasing the drug dosage required and avoiding repeated ad-
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ministrations so lowering undesired side effects [227]. A range of drug delivery
systems for platinum drugs are described in the literature [185, 226], but many
of these systems are not suitable for the delivery of two drugs. In the last few
years, drug carriers for dual drug delivery have raised significant interest [228].
One of the advantages lies in the enhanced synergistic effect when both drugs
are delivered in one nanoparticle [229]. The amount of dual-drug carriers for
platinum drugs is limited, probably owing to the possibility that some drugs can
act as ligand for platinum drugs. Close vicinity may deactivate the platinum
drug. Aryal et. al. have recently co-delivered a new drug obtained by linking
platinum(IV) drug with paclitaxel in a lipid polymer hybrid nanoparticle [230].
Moreover, cisplatin and paclitaxel were both delivered using dendrimers [231]
and micelles [232], respectively, to create nanoparticles against ovarian cancer.
Physical encapsulation of drug can often lead to burst release while the loading
process itself often leads to low drug loading efficiencies. It was recently shown
that chemical conjugation of paclitaxel to polymers can enhance the long-term
therapeutic effect as the drug is only slowly cleaved from the scaffold [233, 234].
In this Chapter, we have therefore developed a pathway to generate polymer-
somes (polymeric vesicles) based on chemically conjugated paclitaxel (Ptx) and
a platinum(IV) (PtPD) complex (Figure 7.1).
Polymersomes are attractive for drug delivery purposes as they show enhanced
stability in contrast to liposomes and they offer the possibility to deliver hy-
drophobic and hydrophilic drugs simultaneously [235]. The polymer chosen here
is a triblock copolymer based on PEG and a poly(glutamic acid), a polymer that
is already used in a clinical setting for the delivery of various drugs [103, 102].
PEG constitutes the hydrophilic and biocompatible layers of the vesicle while the
glutamic acid groups function as anchoring points for the cargo trapped into the
vesicle's wall. The aim is to evaluate the synergistic effect between both drugs
in a lung cancer cell line (A549) and a prostate cancer cell line (LNCaP) when
delivered within one drug carrier. To complement the study the effect of the
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dual-drug delivery on multicellular spheroids was investigated. The advantage of
this work in contrast to existing approaches is that the polymer is initially water-
soluble and will only form self-assembled aggregates once the hydrophobic drugs
are attached. Liberation of both drugs from the carrier revert the amphiphilic
polymer into a fully water-soluble polymer, thus allowing better clearance of the
drug carrier.
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Figure 7.1: Scheme of the block copolymer synthesis and preparation of loaded
vesicles.
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7.2 Results and discussion
The aim of this Chapter is to engineer a drug delivery system which can de-
liver a platinum complex together with the inhibitor paclitaxel as the synergistic
effect of these two drugs was shown to enhance tumour growth inhibition. In
contrast to other drug carriers that attempt to deliver drugs in combination
with paclitaxel, both drugs will be chemically conjugated to the polymer. For
this purpose, a vesicular system consisting of a peptide-based triblock copoly-
mer which can attach the two chemotherapeutics simultaneously was designed.
N -Carboxyanhydride (NCA) Ring Opening Polymerization (ROP) was used to
polymerize amino acid based monomers to give peptide-like block copolymers
which are highly biocompatible and biodegradable. An NCA monomer based on
glutamic acid (NCA-BLG) was chosen and prepared according to the literature.
γ-benzyl-L-glutamate was reacted with triphosgene in THF in the presence of
α-pinene using anhydrous conditions and under a constant flow of argon. The
monomer was precipitated by hexane and recrystallized twice from THF/hexane
mixture [236, 237]. NMR and FT-IR analyses have confirmed the success of the
synthesis (Figure 7.2 to 7.4).
Figure 7.2: 1H NMR, 300 MHz, NCA-BLG in TFA.
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Figure 7.3: 13C NMR, 300 MHz, NCA-BLG in TFA.
Figure 7.4: FT-IR of NCA-BLG.
The triblock copolymer was prepared via NCA-ROP using poly(ethylene gly-
col) bis(amine) as the initiator in a ratio monomer/initiator of 200:1. The poly-
merization was carried out in THF at room temperature for 4 days under anhy-
drous conditions and inert atmosphere and it was terminated by adding a large
excess of succinic anhydride. The conversion of the polymerization was deter-
mined by 1H NMR by comparing the integral from the CH2 of the benzyl groups
to the integral of the CH2 from the PEG block (Figure 7.13). The final composi-
tion of the triblock copolymer is PBLG89-b-PEG68-b-PBLG89. FT-IR spectrum of
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the triblock copolymer in Figure 7.14 shows all the main characteristic stretches.
The protected block copolymer self-assembles into micelles of a diameter Dh =
122 nm and PDI=0.2 in aqueous medium at a concentration of 0.3mg/mL, how-
ever, the micelles start to coalesce at higher concentrations of the polymer. The
structure was confirmed by TEM and it's shown in Figure 7.5.
Figure 7.5: TEM image (UA staining) of protected triblock copolymer at the
final concentration of a) 0.3mg/mL and b) 1mg/mL and DLS results.
The deprotection was carried out in basic conditions to give a fully water
soluble triblock copolymer (P(Glu)89-b-PEG68-b-P(Glu)89). 1H and 13C NMR,
FT-IR and GPC where used to confirm that the polymer was successfully de-
protected (Figure 7.15 to 7.18). After deprotection the carboxylic groups of the
P(Glu) blocks can be used as anchoring point for two anticancer drugs: paclitaxel
(Ptx) and a platinum(IV) complex (PtPD). Ptx was conjugated to the polymer
using DCC and DMAP as coupling agents in DMSO. The purification of the
Ptx-polymer conjugate involves a series of dialyses in DMSO, acetonitrile, ace-
tonitrile/water (1:1), and water which ensured complete removal of free Ptx. 1H
NMR analysis (Figure 7.6) was used to confirm the successful conjugation of Ptx
to the polymer and to determine the conjugation efficiency by comparing the
integrals of the aromatic protons of Ptx to the CH2 of the PEG block. It was
calculated that 14 Ptx were conjugated on the two P(Glu) blocks of each chain.
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Figure 7.6: 1H NMR in D2O of Ptx-conjugated triblock copolymer.
To form nanoparticles, the Ptx-conjugated polymer was dissolved in a min-
imum amount of DMSO, water was added slowly under stirring, followed by
dialysis against MilliQ water. The Ptx-conjugated polymer self-assembled in wa-
ter into vesicles (V(Ptx)) with a diameter Dh = 400 nm and PDI=0.06 (Figure
7.7, a). The formation of polymersomes is not surprising considering that the
hydrophobic block is significantly longer that then hydrophilic one. Conjuga-
tion of Ptx and the further increase in the hydrophobic volume fraction pushes
the structure towards bilayer morphologies. The second drug, [Pt(phen)(S,S -
dach))(OH2)]Cl2, which will be simply called PtPD from now on (Figure 7.1),
was synthesised by F.J. Macias and K. M. Deo and here characterised by 195Pt
NMR (Figure 7.19). PtPD was conjugated through the hydroxo groups on its
axial axis to the Ptx loaded vesicles acqueous solution using EDC and NHS as
coupling agents. The dual-drug loaded vesicles (V(Ptx+PtPD)) were then dial-
ysed against water one more time. Conjugation of PtPD led to a slight increase
in the diameter of the vesicles as evidenced by DLS and TEM characterization
(Figure 7.7, b). The amount of conjugated PtPD was measured by ICP-MS
which revealed that 8 PtPD were conjugated to each polymer chain. The final
164
ratio Ptx/PtPD into the vesicles is, therefore, 14:8.
Figure 7.7: TEM image (UA staining) of a) Ptx loaded vesicles V(Ptx), b)
Ptx/PtPD loaded vesicles V(Ptx+PtPD), and DLS results.
The cytotoxicity of drug loaded vesicles as well as the free drugs was inves-
tigated against a lung cancer cell line (A549) and a prostate cancer cell line
(LNCaP). The IC50 values were determined using a standard SRB assay. Firstly,
the toxicity of pure polymer was tested at various concentrations to exclude any
effect of the carrier on cell growth. The polymer was found to have no effect on
cell growth in the concentration range used for the loaded vesicles (< 0.1µg/mL).
Figure 7.8: Cytotoxicity of unconjugated triblock copolymer on A549 and LNCaP
cell lines.
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Subsequently, the cytotoxicity of the two drugs, Ptx and PtPD, a combination
of them in a [PtPD]:[Ptx]=100:1 ratio, as well as the loaded vesicles V(Ptx)
and V(Ptx+PtPD) were evaluated on A549 and LNCaP cell lines. The IC50
values are summarised in Table 7.1. Ptx is very active towards both cell lines
emphasizing the extreme toxicity of this compound, while PtPD shows IC50 values
two orders of magnitude higher than Ptx in both A549 and LNCaP. However,
when mixing the two drugs at a [PtPD]:[Ptx]=100:1 ratio, the IC50 values of both
drugs decrease with the efficacy of PtPD improving drastically. Interestingly,
the use of polymeric vehicles to deliver Ptx is not effective compared to free
Ptx. The reduced cytotoxicity of Ptx has been previously observed with other
polymer carriers and can be probably associated with a low release of Ptx into the
cell when entrapped into the carrier [238, 239]. The higher IC50 value of polymer
bound Ptx is well-known as the drug needs to be cleaved from the polymer first in
order to be active [240, 241]. Interestingly the rate of hydrolysis can be influenced
by the type of polymer [240]. In contrast, conjugation of PtPD to the vesicles
significantly improve the efficiency of the PtPD drug compared to the free drug.
In addition, the drug carrier seems to improve the performance of Ptx delivered
in the vesicle.
Table 7.1: Summary of IC50 values.
IC50 (nM)
A549 LNCaP
Ptx 3.7 1.13
PtPD 466 347
Ptx/PtPD Ptx: 0.07 PtPD: 7.2 Ptx: 0.43 PtPD: 43.8
V(Ptx) 4565 2545
V(Ptx+PtPD) Ptx: 278 PtPD: 159 Ptx: 138 PtPD: 78.8
The cellular uptake of V(Ptx) and V(Ptx+PtPD) was studied using flow cy-
tometry. For this purpose, the vesicles were labelled with the fluorescent dye
fluorescein isothiocyanate (FITC). Cells were loaded with FITC-labelled vesicles
and incubated for 6 h. After the incubation time, the cells were washed with PBS
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several times, treated with trypsin to detach them from the surface of the culture
dish, re-dispersed in fresh PBS and analysed using flow cytometer. Figure 7.9
shows the normalised fluorescence intensity of the two cell lines incubated with
either V(Ptx) or V(Ptx+PtPD). While there is a difference in cellular uptake
between the cell lines, the internalization of the two carriers is similar in each
cell line. This suggests that the enhanced toxicity of V(Ptx+PtPD) compared to
V(Ptx) is due to the combination effect of the two drugs and not to an increase
in cellular uptake.
Figure 7.9: Cellular uptake of V(Ptx) and V(Ptx+PtPD) on A549 and LNCaP
via flow cytometry analysis.
Another interesting aspect of the functioning of these vesicles is the mech-
anism and profile of drug release. It can be hypothesized that, in the cellular
environment, PtPD comes off first upon reduction of Pt(IV) to Pt(II). Secondly,
Ptx could be release either through the cleavage of the ester bond that connects
it to the polymer or due to the degradation of the polymer itself. Further inves-
tigations are recommended here.
The combination effect between Ptx and PtPD as free drugs as well as vesicles-
incorporated moieties was evaluated using the computer software CalcuSyn for
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Windows (Biosoft, UK). Synergism, additivity or antagonism is defined by the
combination index CI. A CI<1 indicates synergistic effect between the two drugs,
a CI=1 indicates additivity and a CI>1 indicates antagonism. First, the via-
bility of A549 and LNCaP cells treated with Ptx and PtPD as single drugs was
compared to the viability of cells treated with a combination of Ptx and PtPD at
constant concentration ratios. Then, the same experiment was repeated compar-
ing the cell viability in the presence of free Ptx and PtPD drugs in comparison
with the dual-drug loaded vesicles, V(Ptx+PtPD).
The algebraic estimate and the isobolograms obtained by the software analysis
are shown in Figure 7.10. The combination of Ptx and PtPD either as free drugs
or as vesicles cargo has a synergistic effect when CI<1, which is depicted by a
scatter graph below the solid line in the graphs in Figure 7.10, a, c, e and g).
The fractional effect represents the fraction of cells affected (dead cells) by the
drugs, thus higher fractional effects correspond to higher drugs concentrations.
The synergistic effect of the combination of Ptx and PtPD was observed in both
cell lines (CI<1) whether the two drugs are administrated as free drugs or co-
delivered by the carrier (Figure 7.10, a, c, e and g).
Graphs in Figure 7.10, b, d, f and h) show the isobolograms at different
median effective doses (ED50, ED75, ED90). At each ED, the graph shows three
points which represent the effect due to Ptx alone (y axes), the effect due to
PtPD alone (x axes) and the effect due to Ptx/PtPD combination. Therefore, if
the point that represents the effect of Ptx/PtPD as a combination is below the
line for the effect of Ptx and PtPD as single drugs there is synergistic effect at
that ED. If the Ptx/PtPD combination point lays on the line there is an additive
effect, whereas if it is above the line the effect of the two drugs is antagonistic.
Here Ptx and PtPD show a synergistic effect both when administered to cells
as free drugs combination as well as when co-delivered by the vesicles and at all
EDs.
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Figure 7.10: CalcuSyn software evaluation of the synergistic effect of the com-
bination of: free Ptx and PtPD as a) algebraic estimate and b) isobologram
on A549; Ptx and PtPD co-delivered by the vesicles as c) algebraic estimate
and d) isobologram on A549; free Ptx and PtPD as e) algebraic estimate and f)
isobologram on LNCaP; Ptx and PtPD co-delivered by the vesicles as g) algebraic
estimate and h) isobologram on LNCaP.
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3D multicellular tumour spheroids (MCTS) were prepared from lung cancer
cells A549. The A549 spheroids where incubated with Ptx, PtPD, a combina-
tion of Ptx and PtPD in a [Ptx]:[PtPD]=1.75:1 ratio which simulates the ratio
of the two drugs in the polymer vesicles and V(Ptx+PtPD) for up to 14 days.
The concentration of the active ingredients was kept constant across all samples.
The medium and drug solutions were replenished at day 7 simulating a second
administrative dose. The size and morphology of the A549 spheroids were ob-
served after 4, 7 and 14 days of incubation and micrographs are displayed in
Figure 7.11. The morphology of the spheroids remain spherical over time when
incubated with the free drugs. A slight disruption of the morphology is observed
after 14 days incubation with V(Ptx+PtPD). Only subtle differences in spheroid
volume can be observed across all samples, however, the size of treated spheroids
is visibly smaller than that of the control. The microscope images indicate that
inhibition of growth occurs when the spheroids are treated with free drugs and
loaded carrier with the later undermining the morphology of the spheroids. APH
assay was used as quantitative method to measure the viability changes in the
MCTS.
The bar chart in Figure 7.12 shows the APH activity of MCTS after 4, 7 and 14
days when treated with the free drugs and their combination or the loaded carrier
compared to untreated spheroids. Complementing the microscope images, the
control spheroids (grey bar) continued to proliferate up the end of the study at day
14. Incubation with drugs showed a significant decrease in proliferation compared
to the control. Although the differences between the various drug system is not
significant, it shows that the free drug acts slightly faster in comparison to the
vesicles while after 7 and 14 days the drugs are slightly more efficient when
delivered by the vesicle. The longer-lasting performance of drugs delivered by
carriers is well known. Though the free drugs displayed higher activity in the
2D in vitro system (Table 7.1), multicellular spheroid cancers can capture the
performance of the drug carrier after a longer incubation period. For future work
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it would be interesting to evaluate the changes in morphology and the viability
of MCTS using a lower dose of active ingredients to emphasize the difference in
efficiency of free drugs and dual-drug vesicles.
Figure 7.11: Effect of Ptx and PtPD as single drugs, as a combination of free
drugs and as vesicles cargo on A549 MCTS (scale bar = 200µm).
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Figure 7.12: Viability of A549 MCTS afte 4, 7 and 14 days treatment with Ptx
and PtPD as single drugs, as a combination of free drugs and as vesicles cargo.
Data represent means ± SD, n = 8. ∗ = significant difference: P <0.05 (∗), P
<0.01 (∗∗), P <0.001 (∗ ∗ ∗).
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7.3 Conclusions
A triblock copolymer based on PEG and poly(glutamic acid), able to simulta-
neously conjugate paclitaxel and a platinum(IV) drug, was here prepared. The
drug-conjugated polymer assembles into polymersomes, or vesicles, which load a
combination of Ptx and PtPD in their walls. The dual-drug loaded vesicles were
tested on a lung and a prostate cancer cell lines in mono-layered cultures as well
as on lung cancer multi cellular tumour spheroids. Ptx and PtPD showed syner-
gistic effect when used in combination and this effect further improved when the
two drugs were co-delivered by the vesicles. Moreover, viability study on MCTS
showed significant decrease of cells proliferation when MCTS were treated with
Ptx or PtPD as single drugs, as combination of free drugs and co-delivered by
the vesicles compared to untreated MCTS. However, a slight improvement is ob-
served in the case of the dual-drug vesicles. It would be interesting to use a lower
dose of active ingredients to evaluate the changes in morphology and the viability
of MCTS. This could emphasize the difference in efficiency between free drugs
and dual-drug vesicles. Moreover, it would be recommended to study the profile
and mechanism of release of the Ptx/PtPD loaded vesicles.
7.4 Experimental
7.4.1 Materials
Unless otherwise specified, all chemicals were used as received. The platinum com-
plex [Pt(phen)(S,S -dach)(OH)2]Cl2 (PtPD) was synthesised in the research lab-
oratory of Prof. Aldrich-Wright [242]. γ-Benzyl-L-glutamate was purchased from
Meryer (Shanghai) Chemical Technology Co.. Paclitaxel (Ptx, 99%) was pur-
chased from Dato Chemicals. Triphosgene (98%), poly(ethylene glycol) bis(amine)
(PEG, MW = 3000), α-pinene (98%), N,N ′-dicyclohexylcarbodiimide (DCC, 99%),
4-(dimethylamino)pyridine (DMAP, purum, 98.0%), N -(3-(dimethylamino)propyl)-
N ′-ethylcarbodiimide hydrochloride (EDC, BioXtra), N -hydroxysuccinimide (NHS,
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98%), fluorescein isocyanate (FITC, powder), tetrahydrofuran (anhydrous, 99.9%,
inhibitor-free), and hexane (anhydrous, 95%) were purchased from Sigma-Aldrich.
Sodium hydroxide (NaOH) and dimethyl sulfoxide (DMSO) were purchased from
Ajax Finechem. Succinic anhydride (97%) was purchased from Fluka. Trifluo-
roacetic acid-d (TFA-d) dimethylsulfoxide-d6 (DMSO-d6) and deuterium oxide
(D2O) were purchased from Cambridge Isotope Laboratories. MilliQ was pro-
duced internally and had a resistivity of 18.2mΩ/cm.
7.4.2 Synthesis and procedures
Synthesis of NCA-BLG. γ-Benzyl-L-glutamate (10 g, 42mmol) and α-pinene
(13.38mL, 84mmol) were dissolved in anhydrous THF (80mL) in a three-neck
round bottom flask (RBF) equipped with a condenser and an exhaust to a NaOH
solution. The mixture was heated to 50 ◦C under argon and triphosgene (6.23 g,
21mmol) in 20mL of anhydrous THF was added drop-wise over a period of 1 h.
The reaction was stirred for 4 additional hours until it becomes clear. The NCA
monomer was precipitated by addition of dry hexane, filtrated and recrystallized
twice from THF/hexane mixture in a freezer. The final product was obtained in
form of white crystals with a yield of 78%. 1H NMR (400.13MHz, CF3COOD)
δ: 2.35 (CH2, 2H), 2.73 (CH2, 2H), 4.60 (CH, 1H), 5.15 (CH2, 2H), 7.15 - 7.5
(aromatic CH, 5H). 13C NMR (100.62MHz, CF3COOD) δ: 25.8 (CH2CH2CO),
29.1 (CH2CH2CO), 57 (COCHNH), 68.7 (OCH2Ar), 127.9 - 133.9 (Ar), 155.6
(NHCOO), 170.2 (CH2COO), 175.7 (CH2COO). FTIR (cm−1): 1300 - 1500 (C-C
Ar), 1700 - 1850 (C=O), 2800 - 3300 (C-H Ar and CH2), 3300 - 3500 (N-H).
Synthesis of the triblock copolymer. The NCA-BLG monomer (1.75 g,
0.66mmol) was dissolved in 6mL of anhydrous. To this, poly(ethylene glycol)
bis(amine) (0.1 g, 3.3× 10−2mmol) in 2mL of THF was added. The reaction
mixture was stirred at 35 ◦C for 24 h. To this an excess of succinic anhydride
in THF (1mL) was added and the reaction was let stir overnight. The reaction
mixture was concentrated and precipitated in hexane, filtered and dried to obtain
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a white solid. The conversion was determined by 1H NMR (89%).
Self-assembly of triblock copolymer. PBLG89-b-PEG68-b-PBLG89 (2mg,
6.4× 10−5mmol) was dissolved in DMSO (0.2mL), the solution was equally di-
vided in two vials. MilliQ water was added to the vials under stirring at a speed
of 0.1mL/h using a syringe pump up to a final volume of 1mL in one case
and 3ml in the other. The solutions were then dialysed against MilliQ water
(MWCO=3500).
Deprotection of the triblock copolymer. The triblock copolymer was
deprotected by using basic conditions. The polymer was dispersed in H2O and
a large excess of NaOH was added under stirring. The mixture was stirred
overnight, the reaction was completed when turned completely clear. The poly-
mer was then purified via dialysis against MilliQ water and freeze dried. The
successful deprotection was confirmed by 1H NMR.
Paclitaxel-polymer conjugate. The tiblock copolymer P(Glu)89-b-PEG68-
b-P(Glu)89 (10mg, 3.2× 10−5mmol) was dissolved in DMSO (1mL). Paclitaxel
(5.5mg, 6.44× 10−3mmol) in DMSO (1mL) was added at a ratio COOH/Ptx
of 17.8:1. DMAP (7.8mg, 6.45× 10−2mmol) in DMSO (0.5mL) and lastly DCC
(26.6mg, 12.9mmol) in DMSO (0.5mL) were added to the polymer solution under
stirring. The reaction was stirred for 3 days at 40 ◦C. The Ptx-polymer conjugate
was purified via dialysis (MWCO 6000-8000) against DMSO (three times solvent
change over 24 h), followed by acetonitrile (three times solvent change over 24 h),
acetonitrile/MilliQ water in a 1:1 ratio (three times solvent change over 24 h),
MilliQ water (three times solvent change over 24 h) and lyophilisation. The num-
ber of Ptx conjugated to the polymer was calculated via 1H NMR by comparing
the aromatic resonances of Ptx to the CH2 of the PEG block.
Ptx-loaded vesicles (V(Ptx)). Vesicles were obtained by dissolving the
Ptx-conjugated polymer (0.3mg, 6× 10−6mmol) in DMSO (0.1mL) and adding
MilliQ water (0.9mL) at a speed of 0.1mL/h under stirring. The solution was
then dialysed (MWCO=3500 g/mol) against MilliQ water.
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Ptx/PtPD-loaded vesicles (V(Ptx+PtPD). To an aqueous solution of
Ptx-loaded vesicles (0.3mg, 6× 10−6mmol) PtPD (0.3mg, 5.7× 10−5mmol) and
NHS (0.65mg, 5.7× 10−3mmol) were added under stirring, followed by addition
of EDC (4.7mg, 2.5× 10−2mmol). The mixture was stirred overnight and purified
by dialysis (MWCO=3500) against MilliQ water.
Viability of MCTS. Once the MCTS were fully formed, 170µL of medium
was removed from each well and replenished with 200µL of fresh medium sup-
plemented with Ptx, PtPD, a mixture of Ptx and PtPD in a 1.75:1 ratio or
V(Ptx+PtPD) at a total drug concentration of 500 nM. The MCTS were incu-
bated up to 14 days and the medium and vesicles/drugs solutions were changed
at day 7. At day 4, 7 and 14 the MCTS morphology was observed at the opti-
cal microscope and acid phosphate (APH) assay was performed to measure the
viability. The APH assay buffer was made of 2mg/mL p-nitrophenyl phosphate,
0.1M sodium acetate and 0.1% (v/v) triton X-100 (pH4.8). Supernatant and
MCTS from each wells were carefully transferred into standard flat-bottomed
96-well microplates and centrifuged for 5min at 500 g to spin down spheroids,
clusters and single cells. The MCTS were gently washed with PBS twice ending
with a final volume of 100µL of PBS per well. Then, 100µL of APH assay buffer
was added to each well and incubated for 90min at 37 ◦C and 5% CO2. The reac-
tion was terminated with 10µL of 1M NaOH and the absorption was measured
with a microplate reader (Ascent) at 426 nm.
Statistical analysis. A one-way analysis of variance was performed for the
statistical analysis followed by a Tukey's post hoc test for pairwise comparison. A
P<0.05 was considered statistically significant. All statistical analysis was done
with GraphPad Prism 6.0.
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7.4.3 Characterization
Figure 7.13: 1H NMR in DMSO-d6 of PBLG89-b-PEG68-b-PBLG89.
Figure 7.14: FT-IR of PBLG89-b-PEG68-b-PBLG89.
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Figure 7.15: 1H NMR in DMSO-d6 of P(Glu)89-b-PEG68-b-PLAG89.
Figure 7.16: 13C NMR in DMSO-d6 of P(Glu)89-b-PEG68-b-PLAG89.
178
Figure 7.17: FT-IR of of P(Glu)89-b-PEG68-b-PLAG89.
Figure 7.18: GPC in water of of P(Glu)89-b-PEG68-b-PLAG89.
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Figure 7.19: 195Pt NMR, [Pt(phen)(S,S -dach)(OH)2]Cl2 (PtPD) in D2O.
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Chapter 8
Conclusions and future overlook
The aim of this thesis was to engineer, prepare and study polymer nanocarriers
for the delivery of anti-cancer platinum-based drugs. Firstly, glyco-copolymers
were used to engineer actively targeting PNs for platinum drugs delivery as an
alternative to targeting ligands such as folic acid, peptides or antibodies. In
fact, PNs made of glycopolymers are efficiently internalised by cancer cells which
overexpress sugar receptors without needing to add any other targeting moiety. In
this thesis, glucose, galactose, and two isomers of fructose were used to synthesize
four glyco-block copolymers able to chemically bind [Pt(dacp)(H2O)2] and self-
assemble in acqueous medium into micelles. The block-copolymers consisted of
the hydrophilic sugar block and the PMAA block which conjugate the platinum
drug. The cellular uptake of the four carriers was investigated on two breast
cancer cell lines, MCF-7 and MDA-MB-231, and the ovarian cancer cell line
A2780. It was demonstrated that all three cell lines show high cellular uptake
of the 1-substituted fructose coated nanoparticles, with the breast cancer cells
expressing a particularly pronounced preferences towards 1-substituted fructose.
This phenomenon can be explained by the fact that breast cancer cells overexpress
the sugar transporter GLUT5 which has a high affinity for fructose. While the
higher cellular uptake of the platinum loaded fructosylated micelles resulted in
higher toxicity towards the two breast cancer cell lines, the toxicity of the four
micelles on the ovarian cancer cell line seems to be independent by the cellular
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uptake. This suggests that other factors may play a more important role in this
case and further investigations are recommended for future work to have a better
understanding of what these factors may be and how the affect the efficiency of
glycosilated micelles.
The 1-substituted fructose-PMAA block copolymer was then employed to pre-
pare two micelles loading either high or low amounts of a hydrophobic drug which
consisted of a platinum centre coordinating 1,10-phenanthroline, [Pt(phen)Cl2].
Transmission electron microscopy and light scattering of the micelles solutions
together with solid state NMR analyses of the freeze-dried micelles demonstrated
that the extent of drug loading strongly influences the internal morphology of the
drug carrier. On the one hand, micelles loading high amounts of [Pt(phen)] have
domain separation with a well-defined core-shell type of structure and [Pt(phen)]
forms aggregates within the hydrophobic core. On the other hand, micelles load-
ing small amounts of [Pt(phen)] show a gradient type of structure, with the drug
concentration decreasing from the core to the shell. The morphological charac-
teristics of the two micelles were correlated to in vitro studies and they were
discovered to have a crucial role on the interaction between nanoparticles and
cells. In fact, despite having the same outer fructose shell, the micelles with low
drug loading had a better cellular uptake and higher toxicity than the micelles
with high drug loading. While low drug loading is not necessarily an ideal feature
for a drug delivery system, it was here demonstrated that the extent of drug load-
ing is a parameter which must be taken into account together with size, shape
and surface properties when engineering a PN for the delivery of hydrophobic
chemotherapeutics such as platinum based drugs.
The potential shown by fructose-shelled nanoparticles in being selective to-
wards breast cancer cells led to the question of how these compare to similar
nanoparticles with a neutral, non-targeting hydrophilic shell. Of particular inter-
est is to study the differences in the uptake process into breast cancer cells when
using a targeting or a non-targeting drug delivery system applied to platinum
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drugs and to understand the drug release mechanism into the cells by the two
systems. For this purpose, two block copolymers based on a bidentate carboxy-
late monomer block able to conjugate a platinum drug and hydrophilic blocks
made of either 1-substituted fructose or poly(ethylene glyco) were synthesised.
A fluorescent platinum complex was chosen to be used as a probe to investigate
the journey of the platinum complex from cellular uptake of the carriers to the
nucleus, the site of action. The platinum complex [Pt(dafone)Cl2] was chosen as
it appeared to be an ideal candidate because of its fluorescence properties and
its cytotoxicity. However, solution NMR analyses conducted here demonstrated
that [Pt(dafone)Cl2] decomposed when dissolved in DMSO and the cytotoxicity
activity shown in the literature was not evident on the cell lines tested in this
work. The instability of [Pt(dafone)Cl2] makes the conjugation onto the block
copolymers impractical because replacing the chloride groups with the carboxyl
groups of the block copolymers would most likely lead to the dafone ligand release
from the platinum complex, as was observed with DMSO solvent. However, at
this stage, this has not been possible to be confirmed. Future work may include
examining different fluorescent ligands that are coordinatively stable in order to
obtain a stable platinum complex.
The last few years have seen the design of systems that can deliver two drugs
simultaneously. This necessity comes from the fact that certain cancers develop
resistance to cisplatin and its analogues over the course of therapy. In this the-
sis, a triblock copolymer based on PEG and poly(glutamic acid) was synthesised
via NCA-ROP. The polymer can simultaneously conjugate paclitaxel (Ptx) and
a platinum(IV) drug (PtPD). Conjugation of Ptx leads to self-assembly of the
triblock copolymer into polymersomes, or vesicles, and to these PtPD can be
attached for a dual-drug co-delivery system. Tests on a lung and a prostate can-
cer mono-layered cultures highlighted that the synergistic effect between the two
drugs is maintained when the two drug are co-delivered by the vesicles with the
efficiency of PtPD improving drastically. Moreover, morphological and viability
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study on multicellular tumour spheroids (MCTS) showed that cells proliferation
is inhibited when MCTS were treated with Ptx or PtPD as single drugs, as com-
bination of free drugs and co-delivered by the vesicles compared to the control.
The dual-drug delivery system, however, showed slight improvement in terms of
both disrupting the 3D morphology of the MCTS as well as their proliferation.
For future study it would be recommended to evaluate the changes in morphology
and the viability of MCTS using a lower dose of active ingredients. This may
emphasize the difference in efficiency of free drugs and dual-drug vesicles. More-
over, it would be recommended to study the profile and mechanism of release of
the Ptx/PtPD loaded vesicles.
The field of polymer nanocarriers for the delivery of platinum based chemother-
apeutics has significantly matured in the past decade with the number of articles
rapidly increasing every years. With the progress made in polymer science, re-
searchers have a wide range of options to conjugate a platinum complex onto a
polymer, and self-assembled nanoparticles with controlled morphology and size
can now be obtained relatively easily. Nevertheless, to date only three polymer
systems, all based on a PEG hydrophilic block, have made it to the clinic.
The large amount of research done in the past decade on nanoparticles made
of complex synthetic block copolymer as potential vehicles for platinum drug
has enormously enriched our knowledge on platinum-polymer conjugation and
on how nanocarriers improve the efficiency of the drug. However, many examples
found in the literature require several synthetic steps and are therefore difficult
to transfer to commercial production. Moreover, their lack of biodegradability
makes the approval process for clinical use extremely difficult.
As future recommendation, research should now progress towards a new gener-
ation of polymer nanocarriers which should take into consideration more biodegrad-
able and bioactive polymers. An example is certainly represented by glycopoly-
mers which are showing great targeting potential towards certain cancers. Gly-
copolymers can replace the PEG block offering hydrophilicity and functionality
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at the same time.
More investigations are warranted on particles shape. The most easily achieved
and thus the most studied morphology is the spherical micelle. However, recent
years have seen more attention on different type of morphologies such as cylin-
drical micelles, worm-like particles or rods. The morphology can influence the
carrier-cell interaction and thus the internalization pathway.
Finally, combination of platinum chemotherapeutics with other cancer in-
hibitors have shown promising results when treating cisplatin resistant cancers.
However, so far, not many examples of co-delivery of a platinum drug and a
second chemotherapeutic by mean of a polymer nanocarrier are found in the lit-
erature. This is a very promising strategy and more investigations are definitely
recommended.
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Abbreviations
5637 Human Bladder Carcinoma Cells
A2780 Human Ovarian Cancer Cells
A2780cis Platinum Resistant Human Ovarian Cancer Cells
A549 Human Lung Cancer Cells
ABR Auditory Brainstem Response
AIBN 2,2-azobisisobutyronitrile
APH acid phosphate
ATRP Atom Transfer Radical Polymerisation
AUC Area Under the Curve
AcGlcMA 2′,3′,4′,6′-tetra-O-acetyl-D-glucosyloxy) ethyl methacrylate
AcGalMA 2-(2′,3′,4′,6′-tetra-O-acetyl-D-galactosyloxy)ethyl methacrylate
C26 Murine Colon Adenocarcinoma Tumor Cells
CAC Critical Aggregation Concentration
CD cyclodextrin
CDCl3 Deuterated chloroform
CDDP cis-diamminedichloroplatinum(II), Cisplatin
CI Combination Index
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CMC Critical Micelle Concentration
CPADB 4-cyanopentanoic acid dithiobenzoate
CPMAS Cross Polarization Magic Angle Spinning
CPTOSS Cross-Polarization/Total Sideband Suppression
CRC Colorectal Cancer
D2O deuterium oxide
DACH 1R,2R-diaminocyclohexane
DCC N,N ′-dicyclohexylcarbodiimide
DCM dichloromethane
DMSO-d6 Deuterated dimethylsulfoxide
DI water deionised water
DLS Dynamic Light Scattering
DLT Dose Limiting Toxicity
DMAc N,N -dimethylacetamide
DMAP 4-dimethylaminopyridine
DMEM Dulbecco's Modified Eagle's Medium
DMF dimethylformamide
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
DP degree of polymerisation
Ð Dispersity
ECM Extracellular Matrix
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ED Effective Dose
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
EGDMA ethylene glycol dimethacrylate
EPR effect Enhanced Permeability Retention effect
Et2O diethyl ether
FBS Fetal Bovine Serum
FDA Food and Drug Administration
FITC fluorescein isothiocyanate
FPT Freeze Pump Thaw
FRP Free Radical Polymerisation
FT-IR Fourier Transform Infra-Red
GPC Gel Permeability Chromatography
HA hyalorunic acid
HETCOR Heteronuclear Correlation
HeLa Human Cervical Cancer Cells
HGDMA 1,6-hexylene glycol dimethacrylate
HL High drug Loading
HL60 Human Promyelocytic Leukemia Cells
HPLC High Performance Liquid Chromatography
HPMA N -(2-hydroxypropyl)methacrylamide
HaCat Aneuploid Immortal Keratinocyte Cell Line
IC50 Half Maximal Inhibitory Concentration
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ICP-MS Inductively Coupled Plasma Mass Spectrometry
ISR Insoluble-Soluble Ratio
iprFrucMA1 2,3;4,5-di-O-isopropylidene-β-D-fructopyranose
iprFrucMA3 1,2;4,5-di-O-isopropylidene-β-D-fructopyranose
KP1019 trans-[RuCl4(indazole)2]indazoleH
L1210 Mouse Lymphocytic Leukemia Cells
LD50 Median Lethal Dose
LFRP Living Free Radical Polymerisation
LL Low drug Loading
LNCaP Human Prostate Cancer Cells
LSCM Laser Scanning Confocal Microscopy
L-NDDP Liposomal platinum(II) formulation
MAA methacrylic acid
MAHTC 1,1-di-tert-butyl 3-(2-(methacryloyloxy)1,6-hexyl)
butane-1,1,3-tricarboxylate
MAS Magic Angle Spinning
MCF7 Human Breast Cancer Cell Line
MCTS Multicellular Tumour Spheroids
MDA-MB-231 Human Breast Cancer Cells
MRI Magnetic Resonance Imaging
MTD Maximum Tolerated Dose
MWCNT Multi-walled Carbon Nanotubes
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MWCO Molecular Weight Cut Off
NAMI-A trans-[RuCl4(DMSO)(imidazole)]imidazoleH
NC-6004 Nanoplatin
TM
NCA-ROP N -carboxyanhydride Ring Opening Polymerisation
NHS N -hydroxysuccinimide
NMP Nitroxide Mediated Radical Polymerisation
NMR Nuclear Magnetic Resonance
NT Nano-tubes
OEGMEMA oligo-(ethylene glycol) methylether methacrylate
OSC-19 Nude Mice Bearing
OVCAR3 Human Ovarian Cancer Cells
O-PDA O-phenylenediamine
P(Asp) poly(aspartic acid)
P(Glu) poly-L-glutamic acid
PBS Phosphate Buffered Saline
PBLG poly(γ-benzyl-L-glutamate)
PCL poly(-caprolactone)
PN Polymer Nanocarrier/Nanoparticle
PDI Poly Dispersity Index
PEG poly(ethylene glycol)
PHEMA poly(2-hydroxyethyl methacrylate)
PLA poly(D,L-lactide) acid
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PLG poly(glycolide)
PLGA poly(D,L-lactic-co-glycolid acid)
PMA poly(propargyl methacrylate)
PMAA poly(methacrylic acide)
PEGMEMA poly(ethylene glycol) methylether methacrylate
PRE Persistent Radical Effect
PS poly styrene
Pt Platinum
PtPD [Pt(phen)(S,S-dach))(OH2)Cl2]
Ptx Paclitaxel
QD Quantum Dots
RAFT Reversible Addition Fragmentation Chain Transfer
RDRP Reversible Deactivation Radical Polymerisation
RES Reticulo Endothelial System
RGD Arginylglycylaspartic Acid
RPMI Roswell Park Memorial Institute
r.t. room temperature
SD Standard Deviation
SEC Size Exclusion Chromatography
SFRP Stable Free Radical Polymerisation
SKOV3 Human Ovarian Cancer Cells
SNU638 Stomach Cancer Cells
SRB Sulforhodamine B
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SPI-077 Stealth Liposomal Cisplatin
SWCNT Single-Walled Carbon Nanotubes
TCA Trichloroacetic Acid
TEM Transmission Electron Microscopy
TFA-d Deuterated Trifluoroacetic Acid
TGA Thermal Gravimetric Analysis
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